

Bladder Cancer Incidence and Mortality: A Global Overview

European Urology

71, 96-108

DOI: [10.1016/j.eururo.2016.06.010](https://doi.org/10.1016/j.eururo.2016.06.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Translational Andrology and Urology, 2016, 5, 735-744.	1.4	43
2	Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People. Bladder Cancer, 2016, 2, 467-468.	0.4	5
3	Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder. Journal of Cancer, 2016, 7, 2187-2196.	2.5	17
4	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	7.7	19
5	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 267-274.	2.8	58
6	Urothelial generation and regeneration in development, injury, and cancer. Developmental Dynamics, 2017, 246, 336-343.	1.8	46
7	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2017, 77, 1035-1046.	0.9	15
8	Common urologic diseases in older men and their treatment: how they impact fertility. Fertility and Sterility, 2017, 107, 305-311.	1.0	9
9	Targeted glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours. Molecular Oncology, 2017, 11, 895-912.	4.6	50
10	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	3.8	89
11	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treatment Reviews, 2017, 54, 58-67.	7.7	324
12	Bladder cancer. Nature Reviews Disease Primers, 2017, 3, 17022.	30.5	590
13	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 271-280.	2.8	15
14	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Translational Oncology, 2017, 10, 340-345.	3.7	22
15	Effect of Urinary Cytology for Detecting Recurrence in Remnant Urothelium After Radical Cystectomy: Insights From a 10-year Cytology Database. Clinical Genitourinary Cancer, 2017, 15, e783-e791.	1.9	13
16	Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis. Kaohsiung Journal of Medical Sciences, 2017, 33, 215-223.	1.9	89
17	Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment. JAMA Oncology, 2017, 3, 1570.	7.1	38
18	Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 264-271.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. <i>Journal of Drug Targeting</i> , 2017, 25, 626-636.	4.4	54
20	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. <i>British Journal of Cancer</i> , 2017, 116, 1077-1087.	6.4	48
21	Targeting Inflammation for Bladder Cancer Chemoprevention. <i>Current Pharmacology Reports</i> , 2017, 3, 447-457.	3.0	1
22	Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer. <i>IDCases</i> , 2017, 10, 75-78.	0.9	2
23	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 261-274.	0.7	1
24	MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3253-3258.	1.8	28
26	Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 991-1000.	2.2	66
27	The efficacy of Apaziquone in the treatment of bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1781-1788.	1.8	12
28	MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial to mesenchymal transition progression in bladder cancer. <i>Cell Death and Disease</i> , 2017, 8, e3010-e3010.	6.3	53
29	Prospects and progress of immunotherapy for bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	3.1	29
30	Current research development of single cell genome in urological tumor. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 90, 167-171.	2.8	3
31	Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 11702.	3.3	110
32	Melatonin potentiates the antitumor effect of curcumin by inhibiting IKK β /NF- κ B/COX-2 signaling pathway. <i>International Journal of Oncology</i> , 2017, 51, 1249-1260.	3.3	36
33	Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. <i>Medical Oncology</i> , 2017, 34, 170.	2.5	31
34	A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6904-6911.	7.0	315
35	MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene. <i>Tumor Biology</i> , 2017, 39, 101042831771841.	1.8	41
36	Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells. <i>Cell Cycle</i> , 2017, 16, 1509-1514.	2.6	24
37	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. <i>Pharmacogenomics</i> , 2017, 18, 1167-1178.	1.3	7

#	ARTICLE	IF	CITATIONS
38	<i>Long Noncoding RNA Cancer Susceptibility Candidate 8</i> Suppresses the Proliferation of Bladder Cancer Cells via Regulating Glycolysis. <i>DNA and Cell Biology</i> , 2017, 36, 767-774.	1.9	32
39	Circ <i>HIPK3</i> sponges miR-558 to suppress heparanase expression in bladder cancer cells. <i>EMBO Reports</i> , 2017, 18, 1646-1659.	4.5	474
40	Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers. , 2017, , 59-74.		1
41	Pembrolizumab in the treatment of advanced urothelial cancer. <i>Future Oncology</i> , 2017, 13, 2745-2758.	2.4	4
43	Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. <i>Cancer Letters</i> , 2017, 403, 305-317.	7.2	378
44	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. <i>BMC Cancer</i> , 2017, 17, 308.	2.6	7
45	Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 783-791.	3.3	21
46	Global Burden of Urologic Cancers, 1990–2013. <i>European Urology</i> , 2017, 71, 437-446.	1.9	248
47	Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?. <i>European Urology</i> , 2017, 71, 109-110.	1.9	47
48	Gender Differences in Bladder and Kidney Cancers. , 2017, , 603-610.		2
49	Overexpression of CircRNA BCRC4 regulates cell apoptosis and MicroRNA-101/EZH2 signaling in bladder cancer. <i>Current Medical Science</i> , 2017, 37, 886-890.	1.8	38
50	Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1680.	4.1	13
51	Association of smoking status with prognosis in bladder cancer: A meta-analysis. <i>Oncotarget</i> , 2017, 8, 1278-1289.	1.8	36
52	Focal adhesion kinases crucially regulate TGF β -induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1783-1792.	2.0	35
53	Tanshinone IIA Inhibits Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Modulation of STAT3-CCL2 Signaling. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1616.	4.1	35
54	The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. <i>Frontiers in Immunology</i> , 2017, 8, 1147.	4.8	133
55	Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. <i>PLoS ONE</i> , 2017, 12, e0184841.	2.5	18
56	Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. <i>Brazilian Journal of Medical and Biological Research</i> , 2017, 50, e6207.	1.5	12

#	ARTICLE	IF	CITATIONS
57	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	2.0	12
58	Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. <i>PLoS ONE</i> , 2017, 12, e0188827.	2.5	9
59	Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future. <i>Urologia</i> , 2017, 84, 130-141.	0.7	8
60	YRNA expression predicts survival in bladder cancer patients. <i>BMC Cancer</i> , 2017, 17, 749.	2.6	25
61	A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. <i>Virology Journal</i> , 2017, 14, 149.	3.4	6
62	A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. <i>Case Reports in Oncology</i> , 2017, 10, 493-500.	0.7	1
63	DNA Repair Pathway Alterations in Bladder Cancer. <i>Cancers</i> , 2017, 9, 28.	3.7	39
64	Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. <i>International Journal of Medical Sciences</i> , 2017, 14, 811-819.	2.5	42
65	Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. <i>Oncotarget</i> , 2017, 8, 21871-21883.	1.8	12
66	Improving outcome and prognosis prediction in non-muscle invasive bladder cancer using a gene expression score. <i>Translational Andrology and Urology</i> , 2017, 6, 991-993.	1.4	1
67	The clinical significance of COL5A2 in patients with bladder cancer. <i>Medicine (United States)</i> , 2018, 97, e0091.	1.0	56
68	An <scp>FGFR</scp> 3/ <scp>MYC</scp> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	54
69	Effect of selective inhibition of aquaporin 1 on chemotherapy sensitivity of J82 human bladder cancer cells. <i>Oncology Letters</i> , 2018, 15, 3864-3869.	1.8	24
70	Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. <i>Scientific Reports</i> , 2018, 8, 3477.	3.3	13
71	Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 1070-1080.	2.8	91
72	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. <i>World Journal of Urology</i> , 2018, 36, 1073-1078.	2.2	17
73	Durvalumab in urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 311-318.	2.4	8
74	Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. <i>Molecular Cancer</i> , 2018, 17, 19.	19.2	395

#	ARTICLE	IF	CITATIONS
75	The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 66, 56-63.	7.7	24
76	Interest of next-generation sequencing in BCG-treated high-risk bladder cancer. <i>Progres En Urologie</i> , 2018, 28, 344-350.	0.8	5
77	ZFAS1 functions as an oncogenic long non-coding RNA in bladder cancer. <i>Bioscience Reports</i> , 2018, 38, .	2.4	29
78	A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. <i>EBioMedicine</i> , 2018, 31, 54-65.	6.1	25
79	Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 338.e1-338.e11.	1.6	21
80	<scp>CD</scp>169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. <i>Cancer Science</i> , 2018, 109, 1723-1730.	3.9	48
81	Bladder cancer survival: Women better off in the long run. <i>European Journal of Cancer</i> , 2018, 95, 52-58.	2.8	49
82	Therapeutic efficacy of the live-attenuated <i>Mycobacterium tuberculosis</i> vaccine, MTBVAC, in a preclinical model of bladder cancer. <i>Translational Research</i> , 2018, 197, 32-42.	5.0	9
83	Ubenimex, an APN inhibitor, could serve as an anti-tumor drug in RT112 and 5637 cells by operating in an Akt-associated manner. <i>Molecular Medicine Reports</i> , 2018, 17, 4531-4539.	2.4	12
84	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 248-256.e2.	1.9	16
85	MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop. <i>Cell Death and Disease</i> , 2018, 9, 209.	6.3	73
86	A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2018, 78, 2233-2247.	0.9	30
87	Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. <i>Molecular and Cellular Biochemistry</i> , 2018, 446, 105-114.	3.1	23
88	TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer. <i>Cell Death and Disease</i> , 2018, 9, 72.	6.3	20
90	Current work environments: What problems are being faced by Japanese urologists?. <i>International Journal of Urology</i> , 2018, 25, 327-336.	1.0	3
91	Risk Factors and Molecular Features Associated with Bladder Cancer Development. <i>Molecular Pathology Library</i> , 2018, , 3-28.	0.1	1
92	Bladder resident macrophages: Mucosal sentinels. <i>Cellular Immunology</i> , 2018, 330, 136-141.	3.0	27
93	Estimating the impact of body mass index on bladder cancer risk: Stratification by smoking status. <i>Scientific Reports</i> , 2018, 8, 947.	3.3	18

#	ARTICLE	IF	CITATIONS
94	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. <i>Future Oncology</i> , 2018, 14, 277-290.	2.4	19
95	The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. <i>Scientific Reports</i> , 2018, 8, 1129.	3.3	188
96	Role of immunotherapy in bladder cancer: past, present and future. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 629-645.	2.3	35
97	Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2033-2038.	3.6	36
98	Laminar shear stress inhibits high glucose-induced migration and invasion in human bladder cancer cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 120-128.	1.5	6
99	mRNA, microRNA and lncRNA as novel bladder tumor markers. <i>Clinica Chimica Acta</i> , 2018, 477, 141-153.	1.1	71
100	Diagnostic potential of major and trace elements in the serum of bladder cancer patients. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 46, 150-155.	3.0	21
101	Pembrolizumab for the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 107-114.	2.4	12
102	CircRNA-Cdr1as Exerts Anti-Oncogenic Functions in Bladder Cancer by Sponging MicroRNA-135a. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 1606-1616.	1.6	126
103	Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis. <i>Journal of Human Genetics</i> , 2018, 63, 657-668.	2.3	42
104	Identification of differentially expressed genes and biological pathways in bladder cancer. <i>Molecular Medicine Reports</i> , 2018, 17, 6425-6434.	2.4	16
105	Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 605-613.	2.8	6
106	Differences in the Molecular Characteristics of Bladder Cancer between Smokers and Nonsmokers. <i>European Urology Focus</i> , 2018, 4, 98-99.	3.1	0
107	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <i>European Urology</i> , 2018, 73, 40-50.	1.9	107
108	Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 405-411.	3.1	23
109	Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. <i>Clinical and Translational Oncology</i> , 2018, 20, 201-211.	2.4	56
110	A Novel Presentation of Bladder Mass. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, e29-e31.	1.1	0
111	Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. <i>BJU International</i> , 2018, 121, 29-37.	2.5	82

#	ARTICLE	IF	CITATIONS
112	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	1.9	13
113	The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model. Methods in Molecular Biology, 2018, 1655, 155-167.	0.9	15
114	A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer. Methods in Molecular Biology, 2018, 1655, 29-41.	0.9	5
115	Atezolizumab in urothelial bladder carcinoma. Future Oncology, 2018, 14, 331-341.	2.4	10
116	miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. Genes Chromosomes and Cancer, 2018, 57, 150-161.	2.8	26
118	Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World Journal of Urology, 2018, 36, 249-256.	2.2	22
119	Urinary diversion in the genitourinary cancer survivor. Gynecologic Oncology, 2018, 148, 414-421.	1.4	2
120	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. International Journal of Hyperthermia, 2018, 34, 988-993.	2.5	14
121	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews Urology, 2018, 15, 92-111.	3.8	139
122	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. World Journal of Urology, 2018, 36, 231-240.	2.2	32
123	HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/ β -catenin signaling. Molecular Carcinogenesis, 2018, 57, 12-21.	2.7	38
124	Effect of smoking on pathological grade and stage in clinically low-risk patients. African Journal of Urology, 2018, 24, 270-273.	0.4	0
125	Hyperthermic Agent Prepared by One-Pot Modification of Maghemite Using an Aliphatic Polyester Model. Polymer Science - Series B, 2018, 60, 806-815.	0.8	8
126	Three-dimensional organoid culture reveals involvement of Wnt/ β -catenin pathway in proliferation of bladder cancer cells. Oncotarget, 2018, 9, 11060-11070.	1.8	46
127	Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?. Translational Andrology and Urology, 2018, 7, S741-S743.	1.4	0
128	Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 472-480.	3.1	8
129	Current concept of transurethral resection of bladder cancer. Current Opinion in Urology, 2018, 28, 591-597.	1.8	21
130	Can a diagnosis of bladder cancer motivate positive lifestyle changes and prevent recurrent disease?. Translational Andrology and Urology, 2018, 7, S242-S245.	1.4	0

#	ARTICLE	IF	CITATIONS
131	A pictorial review of bladder cancer nodal metastases. <i>Translational Andrology and Urology</i> , 2018, 7, 804-813.	1.4	20
132	Evaluation of lymph node status in patients with urothelial carcinomaâ€”still in search of the perfect imaging modality: a systematic review. <i>Translational Andrology and Urology</i> , 2018, 7, 783-803.	1.4	13
133	Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients. <i>Medicine (United States)</i> , 2018, 97, e11596.	1.0	40
134	Quality of Life in Patients with Bladder Cancer Undergoing Ileal Conduit: A Comparison of Women Versus Men. <i>In Vivo</i> , 2018, 32, 139-143.	1.3	12
135	Synthesis, antitumor activity and molecular mechanism of doxorubicin conjugated trimethyl-chitosan polymeric micelle loading Beclin1 siRNA for drug-resisted bladder cancer therapy. <i>RSC Advances</i> , 2018, 8, 35395-35402.	3.6	8
136	Immunohistochemical Expression of Androgen and Estrogen Receptors. <i>Diagnostic Pathology: Open Access</i> , 2018, 03, .	0.0	1
137	Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. <i>Oncology Letters</i> , 2018, 17, 201-208.	1.8	6
138	MicroRNAâ€154 functions as a tumor suppressor in bladder cancer by directly targeting ATG7. <i>Oncology Reports</i> , 2018, 41, 819-828.	2.6	27
139	Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. <i>Oncotarget</i> , 2018, 9, 14354-14365.	1.8	30
140	Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. <i>BMJ Open</i> , 2018, 8, e020500.	1.9	71
141	Bladder Cancer Segmentation on Multispectral Images. , 2018, , .		0
142	Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer. <i>BMC Urology</i> , 2018, 18, 100.	1.4	11
143	The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. <i>Genes</i> , 2018, 9, 552.	2.4	68
144	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , 2018, 4, 395-401.	0.4	55
145	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , The, 2018, 19, e683-e695.	10.7	74
146	Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. <i>Molecular Cancer</i> , 2018, 17, 161.	19.2	129
147	Magnetic Sensing System for Monitoring the Volume of an Artificial Bladder. , 2018, , .		3
148	Combination of High-Resolution Optical Coherence Tomography and Raman Spectroscopy for Improved Staging and Grading in Bladder Cancer. <i>Applied Sciences (Switzerland)</i> , 2018, 8, 2371.	2.5	22

#	ARTICLE	IF	CITATIONS
149	Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. <i>Nutrients</i> , 2018, 10, 1756.	4.1	178
150	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. <i>Future Science OA</i> , 2018, 4, FSO341.	1.9	8
151	Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 273.	8.6	96
152	Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. <i>Bladder Cancer</i> , 2018, 4, 365-376.	0.4	22
153	Glucocorticoid-Inducible Kinase 2 Promotes Bladder Cancer Cell Proliferation, Migration and Invasion by Enhancing β -catenin/c-Myc Signaling Pathway. <i>Journal of Cancer</i> , 2018, 9, 4774-4782.	2.5	18
154	Outcomes of stage I/II upper tract urothelial carcinoma and adjuvant chemotherapy for locally advanced cancer. <i>Oncology Letters</i> , 2019, 17, 1341-1348.	1.8	10
155	Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 1239.	2.6	16
156	Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 17693.	3.3	17
157	The Effect of Daily Fluid Management and Beverages Consumption on the Risk of Bladder Cancer: A Meta-analysis of Observational Study. <i>Nutrition and Cancer</i> , 2018, 70, 1217-1227.	2.0	11
158	The frequencies of micronuclei, nucleoplasmic bridges and nuclear buds as biomarkers of genomic instability in patients with urothelial cell carcinoma. <i>Scientific Reports</i> , 2018, 8, 17873.	3.3	20
159	OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells. <i>Journal of Cancer</i> , 2018, 9, 4684-4695.	2.5	22
160	MIR-300 in the imprinted DLK1-DIO3 domain suppresses the migration of bladder cancer by regulating the SP1/MMP9 pathway. <i>Cell Cycle</i> , 2018, 17, 2790-2801.	2.6	26
161	New Insights in Bladder Cancer Diagnosis: Urinary miRNAs and Proteins. <i>Medical Sciences (Basel)</i> , 2018, 7, 17.	2.9	17
162	The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression. <i>Cancers</i> , 2018, 10, 484.	3.7	15
163	circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 633-641.	5.1	65
164	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	1.1	2
165	Paclitaxel/Chitosan Nanosuspensions Provide Enhanced Intravesical Bladder Cancer Therapy with Sustained and Prolonged Delivery of Paclitaxel. <i>ACS Applied Bio Materials</i> , 2018, 1, 1992-2001.	4.6	20
166	Inhibition of TPL2 by interferon- γ suppresses bladder cancer through activation of PDE4D. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 288.	8.6	14

#	ARTICLE	IF	CITATIONS
167	Increased Surgical Complications in Smokers Undergoing Radical Cystectomy1. <i>Bladder Cancer</i> , 2018, 4, 403-409.	0.4	22
168	Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 3781-3791.	1.9	25
170	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018, 74, 784-795.	1.9	530
171	Ureteroileal bypass: a new technic to treat ureteroenteric strictures in urinary diversion. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 624-628.	1.5	4
172	Lentivirus-mediated shRNA targeting MUTYH inhibits malignant phenotypes of bladder cancer SW780 cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6101-6109.	2.0	4
173	Down-regulated LncR-MALAT1 suppressed cell proliferation and migration by inactivating autophagy in bladder cancer. <i>RSC Advances</i> , 2018, 8, 31019-31027.	3.6	4
174	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018, 105, 857-861.	1.6	8
175	Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2999.	4.1	42
176	MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2. <i>Bioscience Reports</i> , 2018, 38, .	2.4	48
177	Long Non-Coding RNA Expression Profiles for the Characterization of Different Bladder Cancer Grade. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 1154-1163.	1.6	13
178	Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. <i>Current Urology Reports</i> , 2018, 19, 108.	2.2	18
179	Inducing intravesical hyperthermia of the ex-vivo porcine bladder wall: radiofrequency-induction versus recirculation using a custom-made device. <i>International Journal of Hyperthermia</i> , 2018, 35, 323-329.	2.5	3
180	The Effect of Different Drinking and Voiding Preparations on Magnetic Resonance Imaging Bladder Distention in Normal Volunteers and Patients. <i>Canadian Association of Radiologists Journal</i> , 2018, 69, 383-389.	2.0	4
182	The interplay between adipose-derived stem cells and bladder cancer cells. <i>Scientific Reports</i> , 2018, 8, 15118.	3.3	21
183	Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer. <i>Disease Markers</i> , 2018, 2018, 1-9.	1.3	18
184	Multiregion segmentation of bladder cancer structures in MRI with progressive dilated convolutional networks. <i>Medical Physics</i> , 2018, 45, 5482-5493.	3.0	60
185	Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data. <i>Frontiers in Oncology</i> , 2018, 8, 450.	2.8	49
186	Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1477-1486.	6.4	41

#	ARTICLE	IF	CITATIONS
187	P3H4 is correlated with clinicopathological features and prognosis in bladder cancer. World Journal of Surgical Oncology, 2018, 16, 206.	1.9	7
188	Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e9-531.e17.	1.6	14
189	Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype. ACS Nano, 2018, 12, 9669-9679.	14.6	81
190	ASCO 2018: highlights of urothelial cancer and prostate cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 284-290.	0.5	7
191	Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles. Molecules, 2018, 23, 2157.	3.8	82
192	Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects. Gene, 2018, 679, 241-252.	2.2	14
193	Health related quality of life after urinary diversion. Which technique is better?. Journal of the Egyptian National Cancer Institute, 2018, 30, 93-97.	1.5	9
194	The effect of marital status on the survival of patients with bladder urothelial carcinoma. Medicine (United States), 2018, 97, e11378.	1.0	22
195	Health-related quality of life after treatment for bladder cancer in England. British Journal of Cancer, 2018, 118, 1518-1528.	6.4	55
196	Quality of Life in Bladder Cancer Patients. , 2018, , 507-522.		1
197	A glance at imaging bladder cancer. Clinical and Translational Imaging, 2018, 6, 257-269.	2.1	11
198	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Human Pathology, 2018, 79, 57-65.	2.0	48
199	Identification and characterization of bladder cancer by low-resolution fiber-optic Raman spectroscopy. Journal of Biophotonics, 2018, 11, e201800016.	2.3	37
200	The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study. Cancer Causes and Control, 2018, 29, 675-683.	1.8	23
201	LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. Cancer Medicine, 2018, 7, 3342-3350.	2.8	31
202	Pre-diagnostic circulating insulin-like growth factor-1 and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2018, 143, 2351-2358.	5.1	18
203	Modeling human bladder cancer. World Journal of Urology, 2018, 36, 1759-1766.	2.2	14
204	Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis. World Journal of Urology, 2018, 36, 1997-2008.	2.2	30

#	ARTICLE	IF	CITATIONS
205	Molecularly-driven precision medicine for advanced bladder cancer. World Journal of Urology, 2018, 36, 1749-1757.	2.2	4
206	Urinary Bladder Cancer in Egypt: Are There Gender Differences in Its Histopathological Presentation?. Advances in Urology, 2018, 2018, 1-7.	1.3	9
207	Familial Urinary Bladder Cancer with Other Cancers. European Urology Oncology, 2018, 1, 461-466.	5.4	4
208	Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis. Quality of Life Research, 2018, 27, 2759-2775.	3.1	16
209	The emerging role of circRNAs and their clinical significance in human cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 247-260.	7.4	106
210	Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway. OncoTargets and Therapy, 2018, Volume 11, 1961-1971.	2.0	11
211	Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. Molecular Nutrition and Food Research, 2018, 62, e1800079.	3.3	105
212	Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. EBioMedicine, 2018, 34, 76-84.	6.1	109
213	Targeting DNA Methyltransferases in Urological Tumors. Frontiers in Pharmacology, 2018, 9, 366.	3.5	29
214	Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review. Frontiers in Physiology, 2018, 9, 652.	2.8	14
215	O ₂ -generating MnO ₂ nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia. Theranostics, 2018, 8, 990-1004.	10.0	233
216	Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea. BMC Cancer, 2018, 18, 617.	2.6	14
217	Bladder Cancer: New Insights into Its Molecular Pathology. Cancers, 2018, 10, 100.	3.7	77
218	Update on the Treatment of Metastatic Urothelial Carcinoma. Scientific World Journal, The, 2018, 2018, 1-7.	2.1	34
219	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. International Journal of Molecular Sciences, 2018, 19, 590.	4.1	29
220	Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder. International Journal of Molecular Sciences, 2018, 19, 1622.	4.1	6
221	GUROPA survey: genito-urinary radiation oncology prescription attitudes. Radiologia Medica, 2018, 123, 879-884.	7.7	4
222	Incidence of bladder cancer in Benghazi, Libya over the past three decades. Scientific Reports, 2018, 8, 10822.	3.3	4

#	ARTICLE	IF	CITATIONS
223	Mechanisms of BCG immunotherapy and its outlook for bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 615-625.	3.8	284
224	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. <i>European Urology</i> , 2018, 74, 597-608.	1.9	61
225	Safety and efficacy of tamsulosin as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	2.6	18
226	Fluid Shear Stress Induces Cell Cycle Arrest in Human Urinary Bladder Transitional Cell Carcinoma Through Bone Morphogenetic Protein Receptor-Smad1/5 Pathway. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 185-195.	2.1	13
227	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	1.9	372
228	Evaluating patient-reported outcome measures (<sc>PROM</sc>s) for bladder cancer: a systematic review using the <sc>CO</sc>nsensus-based Standards for the selection of health Measurement INstruments (<sc>COSMIN</sc>) checklist. <i>BJU International</i> , 2018, 122, 760-773.	2.5	34
229	Anti-EGFR Indocyanine Green-Mitomycin C-Loaded Perfluorocarbon Double Nanoemulsion: A Novel Nanostructure for Targeted Photochemotherapy of Bladder Cancer Cells. <i>Nanomaterials</i> , 2018, 8, 283.	4.1	17
230	Baseline Cytokine Profiles of Tuberculin-Specific CD4+ T Cells in Non-muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1212-1219.	3.4	4
231	Fatty Acid Patterns Detected By Ambient Ionization Mass Spectrometry in Canine Invasive Urothelial Carcinoma From Dogs of Different Breeds. <i>Bladder Cancer</i> , 2018, 4, 283-291.	0.4	7
232	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2018, , 1-11.		0
233	Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression. <i>Gene</i> , 2018, 678, 337-342.	2.2	43
234	Diagnostic accuracy of the UBCi ₂ /2 Rapid Test for bladder cancer: A meta-analysis. <i>Oncology Letters</i> , 2018, 16, 3770-3778.	1.8	10
235	Emerging function and potential diagnostic value of circular RNAs in cancer. <i>Molecular Cancer</i> , 2018, 17, 123.	19.2	129
236	Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 1627-1638.	1.9	24
237	Bufalin induced apoptosis of bladder carcinoma cells through the inactivation of Na+K+ATPase. <i>Oncology Letters</i> , 2018, 16, 3826-3832.	1.8	14
238	The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4641-4649.	2.0	14
239	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy. <i>Oncology Letters</i> , 2018, 16, 3013-3021.	1.8	4
240	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 389-399.	1.6	72

#	ARTICLE	IF	CITATIONS
241	Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. International Journal of Oncology, 2018, 53, 515-526.	3.3	34
242	Graphene-based nanomaterials in cancer treatment and diagnosis. , 2018, , 331-374.		20
243	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. European Urology Oncology, 2018, 1, 223-230.	5.4	25
244	<scp>FOXM</scp>1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage <scp>pT</scp>1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2019, 123, 187-196.	2.5	19
245	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	2.2	31
246	Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Î-catenin pathway. Pharmaceutical Biology, 2019, 57, 507-513.	2.9	13
247	Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. Diagnostic Pathology, 2019, 14, 90.	2.0	13
248	N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine, 2019, 47, 195-207.	6.1	146
250	Predictive biomarkers for drug response in bladder cancer. International Journal of Urology, 2019, 26, 1044-1053.	1.0	50
251	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. Future Oncology, 2019, 15, 1505-1524.	2.4	12
252	MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor ÎA in bladder cancer. Journal of Biosciences, 2019, 44, 1.	1.1	22
253	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 76-85.	4.4	9
254	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2019, , 291-301.		1
255	The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Human Pathology, 2019, 91, 61-68.	2.0	50
256	Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. International Journal of Molecular Sciences, 2019, 20, 3162.	4.1	10
257	Synthesis and Evaluation of Boronated Chitosan as a Mucoadhesive Polymer for Intravesical Drug Delivery. Journal of Pharmaceutical Sciences, 2019, 108, 3046-3053.	3.3	36
258	Development of a novel sixâ€long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma. Journal of Cellular Biochemistry, 2019, 120, 19796-19809.	2.6	21
259	KIF5A Promotes Bladder Cancer Proliferation <i>In Vitro</i> and <i>In Vivo</i>. Disease Markers, 2019, 2019, 1-9.	1.3	10

#	ARTICLE	IF	CITATIONS
260	<p><p>Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation</p>. OncoTargets and Therapy, 2019, Volume 12, 4403-4413.	2.0	9
261	lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 549-559.	1.5	65
262	Prognostic Impact of Canonical TGF- β 2 Signaling in Urothelial Bladder Cancer. Medicina (Lithuania), 2019, 55, 302.	2.0	16
263	BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells. Cancer Medicine, 2019, 8, 4792-4805.	2.8	37
264	CircNR3C1 inhibits proliferation of bladder cancer cells by sponging miR-27a-3p and downregulating cyclin D1 expression. Cancer Letters, 2019, 460, 139-151.	7.2	59
265	Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 810.e17-810.e27.	1.6	12
266	Risk of urothelial cancer death among people using antihypertensive drugsâ€”a cohort study from Finland. Scandinavian Journal of Urology, 2019, 53, 185-192.	1.0	5
267	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2019, 475, 599-608.	2.8	45
268	Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Nonâ€”muscle-invasive Bladder Cancer. European Urology Oncology, 2019, 2, 576-583.	5.4	14
269	Programmed death ligandâ€”1/programmed deathâ€”1 inhibition therapy and programmed death ligandâ€”1 expression in urothelial bladder carcinoma. Chronic Diseases and Translational Medicine, 2019, 5, 170-177.	1.2	3
270	β -Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3075-3087.	2.5	4
271	Transgelin, a p53 and PTEN-Upregulated Gene, Inhibits the Cell Proliferation and Invasion of Human Bladder Carcinoma Cells in Vitro and in Vivo. International Journal of Molecular Sciences, 2019, 20, 4946.	4.1	20
272	<p>Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 8161-8177.	2.0	2
273	Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer, 2019, 19, 984.	2.6	81
274	Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation. EBioMedicine, 2019, 48, 316-331.	6.1	55
275	NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Theranostics, 2019, 9, 7156-7167.	10.0	35
276	BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants. Scientific Reports, 2019, 9, 15268.	3.3	12
277	Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines. Scientific Reports, 2019, 9, 14476.	3.3	8

#	ARTICLE	IF	CITATIONS
278	Evaluation of <i>CERS2</i> Gene as a Potential Biomarker for Bladder Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	1.3	8
279	Minimally invasive versus open radical cystectomy for bladder cancer: A systematic review and meta-analysis. <i>Journal of International Medical Research</i> , 2019, 47, 4604-4618.	1.0	11
280	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. <i>Cancer Epidemiology</i> , 2019, 62, 101584.	1.9	4
281	Processed Meat Intake and Bladder Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1993-1997.	2.5	15
282	Evaluating prognostic utility of preoperative Neutrophil to Lymphocyte Ratio and hsa-let-7g/c up-regulation in patients with urinary bladder cancer. <i>Cancer Biomarkers</i> , 2019, 27, 63-73.	1.7	5
283	Preoperative CD4+CD25+/CD4+ and tumor diameter predict prognosis in male patients with bladder cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 1387-1397.	1.4	2
284	The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer. <i>BMC Cancer</i> , 2019, 19, 991.	2.6	12
285	Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. <i>Cancers</i> , 2019, 11, 1219.	3.7	32
286	Chemosensitizing Effect of Cernumidine Extracted from <i>Solanum cernuum</i> on Bladder Cancer Cells <i>in Vitro</i> . <i>Chemistry and Biodiversity</i> , 2019, 16, e1900334.	2.1	11
287	Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies. <i>Gene</i> , 2019, 719, 144077.	2.2	8
288	Bidirectional expression of Toll-like receptor 7 gene in urinary bladder cancer and urinary tract infection of Iraqi patients. <i>Gene Reports</i> , 2019, 17, 100491.	0.8	0
289	The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy. <i>BMC Urology</i> , 2019, 19, 77.	1.4	7
290	Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-9.	1.9	9
291	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. <i>Cancers</i> , 2019, 11, 1277.	3.7	24
292	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 89.	17.0	33
293	Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion. <i>Clinical and Experimental Medicine</i> , 2019, 19, 525-534.	3.6	21
294	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	4.4	20
295	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	3.8	123

#	ARTICLE	IF	CITATIONS
296	To achieve the best performance of transurethral resection of bladder tumor: implication of surgical checklist. <i>Translational Andrology and Urology</i> , 2019, 8, S85-S87.	1.4	2
297	Multicenter Analysis of Postoperative Complications in Octogenarians After Radical Cystectomy and Ureterocutaneostomy: The Role of the Frailty Index. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 402-407.	1.9	33
298	A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 889.	2.8	12
299	Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 8125-8133.	1.9	8
300	Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109490.	5.6	31
301	Palliative Radiation Therapy in Bladder Cancer—Importance of Patient Selection: A Retrospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 389-393.	0.8	23
302	Comprehensive circular RNA profiling reveals the regulatory role of the hsa_circ_0137606/miR-1231 pathway in bladder cancer progression. <i>International Journal of Molecular Medicine</i> , 2019, 44, 1719-1728.	4.0	9
303	Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. <i>British Journal of Radiology</i> , 2019, 92, 20190401.	2.2	54
304	Erdafitinib for the treatment of urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 835-846.	2.4	17
305	Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 2252-2262.	2.5	6
306	Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause. <i>Cancer Causes and Control</i> , 2019, 30, 249-258.	1.8	3
307	Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 495-508.	2.0	61
308	Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF- κ B Pathway in Bladder Cancer Cells. <i>International Journal of Biological Sciences</i> , 2019, 15, 688-700.	6.4	32
309	Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article. <i>Regional Anesthesia and Pain Medicine</i> , 2019, 44, 13-28.	2.3	40
310	Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e461-e471.	1.9	13
311	Comparison of different prognostic models for predicting cancer-specific survival in bladder transitional cell carcinoma. <i>Future Oncology</i> , 2019, 15, 851-864.	2.4	6
312	Dihydrotestosterone increases the risk of bladder cancer in men. <i>Human Cell</i> , 2019, 32, 379-389.	2.7	12
313	Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. <i>EBioMedicine</i> , 2019, 44, 431-438.	6.1	41

#	ARTICLE	IF	CITATIONS
314	Connexins and Gap Junctions in Cancer of the Urinary Tract. <i>Cancers</i> , 2019, 11, 704.	3.7	10
315	Synthesis and biological evaluation of quercetinâ€“zinc (II) complex for anti-cancer and anti-metastasis of human bladder cancer cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 395-404.	1.5	29
316	Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 800-807.	1.6	6
317	Malignancies of suprapubic catheter (SPC) tracts in spinal cord injury patients: a case series and review of literature. <i>Spinal Cord Series and Cases</i> , 2019, 5, 34.	0.6	2
318	USP13 functions as a tumor suppressor by blocking the NF- κ B-mediated PTEN downregulation in human bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 259.	8.6	70
319	Optical biopsy of bladder cancer using confocal laser endomicroscopy. <i>International Urology and Nephrology</i> , 2019, 51, 1473-1479.	1.4	9
320	Trends in socio-economic inequalities in bladder cancer incidence in Canada: 1992â€“2010. <i>Canadian Journal of Public Health</i> , 2019, 110, 722-731.	2.3	10
321	A Pre-operative Nomogram for Prediction of Lymph Node Metastasis in Bladder Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 488.	2.8	11
322	Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 126-132.	1.6	7
323	Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. <i>Molecular Cancer</i> , 2019, 18, 111.	19.2	216
324	Methods for bladder cancer diagnosis â€“ The role of autofluorescence and photodynamic diagnosis. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 27, 141-148.	2.6	19
325	Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miRâ€“1270 inhibition. <i>Molecular Oncology</i> , 2019, 13, 1559-1576.	4.6	85
326	Urothelial Cancer Stem Cell Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 127-151.	1.6	6
327	Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 315-324.	1.5	18
328	<p>High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer</p>.; <i>Cancer Management and Research</i> , 2019, Volume 11, 2987-2995.	1.9	28
329	Cancer mortality in Europe in 2015 and an overview of trends since 1990. <i>Annals of Oncology</i> , 2019, 30, 1356-1369.	1.2	40
330	The association between coffee consumption and bladder cancer in the bladder cancer epidemiology and nutritional determinants (BLEND) international pooled study. <i>Cancer Causes and Control</i> , 2019, 30, 859-870.	1.8	10
331	Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior. <i>RSC Advances</i> , 2019, 9, 17877-17884.	3.6	2

#	ARTICLE	IF	CITATIONS
332	Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 213-216.	1.0	4
333	Increased miR-23a induces bladder cancer cell apoptosis by suppressing c-Met. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 542-549.	1.9	7
334	Does the Use of a Robot Decrease the Complication Rate Adherent to Radical Cystectomy? A Systematic Review and Meta-Analysis of Studies Comparing Open with Robotic Counterparts. <i>Journal of Endourology</i> , 2019, 33, 971-984.	2.1	14
335	Nicotine-induced hypoxia in rat urothelium deteriorates bladder storage functions. <i>Neurourology and Urodynamics</i> , 2019, 38, 1560-1570.	1.5	4
336	Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target. <i>Molecular Oncology</i> , 2019, 13, 1898-1912.	4.6	28
337	Causes of death in long-term bladder cancer survivors: A population-based study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, e167-e174.	1.1	14
338	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 262-275.	3.8	3
339	Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 187-194.	2.3	22
340	Long noncoding RNAs in bladder cancer prognosis: A meta-analysis. <i>Pathology Research and Practice</i> , 2019, 215, 152429.	2.3	10
341	Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer. <i>Small</i> , 2019, 15, e1900936.	10.0	57
342	Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis. <i>Molecular Cancer</i> , 2019, 18, 95.	19.2	126
343	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	2.5	53
344	Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984123.	3.2	20
346	Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 740-751.	2.2	25
347	Organochlorine and organophosphorus pesticides and bladder cancer: A case-control study. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 14847-14859.	2.6	32
348	Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors. <i>European Radiology</i> , 2019, 29, 6182-6190.	4.5	59
349	A Simple Immunohistochemical Panel Could Predict and Correlate to Clinicopathologic and Molecular Subgroups of Urinary Bladder Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e712-e719.	1.9	10
350	Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e784-e792.	1.9	40

#	ARTICLE	IF	CITATIONS
351	Expression of miRâ€‘490â€‘5p, miRâ€‘148aâ€‘3p and miRâ€‘608 in bladder cancer and their effects on the biological characteristics of bladder cancer cells. <i>Oncology Letters</i> , 2019, 17, 4437-4442.	1.8	12
352	Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 492-502.	1.6	25
353	National trends in urinary diversion over the past 20â€‘%years: an Australian study. <i>ANZ Journal of Surgery</i> , 2019, 89, 925-929.	0.7	4
354	Is hysterectomy beneficial in radical cystectomy for female patient with urothelial carcinoma of bladder? A retrospective analysis of consecutive 112 cases from a single institution. <i>BMC Urology</i> , 2019, 19, 28.	1.4	8
355	Interaction Effects of Plasma Vitamins A, E, D, B9, and B12 and Tobacco Exposure in Urothelial Bladder Cancer: A Multifactor Dimensionality Reduction Analysis. <i>Nutrition and Cancer</i> , 2019, 71, 1382-1389.	2.0	4
356	<p>Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3043-3051.	1.9	18
357	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	2.0	17
358	Analysis of the role of mutations in the <sc>KMT</sc>2D histone lysine methyltransferase in bladder cancer. <i>FEBS Open Bio</i> , 2019, 9, 693-706.	2.3	19
359	Circular RNA DOCK1 promotes bladder carcinoma progression via modulating circDOCK1/hsaâ€‘miRâ€‘132â€‘3p/Sox5 signalling pathway. <i>Cell Proliferation</i> , 2019, 52, e12614.	5.3	69
360	Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Followâ€‘Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820.	4.7	27
361	Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer. <i>Urology</i> , 2019, 130, 93-98.	1.0	18
362	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	3.4	148
363	Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. <i>Clinical Chemistry</i> , 2019, 65, 927-936.	3.2	34
364	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA â€” update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	3.8	51
365	Hope and challenge: Precision medicine in bladder cancer. <i>Cancer Medicine</i> , 2019, 8, 1806-1816.	2.8	34
366	Mucopenetration and biocompatibility of polydopamine surfaces for delivery in an Ex Vivo porcine bladder. <i>Journal of Controlled Release</i> , 2019, 300, 161-173.	9.9	34
367	Process improvement strategy to prepare and administer bacillus Calmette-GuÃ©rin vaccine in compliance with United States Pharmacopeia chapter 800 standards. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 613-616.	1.0	0
368	The future burden of cancer in Canada: Long-term cancer incidence projections 2013â€‘2042. <i>Cancer Epidemiology</i> , 2019, 59, 199-207.	1.9	40

#	ARTICLE	IF	CITATIONS
369	Epidemiology, aetiology and screening of bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 5-11.	1.4	97
370	Association between five polymorphisms in vascular endothelial growth factor gene and urinary bladder cancer risk: A systematic review and meta-analysis involving 6671 subjects. <i>Gene</i> , 2019, 698, 186-197.	2.2	20
371	RAB14 activates MAPK signaling to promote bladder tumorigenesis. <i>Carcinogenesis</i> , 2019, 40, 1341-1351.	2.8	25
372	Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. <i>Carcinogenesis</i> , 2019, 40, 965-974.	2.8	14
373	Metallothionein 3 Is a Hypoxia-Upregulated Oncogene Enhancing Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 980.	4.1	18
374	Chlorophyllin-mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells. <i>Oncology Reports</i> , 2019, 41, 2181-2193.	2.6	16
375	The RING domain in the anti-apoptotic protein XIAP stabilizes c-Myc protein and preserves anchorage-independent growth of bladder cancer cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 5935-5944.	3.4	9
376	Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 743-750.	4.1	12
377	lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13487-13493.	2.6	92
378	Patients choose certainty over burden in bladder cancer surveillance. <i>World Journal of Urology</i> , 2019, 37, 2747-2753.	2.2	7
379	Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan. <i>International Journal of Urology</i> , 2019, 26, 649-654.	1.0	13
380	Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100124.	1.7	10
381	A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983305.	2.0	8
382	Prothymosin- α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer. <i>Cancer Science</i> , 2019, 110, 1208-1219.	3.9	14
383	miR-182-5p affects human bladder cancer cell proliferation, migration and invasion through regulating Cofilin 1. <i>Cancer Cell International</i> , 2019, 19, 42.	4.1	32
384	Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. <i>Journal of Medical Economics</i> , 2019, 22, 662-670.	2.1	28
385	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	4.1	47
386	An innovative nurse-led cystoscopy clinic in Denmark. <i>International Journal of Urological Nursing</i> , 2019, 13, 39-43.	0.2	3

#	ARTICLE	IF	CITATIONS
387	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. <i>European Radiology</i> , 2019, 29, 4286-4293.	4.5	48
388	Coffee and tea drinking and risk of cancer of the urinary tract in male smokers. <i>Annals of Epidemiology</i> , 2019, 34, 33-39.	1.9	14
389	Natural products: An upcoming therapeutic approach to cancer. <i>Food and Chemical Toxicology</i> , 2019, 128, 240-255.	3.6	189
390	Single-port Robotic Intracorporeal Ileal Conduit Urinary Diversion During Radical Cystectomy Using the SP Surgical System: Step-by-step Technique. <i>Urology</i> , 2019, 130, 196-200.	1.0	39
391	Management of metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2019, 76, 10-21.	7.7	190
392	Efficacy of China-made praziquantel for treatment of Schistosomiasis haematobium in Africa: A randomized controlled trial. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007238.	3.0	19
393	A spatial study of bladder cancer mortality and incidence in the contiguous US: 2000â€“2014. <i>Science of the Total Environment</i> , 2019, 670, 806-813.	8.0	7
394	YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo- and radio- resistance by suppressing caspase- mediated apoptosis. <i>Journal of Pathology</i> , 2019, 248, 476-487.	4.5	17
395	Association Between Preoperative Hydronephrosis and Prognosis After Radical Cystectomy Among Patients With Bladder Cancer: A Systemic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 158.	2.8	13
397	Microsatellite instability profiling in Egyptian bladder cancer patients: A pilot study. <i>Current Problems in Cancer</i> , 2019, 43, 100472.	2.0	7
398	Which treatment is best for patients with AJCC stage IV bladder cancer?. <i>International Urology and Nephrology</i> , 2019, 51, 1145-1156.	1.4	10
399	PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e618-e626.	1.9	14
400	Urologic Malignancies. <i>Primary Care - Clinics in Office Practice</i> , 2019, 46, 275-285.	1.6	7
401	Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2019, 37, 2067-2071.	2.2	15
402	Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. <i>Journal of Pathology</i> , 2019, 248, 230-242.	4.5	32
403	Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1076-1084.	6.1	43
404	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 76-84.	4.4	9
405	Global Patterns and Trends in Pancreatic Cancer Incidence. <i>Pancreas</i> , 2019, 48, 199-208.	1.1	39

#	ARTICLE	IF	CITATIONS
406	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Current Treatment Options in Oncology, 2019, 20, 12.	3.0	20
407	Integrated Fourier Transform Infrared Imaging and Proteomics for Identification of a Candidate Histochemical Biomarker in Bladder Cancer. American Journal of Pathology, 2019, 189, 619-631.	3.8	39
408	Assessment of the use of the Internet and social media among people with bladder cancer and their carers, and the quality of available patient-centric online resources: a systematic review. BJU International, 2019, 123, 10-18.	2.5	18
409	The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets. Journal of Cellular Physiology, 2019, 234, 15607-15618.	4.1	30
410	Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Molecular Cancer, 2019, 18, 27.	19.2	137
411	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. British Journal of Cancer, 2019, 120, 555-564.	6.4	23
412	CTHRC1 facilitates bladder cancer cell proliferation and invasion through regulating the PI3K/Akt signaling pathway. Archives of Medical Science, 2019, 18, 183-194.	0.9	2
413	Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients. BMJ Open, 2019, 9, e030850.	1.9	6
414	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 2019, 5, 263-272.	0.4	10
415	Trends in cancer incidence in Uruguay:2002 - 2015. Colombia Medica, 2019, 50, 224-238.	0.2	5
416	Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis. BMJ Open, 2019, 9, e028173.	1.9	15
417	Technical developments in transurethral resection of bladder tumours. Wspolczesna Onkologia, 2019, 23, 195-201.	1.4	2
418	<p><Resveratrol Reverses Cigarette Smoke-Induced Urocystic Epithelialâ€Mesenchymal Transition via Suppression of STAT3 Phosphorylation in SV-HUC-1-Immortalized Human Urothelial Cells</p><p><OncoTargets and Therapy, 2019, Volume 12, 10227-10237.	2.0	7
419	EAUâ€ESMO consensus statements on the management of advanced and variant bladder cancerâ€an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	1.2	96
420	En-bloc resection versus conventional transurethral resection for patients with non-muscle-invasive bladder cancer. The Cochrane Library, 2019, , .	2.8	0
421	Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Molecular Cancer Therapeutics, 2019, 18, 1947-1960.	4.1	29
422	The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer. Progres En Urologie, 2019, 29, 270-281.	0.8	12
423	The impact of age on intravesical instillation of Bacille Calmetteâ€Guerin treatment in patients with high-grade T1 bladder cancer. Medicine (United States), 2019, 98, e16223.	1.0	9

#	ARTICLE	IF	CITATIONS
424	Young Girl With Intermittent Hematuria. <i>Annals of Emergency Medicine</i> , 2019, 74, e21-e22.	0.6	1
425	Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1. <i>Molecular Cancer</i> , 2019, 18, 168.	19.2	122
426	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019, 19, 1133.	2.6	14
427	The bladder cancer patient survey: Global perspectives on awareness and treatment of bladder cancer. <i>Journal of Cancer Policy</i> , 2019, 22, 100207.	1.4	6
428	<p>Circular RNA circ-Foxo3 induced cell apoptosis in urothelial carcinoma via interaction with miR-191-5p. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8085-8094.	2.0	37
429	The interaction of gender and smoking on bladder cancer risks. <i>Current Opinion in Urology</i> , 2019, 29, 249-255.	1.8	25
430	Effect of Ostomy Care Team Intervention on Patients With Ileal Conduit. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2019, 46, 413-417.	1.0	17
431	Skeletal Muscle Metastasis to Vastus Lateralis from a Urothelial Carcinoma: A Case Report and Review of Its Diagnosis and Management. <i>Case Reports in Urology</i> , 2019, 2019, 1-4.	0.3	1
432	LncRNAs act as prognostic biomarkers in bladder carcinoma: A meta-analysis. <i>Heliyon</i> , 2019, 5, e02785.	3.2	4
433	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	3.7	59
434	Bladder cancer survival nomogram. <i>Medicine (United States)</i> , 2019, 98, e17725.	1.0	29
435	Rapid testicular metastasis from bladder transitional urothelial carcinoma after radical cystoprostatectomy. <i>Medicine (United States)</i> , 2019, 98, e18000.	1.0	2
436	Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 251-256.	4.3	9
437	<p>miR-204 Negatively Regulates Cell Growth And Metastasis By Targeting ROBO4 In Human Bladder Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8515-8524.	2.0	8
438	Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System. <i>Frontiers in Oncology</i> , 2019, 9, 1402.	2.8	3
439	The molecular limitations of biomarker research in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 837-848.	2.2	31
440	Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors. <i>ACS Nano</i> , 2019, 13, 429-439.	14.6	182
441	Knockdown of lncRNA SNHG7 inhibited cell proliferation and migration in bladder cancer through activating Wnt/ β -catenin pathway. <i>Pathology Research and Practice</i> , 2019, 215, 302-307.	2.3	31

#	ARTICLE	IF	CITATIONS
442	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 372-379.	1.6	24
443	Strategies for managing multi-patient 3D mass spectrometry imaging data. <i>Journal of Proteomics</i> , 2019, 193, 184-191.	2.4	19
444	MMPâ€2 and MMPâ€9 as prognostic markers for the early detection of urinary bladder cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22275.	3.0	23
445	Molecular profiling in muscleâ€invasive bladder cancer: more than the sum of its parts. <i>Journal of Pathology</i> , 2019, 247, 563-573.	4.5	63
446	Inhibition of stearoyl CoA desaturaseâ€1 activity suppresses tumour progression and improves prognosis in human bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2064-2076.	3.6	42
447	The relationship between microRNAs and Rab family GTPases in human cancers. <i>Journal of Cellular Physiology</i> , 2019, 234, 12341-12352.	4.1	10
448	Impact of endothelial nitric oxide synthase polymorphisms on urothelial cell carcinoma development. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 293.e1-293.e9.	1.6	7
449	High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 293.e11-293.e24.	1.6	21
450	MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer. <i>Cancer Biomarkers</i> , 2019, 24, 159-172.	1.7	52
451	Molecular characterization of low grade and high grade bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0210635.	2.5	17
452	Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 297.	4.1	33
453	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019, 125, 533-540.	4.1	38
454	The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 291.e1-291.e7.	1.6	3
455	Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. <i>BMC Cancer</i> , 2019, 19, 46.	2.6	52
456	Anterior versus posterior approach laparoscopic radical cystectomy: a retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 9.	1.9	4
457	Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian metaâ€analysis. <i>International Journal of Urology</i> , 2019, 26, 102-112.	1.0	18
458	Sonic Hedgehog Expression is Associated with Lymph Node Invasion in Urothelial Bladder Cancer. <i>Pathology and Oncology Research</i> , 2019, 25, 1067-1073.	1.9	11
459	Melatoninâ€mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKTâ€MMPâ€9 signaling pathway. <i>Journal of Pineal Research</i> , 2019, 66, e12536.	7.4	41

#	ARTICLE	IF	CITATIONS
460	MicroRNA-133b suppresses bladder cancer malignancy by targeting TAGLN-mediated cell cycle. Journal of Cellular Physiology, 2019, 234, 4910-4923.	4.1	33
461	Chromatin-regulatory genes served as potential therapeutic targets for patients with urothelial bladder carcinoma. Journal of Cellular Physiology, 2019, 234, 6976-6982.	4.1	7
462	RSPO3 promotes the aggressiveness of bladder cancer via Wnt/ β 2-catenin and Hedgehog signaling pathways. Carcinogenesis, 2019, 40, 360-369.	2.8	20
463	Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. Journal of Cellular Biochemistry, 2019, 120, 9956-9963.	2.6	10
464	LncRNA OIP5-AS1 predicts poor prognosis and regulates cell proliferation and apoptosis in bladder cancer. Journal of Cellular Biochemistry, 2019, 120, 7499-7505.	2.6	36
465	Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. Journal of Cellular Biochemistry, 2019, 120, 6347-6360.	2.6	11
466	3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF- κ B pathway inhibition. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3822-3837.	3.5	10
467	Quantitative Identification of Nonmuscle-Invasive and Muscle-Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis. Journal of Magnetic Resonance Imaging, 2019, 49, 1489-1498.	3.4	71
469	Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. European Urology Focus, 2019, 5, 650-657.	3.1	38
470	Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer. European Journal of Cancer Prevention, 2019, 28, 40-44.	1.3	3
471	Pyelonephritis in persons after age 50 as a clinical marker of urogenital cancer. Clinical Microbiology and Infection, 2019, 25, 87-91.	6.0	3
472	Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 380-386.	1.6	26
473	Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness. European Urology Focus, 2020, 6, 1180-1187.	3.1	14
474	The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer Gene Therapy, 2020, 27, 189-202.	4.6	21
475	An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies. European Journal of Nutrition, 2020, 59, 287-296.	3.9	38
476	Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. European Urology Focus, 2020, 6, 683-697.	3.1	10
477	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. European Urology Oncology, 2020, 3, 663-670.	5.4	10
478	Intake of milk and other dairy products and the risk of bladder cancer: a pooled analysis of 13 cohort studies. European Journal of Clinical Nutrition, 2020, 74, 28-35.	2.9	16

#	ARTICLE	IF	CITATIONS
479	Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging. <i>European Urology</i> , 2020, 77, 727-732.	1.9	20
480	Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis. <i>Pathology and Oncology Research</i> , 2020, 26, 1063-1072.	1.9	9
481	The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 127-129.	3.1	2
482	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	5.4	41
483	RNA-Binding Protein <i>ZFP36L1</i> Suppresses Hypoxia and Cell-Cycle Signaling. <i>Cancer Research</i> , 2020, 80, 219-233.	0.9	40
484	PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 211-220.	4.1	32
485	Tobacco smoking and death from prostate cancer in US veterans. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 252-259.	3.9	13
486	Bladder tissue characterization using probe-based Raman spectroscopy: Evaluation of tissue heterogeneity and influence on the model prediction. <i>Journal of Biophotonics</i> , 2020, 13, e201960025.	2.3	23
487	Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging. <i>European Urology</i> , 2020, 77, 251-259.	1.9	28
488	Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?. <i>World Journal of Urology</i> , 2020, 38, 1187-1193.	2.2	5
489	Neoplasms of the Urinary Bladder. , 2020, , 230-321.e19.		3
490	STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. <i>Pathology and Oncology Research</i> , 2020, 26, 1243-1249.	1.9	10
491	Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated G_{12} protein/MAPK/MMP9 intracellular signaling. <i>Oncogene</i> , 2020, 39, 574-586.	5.9	27
492	Implementation of enhanced recovery after surgery in patients undergoing radical cystectomy: A retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 202-208.	1.0	22
493	The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23049.	2.1	58
494	Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. <i>Oncogene</i> , 2020, 39, 1696-1709.	5.9	88
495	Update on the guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 197-205.	2.5	63
496	Cancer mortality predictions for 2019 in Latin America. <i>International Journal of Cancer</i> , 2020, 147, 619-632.	5.1	36

#	ARTICLE	IF	CITATIONS
497	MicroRNA-769-5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer. Journal of Clinical Laboratory Analysis, 2020, 34, e23193.	2.1	15
498	Targeted multifunctional nanomaterials with MRI, chemotherapy and photothermal therapy for the diagnosis and treatment of bladder cancer. Biomaterials Science, 2020, 8, 342-352.	5.4	33
499	Recent cancer incidence trends in Ukraine and short-term predictions to 2022. Cancer Epidemiology, 2020, 65, 101663.	1.9	21
500	Exosomal miR-663b targets Ets2 repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells. Cell Biology International, 2020, 44, 958-965.	3.0	20
501	Dietary fiber intake and the risk of bladder cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort. Carcinogenesis, 2020, 41, 478-482.	2.8	11
502	Microbe-MUC1 Crosstalk in Cancer-Associated Infections. Trends in Molecular Medicine, 2020, 26, 324-336.	6.7	24
503	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathology Research and Practice, 2020, 216, 152663.	2.3	1
504	Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer. American Journal of Clinical Pathology, 2020, 153, 274-284.	0.7	4
505	The Cost to Medicare of Bladder Cancer Care. European Urology Oncology, 2020, 3, 515-522.	5.4	48
506	Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. Clinical Genitourinary Cancer, 2020, 18, 162-170.e4.	1.9	12
507	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer, 2020, 20, 8.	2.6	19
508	Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score. European Urology Focus, 2020, 6, 458-462.	3.1	15
509	Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer. Journal of Cancer, 2020, 11, 1082-1093.	2.5	13
510	Appendix 1: The academic literature used. , 2020, , 109-115.		0
511	Occupational disparities in bladder cancer survival: A population-based cancer registry study in Japan. Cancer Medicine, 2020, 9, 894-901.	2.8	11
512	En bloc resection for nonmuscle invasive bladder cancer. Current Opinion in Urology, 2020, 30, 41-47.	1.8	40
513	Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 1804-1821.	3.6	21
514	Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 39.e11-39.e19.	1.6	5

#	ARTICLE	IF	CITATIONS
515	Low-resolution fiber-optic Raman spectroscopy for bladder cancer diagnosis: A comparison study of varying laser power, integration time, and classification methods. <i>Journal of Raman Spectroscopy</i> , 2020, 51, 323-334.	2.5	11
516	Nuclear Factor κ B Signaling and Its Related Non-coding RNAs in Cancer Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 208-217.	5.1	30
517	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
518	Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis. <i>Oncogene</i> , 2020, 39, 1983-1996.	5.9	38
519	Arsenic exposure: A public health problem leading to several cancers. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 110, 104539.	2.7	246
520	Silencing of miR-152 contributes to DNMT1-mediated CpG methylation of the PTEN promoter in bladder cancer. <i>Life Sciences</i> , 2020, 261, 118311.	4.3	12
521	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	1.6	7
522	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. <i>Cancers</i> , 2020, 12, 2882.	3.7	13
523	<p>STAT3-Induced Upregulation of lncRNA CASC9 Promotes the Progression of Bladder Cancer by Interacting with EZH2 and Affecting the Expression of PTEN<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9147-9157.	2.0	7
524	Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1643.	2.8	4
525	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020, 78, 893-906.	1.9	112
526	Nested Variant Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2020, 144, 9-12.	1.0	2
527	Herbal and Natural Dietary Products: Upcoming Therapeutic Approach for Prevention and Treatment of Hepatocellular Carcinoma. <i>Nutrition and Cancer</i> , 2021, 73, 2130-2154.	2.0	19
528	Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. <i>BMC Urology</i> , 2020, 20, 158.	1.4	34
529	Prognostic Role of Circular RNAs Expression in Bladder Carcinoma: A Meta-Analysis. <i>Genetic Testing and Molecular Biomarkers</i> , 2020, 24, 692-700.	0.7	10
530	Continent diversion: five decades of developments and evolution. <i>BJU International</i> , 2020, 126, 653-660.	2.5	2
531	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. <i>PLoS ONE</i> , 2020, 15, e0239338.	2.5	14
532	Puerarin Inhibits the Progression of Bladder Cancer by Regulating circ_0020394/miR-328-3p/NRBP1 Axis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 435-450.	1.0	10

#	ARTICLE	IF	CITATIONS
533	Bioinformatic Identification of Potential Hub Genes in Muscle-Invasive Bladder Urothelial Carcinoma. Cell Transplantation, 2020, 29, 096368972096517.	2.5	2
534	<p>Predictive Values of Preoperative Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Long-Term Survival in High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Single-Centre Retrospective Study</p>. Cancer Management and Research, 2020, Volume 12, 9471-9483.	1.9	24
535	Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies. Frontiers in Oncology, 2020, 10, 1774.	2.8	8
536	Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nature Communications, 2020, 11, 5077.	12.8	281
537	Efficacy of intravesical therapies on the prevention of recurrence and progression of nonâ€muscleâ€invasive bladder cancer: A systematic review and network metaâ€analysis. Cancer Medicine, 2020, 9, 7800-7809.	2.8	30
538	Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity. Journal of Cancer, 2020, 11, 6633-6641.	2.5	8
539	Air pollution exposure and bladder, kidney and urinary tract cancer risk: A systematic review. Environmental Pollution, 2020, 267, 115328.	7.5	56
540	Recent advances and possibilities for the use of plant phenolic compounds to manage ageing-related diseases. Journal of Functional Foods, 2020, 75, 104203.	3.4	39
541	Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: Chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway. Genomics, 2020, 112, 5055-5065.	2.9	13
542	Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. Scientific Reports, 2020, 10, 16145.	3.3	5
543	Non-muscle invasive bladder cancer tissues have increased base excision repair capacity. Scientific Reports, 2020, 10, 16371.	3.3	10
544	Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urology, 2020, 20, 97.	1.4	20
545	BORA regulates cell proliferation and migration in bladder cancer. Cancer Cell International, 2020, 20, 290.	4.1	1
546	Short- and Long-Term Evaluation of Renal Function after Radical Cystectomy and Cutaneous Ureterostomy in High-Risk Patients. Journal of Clinical Medicine, 2020, 9, 2191.	2.4	9
547	Partitioning of time trends in prevalence and mortality of bladder cancer in the United States. Annals of Epidemiology, 2020, 47, 25-29.	1.9	7
548	Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model. Cancer Letters, 2020, 490, 89-99.	7.2	21
549	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	4.1	18
550	Bladder cancer incidence rates and trends in young adults aged 20-39 years. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 934.e11-934.e19.	1.6	5

#	ARTICLE	IF	CITATIONS
551	Upregulation of lncRNA plasmacytoma variant translocation 1 predicts poor prognosis in patients with muscle-invasive bladder cancer. <i>Medicine (United States)</i> , 2020, 99, e21059.	1.0	5
552	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2020, 8, 1-5.	3.7	9
553	Transurethral needle electrode resection and transurethral holmium laser resection of bladder cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 166.	1.9	4
554	CFlm25 in Solid Tumors: Current Research Progress. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382093396.	1.9	2
555	Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/ β -catenin signaling pathway in bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 136.	8.6	31
556	Enhanced recovery after surgery (ERAS) in patients treated with radical cystectomy. <i>AME Medical Journal</i> , 2020, 5, 3-3.	0.4	1
557	Bladder cancer-related microbiota: examining differences in urine and tissue samples. <i>Scientific Reports</i> , 2020, 10, 11042.	3.3	67
558	EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF- κ B/MDM2/p53 Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 606123.	3.7	17
559	Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 538.	4.1	5
560	DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. <i>Cell Death and Disease</i> , 2020, 11, 986.	6.3	22
561	Short-term mortality risks among patients with non-metastatic bladder cancer. <i>BMC Cancer</i> , 2020, 20, 1148.	2.6	10
562	lncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis. <i>Pathobiology</i> , 2020, 87, 345-355.	3.8	16
563	Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder. <i>Translational Cancer Research</i> , 2020, 9, 5155-5165.	1.0	1
564	Identification of Sex Differences in Tumor-Specific T Cell Infiltration in Bladder Tumor-Bearing Mice Treated with BCG Immunotherapy. <i>Bladder Cancer</i> , 2020, 6, 507-524.	0.4	3
565	CTLA-4 +49A/G Polymorphism Increases the Susceptibility to Bladder Cancer in Chinese Han Participants: A Case-Control Study. <i>Disease Markers</i> , 2020, 2020, 1-5.	1.3	7
566	Identification of grade-related genes and construction of a robust genomic-clinicopathologic nomogram for predicting recurrence of bladder cancer. <i>Medicine (United States)</i> , 2020, 99, e23179.	1.0	4
567	A Multiscale Approach for Whole-Slide Image Segmentation of five Tissue Classes in Urothelial Carcinoma Slides. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094678.	1.9	19
568	Radical cystectomy—what is the optimal surgical approach?. <i>Translational Andrology and Urology</i> , 2020, 9, 2308-2312.	1.4	4

#	ARTICLE	IF	CITATIONS
569	Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 549338.	3.5	5
570	Identification of immune-related genes as prognostic factors in bladder cancer. <i>Scientific Reports</i> , 2020, 10, 19695.	3.3	15
571	Progress in cancer mortality, incidence, and survival: a global overview. <i>European Journal of Cancer Prevention</i> , 2020, 29, 367-381.	1.3	113
572	Bioinformatic identification of prognostic indicators in bladder cancer. <i>Biomarkers in Medicine</i> , 2020, 14, 1243-1254.	1.4	7
573	Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer via Inactivating the β -Catenin Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 1332.	2.8	9
574	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 755-763.	2.4	14
575	Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. <i>Journal of Translational Medicine</i> , 2020, 18, 303.	4.4	11
576	Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 1252-1266.	4.7	21
577	miR-21 inhibits autophagy and promotes malignant development in the bladder cancer T24 cell line. <i>International Journal of Oncology</i> , 2020, 56, 986-998.	3.3	10
578	Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer. <i>International Journal of Biological Markers</i> , 2020, 35, 59-66.	1.8	8
579	Urinary exfoliated tumor single-cell metabolomics technology for establishing a drug resistance monitoring system for bladder cancer with intravesical chemotherapy. <i>Medical Hypotheses</i> , 2020, 143, 110100.	1.5	5
580	Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106818.	3.8	10
581	Isoflurane promotes epithelial-to-mesenchymal transition and metastasis of bladder cancer cells through HIF-1 α - β -catenin/Notch1 pathways. <i>Life Sciences</i> , 2020, 258, 118154.	4.3	20
582	An overview on precision therapy in bladder cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 347-361.	0.7	0
583	Smoking and bladder cancer: review of the recent literature. <i>Current Opinion in Urology</i> , 2020, 30, 720-725.	1.8	17
584	Long-term trends in sex difference in bladder cancer survival 1975-2009: A population-based study in Osaka, Japan. <i>Cancer Medicine</i> , 2020, 9, 7330-7340.	2.8	4
585	Development and Validation of a Nomogram to Predict Lymph Node Metastasis in Patients With T1 High-Grade Urothelial Carcinoma of the Bladder. <i>Frontiers in Oncology</i> , 2020, 10, 532924.	2.8	5
586	The role of surgery on the primary tumor site in bladder cancer with distant metastasis: significance of histology type and metastatic pattern. <i>Cancer Medicine</i> , 2020, 9, 9293-9302.	2.8	15

#	ARTICLE	IF	CITATIONS
587	C1QTNF6 Overexpression Acts as a Predictor of Poor Prognosis in Bladder Cancer Patients. BioMed Research International, 2020, 2020, 1-11.	1.9	3
588	Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. Stem Cell Research and Therapy, 2020, 11, 457.	5.5	12
589	Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression. International Journal of Molecular Sciences, 2020, 21, 7726.	4.1	3
590	Gel-Based Nanocarrier for Intravesical Chemotherapy Delivery: In Vitro and In Vivo Study. Pharmaceuticals, 2020, 13, 329.	3.8	2
591	Roles of N ⁶ -methyladenosine (m ⁶ A) RNA modifications in urological cancers. Journal of Cellular and Molecular Medicine, 2020, 24, 10302-10310.	3.6	10
592	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.9	49
593	16-Hydroxycyclohexa-3,13-Dien-15,16-Epoxide Induces Apoptosis in Human Bladder Cancer Cells through Cell Cycle Arrest, Mitochondria ROS Overproduction, and Inactivation of EGFR-Related Signalling Pathways. Molecules, 2020, 25, 3958.	3.8	9
594	Is It Safe to Offer Radical Cystectomy to Patients above 85 Years of Age? A Long-Term Follow-Up in a Single-Center Institution. Urologia Internationalis, 2020, 104, 975-981.	1.3	8
595	Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer. Journal of Nanobiotechnology, 2020, 18, 124.	9.1	23
596	Gallic Acid Inhibits Bladder Cancer T24 Cell Progression Through Mitochondrial Dysfunction and PI3K/Akt/NF- κ B Signaling Suppression. Frontiers in Pharmacology, 2020, 11, 1222.	3.5	28
597	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nature Communications, 2020, 11, 4858.	12.8	124
598	TRPM8 Inhibition Regulates the Proliferation, Migration and ROS Metabolism of Bladder Cancer Cells. OncoTargets and Therapy, 2020, Volume 13, 8825-8835.	2.0	11
599	lncRNA OTUD6B-AS1 Exacerbates As ² O ³ -Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-22.	4.0	9
600	Development and Validation of a Model for Predicting Urethral Recurrence in Male Patients with Muscular Invasive Bladder Cancer After Radical Cystectomy Combined with Urinary Diversion. Cancer Management and Research, 2020, Volume 12, 7649-7657.	1.9	5
601	Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 6034.	4.1	17
602	Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Medicine, 2020, 9, 7729-7741.	2.8	35
603	Mutational Landscape and Environmental Effects in Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 6072.	4.1	30
604	Serum LUCAT1 implicates the pathogenesis of muscle-invasive bladder cancer via targeting miR-199a-5p and miR-199b-5p. Journal of Molecular Histology, 2020, 51, 583-591.	2.2	3

#	ARTICLE	IF	CITATIONS
605	Knockdown of lncRNA ZNRD1a inhibits progression of bladder cancer by regulating miR-194 and ZEB1. Cancer Medicine, 2020, 9, 7695-7705.	2.8	13
606	ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. Frontiers in Genetics, 2020, 11, 933.	2.3	32
607	Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5 ⁺ CD8 ⁺ T cell abundance. OncoImmunology, 2020, 9, 1810489.	4.6	7
609	Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells. Anticancer Research, 2020, 40, 5221-5227.	1.1	9
610	Efficacy and safety of Bacillus Calmette-Guerin for bladder cancer. Medicine (United States), 2020, 99, e21930.	1.0	5
611	1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression. BMC Cancer, 2020, 20, 869.	2.6	9
612	UBAC2 promotes bladder cancer proliferation through BCRC-3/miRNA-182-5p/p27 axis. Cell Death and Disease, 2020, 11, 733.	6.3	11
613	Role of tyrosine kinases in bladder cancer progression: an overview. Cell Communication and Signaling, 2020, 18, 127.	6.5	19
614	Intratumoral TIGIT ⁺ CD8 ⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
615	Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. Cell Death and Disease, 2020, 11, 1038.	6.3	25
616	The invasion depth measurement of bladder cancer using T2-weighted magnetic resonance imaging. BioMedical Engineering OnLine, 2020, 19, 92.	2.7	7
617	Profiling Analysis Reveals the Crucial Role of the Endogenous Peptides in Bladder Cancer Progression. OncoTargets and Therapy, 2020, Volume 13, 12443-12455.	2.0	1
618	Super-Enhancer lncRNA LINC00162 Promotes Progression of Bladder Cancer. IScience, 2020, 23, 101857.	4.1	13
619	The circ_0004463/miR-380-3p/FOXO1 axis modulates mitochondrial respiration and bladder cancer cell apoptosis. Cell Cycle, 2020, 19, 3563-3580.	2.6	12
621	Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer. Cancer Cell International, 2020, 20, 560.	4.1	39
622	tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5â€²-tRF-LysCTT Results in Disease Early Progression and Patientsâ€™ Poor Treatment Outcome. Cancers, 2020, 12, 3661.	3.7	31
623	MAP30 Inhibits Bladder Cancer Cell Migration and Invasion <i>In Vitro</i> Through Suppressing Akt Pathway and the Epithelial/Mesenchymal Transition Process. DNA and Cell Biology, 2020, 39, 1948-1960.	1.9	8
624	A novel prognostic biomarker for muscle invasive bladder urothelial carcinoma based on 11 DNA methylation signature. Cancer Biology and Therapy, 2020, 21, 1119-1127.	3.4	3

#	ARTICLE	IF	CITATIONS
625	Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions. <i>Applied Sciences</i> (Switzerland), 2020, 10, 7102.	2.5	5
626	Inguinal lymph node metastasis of bladder carcinoma after radical cystectomy: A case report and review of literature. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 385-389.	0.6	2
627	Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 1-8.	0.4	3
628	Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer. <i>DNA and Cell Biology</i> , 2020, 39, 1072-1089.	1.9	6
629	Investigation of Leptin G19A polymorphism with bladder cancer risk: A caseâ€control study. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23351.	2.1	6
630	Putting the Brakes on Tumorigenesis with Natural Products of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Cancer Treatment. <i>Cells</i> , 2020, 9, 1213.	4.1	17
631	Effects of different chemical groups on behaviors of bladder cancer cells. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 2484-2490.	4.0	2
632	Prognostic significance of red cell distribution width in bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 295-302.	1.4	14
633	Temporal trends of kidney cancer incidence and mortality from 1990 to 2016 and projections to 2030. <i>Translational Andrology and Urology</i> , 2020, 9, 166-181.	1.4	21
634	Temporal trends of bladder cancer incidence and mortality from 1990 to 2016 and projections to 2030. <i>Translational Andrology and Urology</i> , 2020, 9, 153-165.	1.4	18
635	Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 607.	2.3	24
636	CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. <i>Cancers</i> , 2020, 12, 1253.	3.7	21
637	Characterization of <i>PHGDH</i> expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. <i>Molecular Oncology</i> , 2020, 14, 2190-2202.	4.6	17
638	Hsa_circ_0068307 mediates bladder cancer stem cell-like properties via miR-147/c-Myc axis regulation. <i>Cancer Cell International</i> , 2020, 20, 151.	4.1	20
639	A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 1304.	3.7	15
640	Early life body size and its associations with adult bladder cancer. <i>Annals of Human Biology</i> , 2020, 47, 166-172.	1.0	4
641	Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3360.	4.1	12
642	Targeted uptake of folic acid-functionalized polymeric nanoparticles loading glycoalkaloidic extract in vitro and in vivo assays. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 192, 111106.	5.0	26

#	ARTICLE	IF	CITATIONS
643	PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?. European Journal of Pharmacology, 2020, 881, 173226.	3.5	44
644	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1459-1474.	2.2	25
645	Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis. Journal of Experimental and Clinical Cancer Research, 2020, 39, 94.	8.6	36
646	Circular RNA circKIF4A Sponges miR-375/1231 to Promote Bladder Cancer Progression by Upregulating NOTCH2 Expression. Frontiers in Pharmacology, 2020, 11, 605.	3.5	24
647	Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers, 2020, 12, 1507.	3.7	33
648	lncRNA MORT Regulates Bladder Cancer Behaviors by Downregulating MicroRNA-146a-5p. Nephron, 2020, 144, 351-357.	1.8	7
649	microRNA-324 plays an oncogenic role in bladder cancer cell growth and motility. Translational Cancer Research, 2020, 9, 707-716.	1.0	5
650	CASC9 Facilitates Cell Proliferation in Bladder Cancer by Regulating CBX2 Expression. Nephron, 2020, 144, 388-399.	1.8	11
651	Adherence to a Western dietary pattern and risk of bladder cancer: A pooled analysis of 13 cohort studies of the Bladder Cancer Epidemiology and Nutritional Determinants international study. International Journal of Cancer, 2020, 147, 3394-3403.	5.1	19
652	<p>The Biogenesis, Functions, and Roles of circRNAs in Bladder Cancer</p>. Cancer Management and Research, 2020, Volume 12, 3673-3689.	1.9	9
653	Probing the recognition specificity of $\alpha_5\beta_2$ integrin and syndecan-4 using force spectroscopy. Micron, 2020, 137, 102888.	2.2	4
654	Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. Cancers, 2020, 12, 1400.	3.7	42
655	Signet-Ring Cell Carcinoma as an Independent Prognostic Factor for Patients With Urinary Bladder Cancer: A Population-Based Study. Frontiers in Oncology, 2020, 10, 653.	2.8	10
656	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers, 2020, 12, 1449.	3.7	72
657	<p>Overexpression of GAS6 Promotes Cell Proliferation and Invasion in Bladder Cancer by Activation of the PI3K/AKT Pathway</p>. OncoTargets and Therapy, 2020, Volume 13, 4813-4824.	2.0	25
658	Effects of Arsenic (+3 Oxidation State) Methyltransferase Gene Polymorphisms and Expression on Bladder Cancer: Evidence from a Systematic Review, Meta-analysis and TCGA Dataset. Toxicological Sciences, 2020, 177, 27-40.	3.1	5
659	Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomedicine and Pharmacotherapy, 2020, 129, 110393.	5.6	98
660	Preoperative frailty and outcome in patients undergoing radical cystectomy. BJU International, 2020, 126, 388-395.	2.5	17

#	ARTICLE	IF	CITATIONS
661	Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis. <i>Cancer Medicine</i> , 2020, 9, 4897-4906.	2.8	11
662	DNA methylation-based classification and identification of bladder cancer prognosis-associated subgroups. <i>Cancer Cell International</i> , 2020, 20, 255.	4.1	14
663	<p><p>LncRNA NCK1-AS1 Promotes Cancer Cell Proliferation and Increase Cell Stemness in Urinary Bladder Cancer Patients by Downregulating miR-143</p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1661-1668.	1.9	19
664	LINC00319-Mediated miR-3127 Repression Enhances Bladder Cancer Progression Through Upregulation of RAP2A. <i>Frontiers in Genetics</i> , 2020, 11, 180.	2.3	11
665	MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI. <i>Frontiers in Pharmacology</i> , 2020, 11, 164.	3.5	16
666	The association between type 2 diabetes mellitus and bladder cancer risk among postmenopausal women. <i>Cancer Causes and Control</i> , 2020, 31, 503-510.	1.8	5
667	Current updates on the role of reactive oxygen species in bladder cancer pathogenesis and therapeutics. <i>Clinical and Translational Oncology</i> , 2020, 22, 1687-1697.	2.4	15
668	Bladder, penile, renal pelvis and testis cancers: A population based analysis of incidence and survival 1977-2013. <i>Cancer Epidemiology</i> , 2020, 65, 101692.	1.9	7
669	Bladder-sparing treatment options in localized muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 179-188.	2.4	8
670	Mycobacterium bovis infection of a femorofemoral bypass graft following intravesical Bacillus Calmetteâ€GuÃ©rin (BCG) immunotherapy. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020, 19, 100152.	1.3	4
671	Circular RNA CIRC_HIPK3 Promotes Gemcitabine Sensitivity in Bladder Cancer. <i>Journal of Cancer</i> , 2020, 11, 1907-1912.	2.5	30
672	Design of high stability thin-film transistor biosensor for the diagnosis of bladder cancer. <i>Chinese Chemical Letters</i> , 2020, 31, 1387-1391.	9.0	26
673	CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation. <i>Journal of Cancer</i> , 2020, 11, 2408-2420.	2.5	30
674	A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110059.	5.6	17
675	SNHG16 regulates invasion and migration of bladder cancer through induction of epithelial-to-mesenchymal transition. <i>Human Cell</i> , 2020, 33, 737-749.	2.7	21
676	Evaluation of autofluorescence and photodynamic diagnosis in assessment of bladder lesions. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 30, 101719.	2.6	2
677	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€C vs surgical management in lowâ€risk nonâ€muscleâ€invasive bladder cancer. <i>BJU International</i> , 2020, 125, 817-826.	2.5	27
678	Simultaneously Quantifying Both Youngâ€™s Modulus and Specific Membrane Capacitance of Bladder Cancer Cells with Different Metastatic Potential. <i>Micromachines</i> , 2020, 11, 249.	2.9	3

#	ARTICLE	IF	CITATIONS
679	HDMAC: A Web-Based Interactive Program for High-Dimensional Analysis of Molecular Alterations in Cancer. <i>Scientific Reports</i> , 2020, 10, 3953.	3.3	3
680	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 863-870.	1.8	7
681	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , 2020, 21, 8-12.	1.1	6
682	Influence of natural convection on gold nanorods-assisted photothermal treatment of bladder cancer in mice. <i>International Journal of Hyperthermia</i> , 2020, 37, 634-650.	2.5	6
683	Comparing Perioperative Complications Between Laparoscopic and Robotic Radical Cystectomy for Bladder Cancer. <i>Journal of Endourology</i> , 2020, 34, 1033-1040.	2.1	9
684	CT-based radiomics to predict the pathological grade of bladder cancer. <i>European Radiology</i> , 2020, 30, 6749-6756.	4.5	42
686	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392.	0.4	1
687	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. <i>Bladder Cancer</i> , 2020, 6, 201-210.	0.4	10
688	Tumor Cell Dissociation Removes Malignant Bladder Tumors. <i>CheM</i> , 2020, 6, 2283-2299.	11.7	33
689	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 774-782.	1.6	26
690	N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: An updated meta-analysis based on 54 case-control studies. <i>Gene</i> , 2020, 757, 144924.	2.2	11
691	Metastatic retro-crural lymph nodes from transitional cell carcinoma of bladder successfully treated with single session cryoablation. <i>Radiology Case Reports</i> , 2020, 15, 1197-1201.	0.6	3
692	Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1. <i>Cancer Medicine</i> , 2020, 9, 6009-6019.	2.8	32
693	Identification of a potentially functional circRNA-miRNA-mRNA regulatory network for investigating pathogenesis and providing possible biomarkers of bladder cancer. <i>Cancer Cell International</i> , 2020, 20, 31.	4.1	15
694	Targeting the Immune system and Epigenetic Landscape of Urological Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 829.	4.1	15
695	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. <i>Frontiers in Oncology</i> , 2019, 9, 1493.	2.8	51
696	An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC). <i>Cancer Medicine</i> , 2020, 9, 2774-2790.	2.8	63
697	A Multiplex Test Assessing MiR663 and VIM in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. <i>Journal of Clinical Medicine</i> , 2020, 9, 605.	2.4	7

#	ARTICLE	IF	CITATIONS
698	Biological and Clinical Significance of GATA3 Detected from TCGA Database and FFPE Sample in Bladder Cancer Patients. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 945-958.	2.0	12
699	Impact of age on bladder cancer management practices: a general population study. <i>Acta Oncologica</i> , 2020, 59, 462-466.	1.8	4
700	SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer. <i>IUBMB Life</i> , 2020, 72, 1175-1188.	3.4	11
701	Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020, 80, 1707-1719.	0.9	61
702	Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 590-598.	1.6	30
703	Androgen receptor-regulated circ FNTA activates KRAS signaling to promote bladder cancer invasion. <i>EMBO Reports</i> , 2020, 21, e48467.	4.5	60
704	Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer. <i>International Journal of Medical Sciences</i> , 2020, 17, 89-96.	2.5	37
705	Hyperthermic therapy using warm sterile water enhances cytotoxic effects on bladder cancer cells. <i>Scandinavian Journal of Urology</i> , 2020, 54, 65-69.	1.0	2
706	Trihalomethanes in Drinking Water and Bladder Cancer Burden in the European Union. <i>Environmental Health Perspectives</i> , 2020, 128, 17001.	6.0	101
707	Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection. <i>World Journal of Urology</i> , 2020, 38, 2849-2856.	2.2	1
708	Circular RNA FAM114A2 suppresses progression of bladder cancer via regulating miR-762. <i>Cell Death and Disease</i> , 2020, 11, 47.	6.3	34
709	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses' Health Study and Nurses' Health Study II. <i>International Journal of Epidemiology</i> , 2020, 49, 599-607.	1.9	10
710	Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics. <i>Frontiers in Oncology</i> , 2019, 9, 1533.	2.8	53
711	New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer. <i>Materials Science and Engineering C</i> , 2020, 110, 110662.	7.3	27
712	Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data. <i>BioMed Research International</i> , 2020, 2020, 1-20.	1.9	32
713	Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. <i>Cells</i> , 2020, 9, 291.	4.1	18
714	The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). <i>International Journal of Surgery</i> , 2020, 75, 130-138.	2.7	37
715	Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. <i>Scientific Reports</i> , 2020, 10, 1292.	3.3	35

#	ARTICLE	IF	CITATIONS
716	The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 212-221.	0.8	22
717	The Effectiveness of Psychological Treatments in Women with Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 209.	2.4	42
718	Sodium butyrate inhibits migration and induces AMPK-dependent autophagy and ROS-mediated apoptosis via the miR-139a/Bmi-1 axis in human bladder cancer cells. <i>FASEB Journal</i> , 2020, 34, 4266-4282.	0.5	70
719	Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. <i>Cells</i> , 2020, 9, 235.	4.1	49
720	Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. <i>European Journal of Epidemiology</i> , 2020, 35, 523-535.	5.7	14
721	Down-regulation of CIT can inhibit the growth of human bladder cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2020, 124, 109830.	5.6	10
722	Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 189, 110832.	5.0	59
723	Modifiable lifestyle behaviours impact the health-related quality of life of bladder cancer survivors. <i>BJU International</i> , 2020, 125, 836-842.	2.5	13
724	Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2. <i>Molecular Cancer</i> , 2020, 19, 25.	19.2	74
725	circRNA circFUT8 upregulates Krüppel-like Factor 10 to Inhibit the Metastasis of Bladder Cancer via Sponging miR-570-3p. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 172-187.	4.4	37
726	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
727	Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. <i>European Urology</i> , 2020, 78, 256-264.	1.9	96
728	Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. <i>Cancer Imaging</i> , 2020, 20, 26.	2.8	38
729	Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage. <i>Cancers</i> , 2020, 12, 870.	3.7	16
730	Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and predict poor prognosis for bladder cancer patients. <i>Cancer Medicine</i> , 2020, 9, 3885-3903.	2.8	34
731	Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer. <i>Biochemical Genetics</i> , 2020, 58, 490-507.	1.7	9
732	LncRNA-ATB in cancers: what do we know so far?. <i>Molecular Biology Reports</i> , 2020, 47, 4077-4086.	2.3	13
733	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020, 39, 4077-4091.	5.9	19

#	ARTICLE	IF	CITATIONS
734	Bladder neoplasms and NF- κ B: an unfathomed association. Expert Review of Molecular Diagnostics, 2020, 20, 497-508.	3.1	8
735	En bloc resection of bladder tumors. Current Opinion in Urology, 2020, 30, 421-427.	1.8	11
736	Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF α - κ B pathway in human colon cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5021-5027.	3.6	39
737	Gene Expression Profiles Identified Novel Urine Biomarkers for Diagnosis and Prognosis of High-Grade Bladder Urothelial Carcinoma. Frontiers in Oncology, 2020, 10, 394.	2.8	14
738	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 2825.	4.1	11
739	Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway. Cancer Medicine, 2020, 9, 4420-4432.	2.8	7
740	Alternative splicing related genetic variants contribute to bladder cancer risk. Molecular Carcinogenesis, 2020, 59, 923-929.	2.7	27
741	European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Annals of Oncology, 2020, 31, 650-658.	1.2	121
742	Overview of VI-RADS in Bladder Cancer. American Journal of Roentgenology, 2020, 214, 1259-1268.	2.2	47
743	Catalog of exogenous risk factors for bladder carcinogenesis. Current Opinion in Urology, 2020, 30, 449-456.	1.8	14
744	Nomogram for predicting overall survival of patients with bladder cancer: A population-based study. International Journal of Biological Markers, 2020, 35, 29-39.	1.8	24
745	Sex differences in cancer mechanisms. Biology of Sex Differences, 2020, 11, 17.	4.1	169
746	Trends and Utilization of Inpatient Palliative Care Among Patients With Metastatic Bladder Cancer. Journal of Palliative Care, 2021, 36, 105-112.	1.0	8
747	Gender Differences in Incidence, Diagnosis, Treatments, and Outcomes in Clinically Localized Bladder and Renal Cancer. Urology, 2021, 151, 176-181.	1.0	9
748	Patientsâ€™ Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clinical Genitourinary Cancer, 2021, 19, 76-82.e6.	1.9	12
749	Dietary glycemic index, glycemic load and risk of bladder cancer: a prospective study. European Journal of Nutrition, 2021, 60, 1041-1048.	3.9	4
750	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. European Urology Oncology, 2021, 4, 204-214.	5.4	20
751	Metabolic Imaging of Urothelial Carcinoma by Simultaneous Autofluorescence Lifetime Imaging (FLIM) of NAD(P)H and FAD. Clinical Genitourinary Cancer, 2021, 19, e31-e36.	1.9	4

#	ARTICLE	IF	CITATIONS
752	Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression. <i>Journal of Cellular Physiology</i> , 2021, 236, 1321-1331.	4.1	21
753	LncRNA ZNF503-AS1 acts as a tumor suppressor in bladder cancer by up-regulating Ca ²⁺ concentration via transcription factor GATA6. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 219-233.	4.4	14
754	LINC00460 Enhances Bladder Carcinoma Cell Proliferation and Migration by Modulating miR-612/FOXK1 Axis. <i>Pharmacology</i> , 2021, 106, 79-90.	2.2	11
755	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 236.e1-236.e7.	1.6	10
756	Coffee in cancer chemoprevention: an updated review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 69-85.	3.3	11
757	Prognostic Significance of Plasma Folate and Cobalamin Concentrations in Non-Muscle-Invasive Bladder Cancer: A Prospective Cohort Study. <i>Cancer Investigation</i> , 2021, 39, 240-250.	1.3	3
758	Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers. <i>Gene</i> , 2021, 769, 145224.	2.2	12
759	Cell blocks in urine cytopathology: do they add value to the diagnosis? A pilot study. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 47-55.	0.5	5
760	Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20. <i>Journal of Immunoassay and Immunochemistry</i> , 2021, 42, 236-251.	1.1	5
761	Rs-1884444 G/T variant in IL-23 receptor is likely to modify risk of bladder urothelial carcinoma by regulating IL-23/IL-17 inflammatory pathway. <i>Cytokine</i> , 2021, 138, 155355.	3.2	7
762	Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. <i>International Immunopharmacology</i> , 2021, 90, 107146.	3.8	45
763	The natural history of muscle-invasive bladder cancer in geriatric patients undergoing transurethral resection only: Outcome and cost. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 300.e7-300.e13.	1.6	1
764	Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22674.	3.0	25
765	Wnt signalling pathway in bladder cancer. <i>Cellular Signalling</i> , 2021, 79, 109886.	3.6	17
766	Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report. <i>Urology Case Reports</i> , 2021, 34, 101444.	0.3	3
767	The role of URO17, a biomarker to enhance diagnosis of urothelial cancer in new hematuria patients—First European Data. <i>BJU Compass</i> , 2021, 2, 46-52.	1.3	14
769	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. <i>Materials Science and Engineering C</i> , 2021, 119, 111460.	7.3	14
770	Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation. <i>International Journal of Cancer</i> , 2021, 148, 1808-1820.	5.1	1

#	ARTICLE	IF	CITATIONS
771	Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond. International Journal of Cancer, 2021, 148, 2364-2374.	5.1	10
772	LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by targeting MiR-218-5p/HS3ST3B1. Cancer Gene Therapy, 2021, 28, 212-220.	4.6	29
773	Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Seminars and Original Investigations, 2021, 39, 77.e9-77.e16.	1.6	17
774	Current status and future perspectives of immunotherapy in bladder cancer treatment. Science China Life Sciences, 2021, 64, 512-533.	4.9	21
775	Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. European Radiology, 2021, 31, 875-883.	4.5	28
776	Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers. European Urology Oncology, 2021, 4, 246-255.	5.4	10
777	Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. European Urology Focus, 2021, 7, 117-123.	3.1	5
778	Bladder cancer trends in Latvia during 1990â€“2017: incidence, mortality, and survival rates. Central European Journal of Urology, 2021, 74, 14-23.	0.3	0
779	Patientâ€“derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CARâ€“T cells <i>in vitro</i>. Clinical and Translational Immunology, 2021, 10, e1248.	3.8	41
780	Research on the circadian clock gene HNF4a in different malignant tumors. International Journal of Medical Sciences, 2021, 18, 1339-1347.	2.5	0
781	The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIROâ€“uro-group. Medical Oncology, 2021, 38, 14.	2.5	0
782	Systematic Analysis of the Global, Regional and National Burden of Kidney Cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017. European Urology Focus, 2022, 8, 302-319.	3.1	2
783	Identification of a potentially functional circRNA-miRNA-mRNA ceRNA regulatory network in bladder cancer by analysis of microarray data. Translational Andrology and Urology, 2021, 10, 24-36.	1.4	6
784	Systematic review and meta-analysis on bipolar versus monopolar transurethral resection of bladder tumors. Translational Andrology and Urology, 2021, 10, 37-48.	1.4	5
785	Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer. Journal of Cancer, 2021, 12, 5605-5621.	2.5	6
786	Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis. Central European Journal of Urology, 2021, 74, 348-354.	0.3	0
787	Trans-disciplinary diagnosis for an in-depth reform of regulatory expertise in the field of environmental toxicology and security. Toxicological Research, 2021, 37, 405-419.	2.1	1
788	Global Burden of Cancer. , 2021, , 459-494.		0

#	ARTICLE	IF	CITATIONS
789	Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers. <i>Methods in Molecular Biology</i> , 2021, 2292, 73-94.	0.9	4
790	Five-year Survival Rate of Bladder Cancer in Iran during 2001-2007. <i>Iranian Journal of Pathology</i> , 2021, 16, 69-74.	0.5	4
791	Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?. <i>Translational Andrology and Urology</i> , 2021, 10, 356-373.	1.4	2
792	Exploring the five different genes associated with PKC δ in bladder cancer based on gene expression microarray. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1759-1770.	3.6	5
793	Propofol Inhibits the Proliferation, Migration, and Stem-like Properties of Bladder Cancer Mainly by Suppressing the Hedgehog Pathway. <i>Cell Transplantation</i> , 2021, 30, 096368972098511.	2.5	9
794	Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/ β -catenin pathway and upregulating PTEN. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 45-59.	4.4	69
795	Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 51.	2.6	7
796	An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer. <i>Bioscience Reports</i> , 2021, 41, .	2.4	33
797	Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. <i>Cells</i> , 2021, 10, 159.	4.1	6
798	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	3.7	153
799	USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway. <i>International Journal of Biological Sciences</i> , 2021, 17, 2417-2429.	6.4	62
800	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	2.2	18
801	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 598599.	3.5	4
802	Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. <i>Bioengineered</i> , 2021, 12, 4946-4961.	3.2	10
803	Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 6262-6287.	1.9	11
804	Radical Cystectomy. , 2021, , 139-175.		0
805	YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition. <i>Annals of Medicine</i> , 2021, 53, 1171-1179.	3.8	13
806	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114.	3.8	57

#	ARTICLE	IF	CITATIONS
807	Successive treatment with naltrexone induces epithelial–mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells. Acta Biochimica Et Biophysica Sinica, 2021, 53, 238-248.	2.0	7
808	Antiproliferative and apoptosis inducing effect of delphinidin against human bladder cancer cell line. Pharmacognosy Magazine, 2021, 17, 101.	0.6	3
809	Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF-ÎB Pathway via Transcriptional Dysregulation of S100A8. Molecular Therapy, 2021, 29, 275-290.	8.2	8
810	Confirming Whether KLHL23 Deficiency Potentiates Migration in Urothelial Carcinoma. Chinese Journal of Physiology, 2021, 64, 142-149.	1.0	0
811	Human Chemotherapy by China-Made Praziquantel in Zanzibar: Efficacy and Safety. Parasitology Research Monographs, 2021, , 161-178.	0.3	0
812	NCR3LG1 (B7-H6) is a potential prognostic factor for bladder cancer patients. Biomarkers, 2021, 26, 260-267.	1.9	5
813	Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 93-99.	1.5	3
814	Neoadjuvant Chemotherapyâ€“Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Cancer Research and Treatment, 2021, 53, 1156-1165.	3.0	10
815	Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation. Oncogene, 2021, 40, 2051-2064.	5.9	12
816	Comparison of open and intracorporeal modified ureterosigmoidostomy (Mainz II) after laparoscopic radical cystectomy with bladder cancer. World Journal of Surgical Oncology, 2021, 19, 57.	1.9	6
817	Reduction of Bladder Cancer Chemosensitivity Induced by the Effect of HOXA-AS3 as a ceRNA for miR-455-5p That Upregulates Notch1. Frontiers in Oncology, 2020, 10, 572672.	2.8	14
819	LINC00649 promotes bladder cancer malignant progression by regulating the miRâ€“15aâ€“5p/HMGA1 axis. Oncology Reports, 2021, 45, .	2.6	6
820	Radical cystectomy and perioperative chemotherapy in octogenarians with bladder cancer. Canadian Urological Association Journal, 2021, 15, E465-E470.	0.6	2
821	Radiomics Analysis Based on Ultrasound Images to Distinguish the Tumor Stage and Pathological Grade of Bladder Cancer. Journal of Ultrasound in Medicine, 2021, 40, 2685-2697.	1.7	8
822	Modern possibilities of radiological diagnosis of bladder cancer. Journal of Modern Oncology, 2020, 22, 101-108.	0.3	2
823	FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clinical and Translational Medicine, 2021, 11, e310.	4.0	81
824	Anticancer Properties and Mechanisms of Singly-Protonated Dehydronorcantharidin Silver Coordination Polymer in a Bladder Cancer Model. Frontiers in Pharmacology, 2021, 12, 618668.	3.5	1
825	Submucosal urothelial bladder cancer: A case report. Molecular and Clinical Oncology, 2021, 14, 77.	1.0	0

#	ARTICLE	IF	CITATIONS
826	A Longitudinal Study of the Bladder Cancer Applying a State-Space Model with Non-Exponential Staying Time in States. <i>Mathematics</i> , 2021, 9, 363.	2.2	0
827	Effects of targeted Notch1 silencing on the biological processes of the T24 and 5637 cells in vitro. <i>Oncology Letters</i> , 2021, 21, 305.	1.8	1
829	Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model. <i>Aging</i> , 2021, 13, 6957-6981.	3.1	4
830	Deep learning based digital cell profiles for risk stratification of urine cytology images. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 732-742.	1.5	21
831	Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies. <i>Diagnostics</i> , 2021, 11, 351.	2.6	19
832	Expression of aquaporins 3 in low grade risk of recurrence primary bladder cancer. <i>Urologia</i> , 2021, 88, 190-193.	0.7	1
833	Altered expression of striatin is associated with poor prognosis in bladder transitional cell carcinoma. <i>Oncology Letters</i> , 2021, 21, 331.	1.8	4
834	The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder Cancer. <i>Current Molecular Medicine</i> , 2022, 22, 941-949.	1.3	7
835	Identification of Co-Deregulated Genes in Urinary Bladder Cancer Using High-Throughput Methodologies. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1785.	2.5	0
836	Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 1943-1953.	1.9	3
837	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 209-249.	329.8	52,977
838	Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer. <i>Current Urology</i> , 2021, 15, 11-15.	0.6	3
839	Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis. <i>International Journal of Urology</i> , 2021, 28, 673-680.	1.0	10
840	Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy. <i>Immunotherapy</i> , 2021, 13, 271-275.	2.0	0
841	Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing. <i>Oncogene</i> , 2021, 40, 2382-2394.	5.9	8
842	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , 2021, 128, 225-235.	2.5	9
843	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 397-405.	3.7	14
844	Circular RNA_0000629 Suppresses Bladder Cancer Progression Mediating MicroRNA-1290/CDC73. <i>Cancer Management and Research</i> , 2021, Volume 13, 2701-2715.	1.9	11

#	ARTICLE	IF	CITATIONS
845	Establishing the Bladder Cancer Research Centre at the University of Birmingham. <i>Nature Reviews Urology</i> , 2021, 18, 318-320.	3.8	1
846	Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis. <i>Immunogenetics</i> , 2021, 73, 207-226.	2.4	6
847	Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals. <i>International Journal of Urology</i> , 2021, 28, 706-707.	1.0	0
848	Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3510.	4.1	11
849	Pathogenic mechanisms and the potential clinical value of circFoxo3 in cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 908-917.	5.1	13
850	Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Frontiers in Oncology</i> , 2021, 11, 641385.	2.8	1
851	Applicability of the Paris System for veterans: high rates of undiagnosed low-grade urothelial neoplasia. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 357-365.	0.5	4
852	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	4.1	18
853	Arsenic exposure from groundwater: environmental contamination, human health effects, and sustainable solutions. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2021, 24, 119-135.	6.5	57
854	Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655000.	2.8	11
855	Diallyl trisulfide inhibited tobacco smoke-mediated bladder EMT and cancer stem cell marker expression via the NF- κ B pathway <i>in vivo</i> . <i>Journal of International Medical Research</i> , 2021, 49, 030006052199290.	1.0	6
856	Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. <i>BMC Medicine</i> , 2021, 19, 56.	5.5	17
857	The feasibility of multimodal fiber optic spectroscopy analysis in bladder cancer detection, grading, and staging. <i>Urologia</i> , 2021, 88, 039156032110070.	0.7	2
858	Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3056.	4.1	13
859	Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment. <i>Bladder Cancer</i> , 2021, 7, 1-11.	0.4	3
860	Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2021, 7, 71-78.	0.4	0
861	Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 161-170.	1.6	19
862	Punica granatum Extract Inhibits Bladder Cancer Cell Viability, Invasion and Migration through Down-Regulation of HOXD10 Signalling Pathway. <i>Doklady Biochemistry and Biophysics</i> , 2021, 497, 130-136.	0.9	6

#	ARTICLE	IF	CITATIONS
863	Application of bi-planar reduced field-of-view DWI (rFOV DWI) in the assessment of muscle-invasiveness of bladder cancer. <i>European Journal of Radiology</i> , 2021, 136, 109486.	2.6	14
864	Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer. <i>Cancer Science</i> , 2021, 112, 1987-1996.	3.9	16
865	Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer. <i>Current Urology</i> , 2021, 15, 16-21.	0.6	5
866	Immunohistochemistry as a paramount tool in research of normal urothelium, bladder cancer and bladder pain syndrome. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	4
867	Pegylated Recombinant Human Arginase 1 Induces Autophagy and Apoptosis via the ROS-Activated AKT/mTOR Pathway in Bladder Cancer Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	4.0	10
868	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	1.4	6
869	Circular RNA Foxo3: A Promising Cancer-Associated Biomarker. <i>Frontiers in Genetics</i> , 2021, 12, 652995.	2.3	13
870	RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4188.	4.1	6
871	CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 871-887.	4.4	6
872	Morphometric analysis of nuclear symmetry in urothelial carcinoma for predicting tumor recurrence. <i>Microscopy Research and Technique</i> , 2021, 84, 2559-2564.	2.2	1
873	LncRNA DANCER regulates lymphatic metastasis of bladder cancer via the miR-335/VEGF-C axis. <i>Translational Andrology and Urology</i> , 2021, 10, 1743-1753.	1.4	11
874	Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo. <i>Cancer Cell International</i> , 2021, 21, 242.	4.1	8
875	Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA. <i>World Journal of Surgical Oncology</i> , 2021, 19, 133.	1.9	10
876	APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival. <i>Heliyon</i> , 2021, 7, e06756.	3.2	11
877	The VIM-AS1/miR-655/ZEB1 axis modulates bladder cancer cell metastasis by regulating epithelialâ€”mesenchymal transition. <i>Cancer Cell International</i> , 2021, 21, 233.	4.1	11
878	Circ-ZFR Promotes Progression of Bladder Cancer by Upregulating WNT5A Via Sponging miR-545 and miR-1270. <i>Frontiers in Oncology</i> , 2020, 10, 596623.	2.8	18
879	Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway. <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	11
880	Combining volumetric apparent diffusion coefficient histogram analysis with vesical imaging reporting and data system to predict the muscle invasion of bladder cancer. <i>Abdominal Radiology</i> , 2021, 46, 4301-4310.	2.1	14

#	ARTICLE	IF	CITATIONS
881	Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer. <i>Genes</i> , 2021, 12, 550.	2.4	7
882	Cancer-associated fibroblasts and the related Runt-related transcription factor 2 (RUNX2) promote bladder cancer progression. <i>Gene</i> , 2021, 775, 145451.	2.2	21
883	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. <i>Current Oncology</i> , 2021, 28, 1652-1662.	2.2	4
884	Autophagy-Related Long Non-coding RNA Is a Prognostic Indicator for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 647236.	2.8	33
885	Survey of Mast Cell Density in Transitional Cell Carcinoma. <i>Iranian Journal of Pathology</i> , 2021, 16, 119-127.	0.5	4
886	Evaluation of a developed IMB based-ELISA in diagnosis of urinary schistosomiasis in areas at risk in Upper Egypt. <i>Parasitologists United Journal</i> , 2021, 14, 63-71.	0.3	1
887	The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	1.3	5
888	LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28/TGF- β 2/Smad pathway. <i>Cellular Signalling</i> , 2021, 81, 109932.	3.6	18
889	The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem. <i>Scandinavian Journal of Urology</i> , 2021, 55, 263-267.	1.0	3
890	Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response. <i>Journal of Translational Medicine</i> , 2021, 19, 205.	4.4	11
891	Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 636791.	1.4	6
892	Effect of Yes Associated Protein 1 Silence on Proliferation and Apoptosis of Bladder Cancer Cells. <i>Journal of Biomaterials and Tissue Engineering</i> , 2021, 11, 857-863.	0.1	0
893	Down-regulation LncRNA-SNHG15 contributes to proliferation and invasion of bladder cancer cells. <i>BMC Urology</i> , 2021, 21, 83.	1.4	11
894	Detecting Muscle Invasion of Bladder Cancer Using a Proposed Magnetic Resonance Imaging Strategy. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1212-1221.	3.4	18
895	Prognostic value of members of NFAT family for pan-cancer and a prediction model based on NFAT2 in bladder cancer. <i>Aging</i> , 2021, 13, 13876-13897.	3.1	5
896	Vesical Imaging-Reporting and Data System (VI-RADS®): experiencia inicial en la clasificaci3n del c4ncer de vejiga m4sculo-infiltrante. <i>Actas Urol3gicas Espaol4s</i> , 2021, 45, 320-325.	0.7	6
897	Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. <i>Cancer Biology and Therapy</i> , 2021, 22, 357-371.	3.4	27
898	Molecular markers of systemic therapy response in urothelial carcinoma. <i>Asian Journal of Urology</i> , 2021, 8, 376-390.	1.2	22

#	ARTICLE	IF	CITATIONS
899	Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 646.	2.6	3
900	HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122629.	2.3	5
901	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	3.7	8
902	Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5237.	2.6	4
903	The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis. <i>World Journal of Urology</i> , 2021, 39, 4151-4158.	2.2	16
904	Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer. <i>Cancer Cell International</i> , 2021, 21, 251.	4.1	16
905	Attachment of Cancer Urothelial Cells to the Bladder Epithelium Occurs on Uroplakin-Negative Cells and Is Mediated by Desmosomal and Not by Classical Cadherins. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5565.	4.1	5
906	The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study. <i>Frontiers in Oncology</i> , 2021, 11, 651657.	2.8	1
907	Vesical Imaging-Reporting and Data System (VI-RADS®): Initial experience in the classification of muscle-invasive bladder cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 320-325.	0.2	2
908	The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment. <i>Diagnostics</i> , 2021, 11, 863.	2.6	4
909	Long Noncoding RNA SNHG1 Activates Autophagy and Promotes Cell Invasion in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 660551.	2.8	16
910	Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. <i>BJU International</i> , 2021, 128, 343-351.	2.5	23
911	Cancer Cell Direct Bioprinting: A Focused Review. <i>Micromachines</i> , 2021, 12, 764.	2.9	6
912	Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 701298.	2.8	9
913	Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 692941.	3.5	5
914	Sustainable use of polypropylene fibers and palm oil fuel ash in the production of geopolymer concrete. <i>IOP Conference Series: Materials Science and Engineering</i> , 2021, 1136, 012046.	0.6	1
915	Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 574196.	2.3	19
916	Outcomes and Complications of Bipolar vs. Monopolar Energy for Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Surgery</i> , 2021, 8, 583806.	1.4	4

#	ARTICLE	IF	CITATIONS
917	Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. <i>Nature Communications</i> , 2021, 12, 3427.	12.8	14
918	MicroRNA-16-5p/BIMP1/NF- κ B axis regulates autophagy to exert a tumor-suppressive effect on bladder cancer. <i>Molecular Medicine Reports</i> , 2021, 24, .	2.4	9
919	A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 660273.	2.8	6
920	Bladder and upper urinary tract cancers as first and second primary cancers. <i>Cancer Reports</i> , 2021, 4, e1406.	1.4	7
921	Preliminary Exploration of the Application of Vesical <scp>Imaging-Reporting</scp> and Data System (<scp>ViRADS</scp>) in Post-treatment Patients With Bladder Cancer: A Prospective Single-Center Study. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 275-286.	3.4	12
922	<i>TEAD4</i> is an Immune Regulating-Related Prognostic Biomarker for Bladder Cancer and Possesses Generalization Value in Pan-Cancer. <i>DNA and Cell Biology</i> , 2021, 40, 798-810.	1.9	7
923	The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102309.	2.6	6
924	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 5375-5391.	2.8	6
925	Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors. <i>Scientific Reports</i> , 2021, 11, 11629.	3.3	28
926	Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study). <i>Egyptian Journal of Medical Research</i> , 2021, 2, 250-261.	0.1	0
927	Can Smoking Cause Differences in Urine Microbiome in Male Patients With Bladder Cancer? A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 677605.	2.8	17
928	Long non-coding RNA-00858 knockdown alleviates bladder cancer via regulation of the miR-3064-5p/CTGF axis. <i>Oncology Reports</i> , 2021, 46, .	2.6	3
929	A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 684879.	4.8	7
930	Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025. <i>European Urology Oncology</i> , 2021, 4, 677-696.	5.4	15
931	Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 148-152.	0.8	1
932	CircCA12 Promotes Malignant Process via Sponging miR-1184 and Upregulating RAS Family in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 663982.	2.3	5
933	The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer. <i>International Journal of Surgical Pathology</i> , 2022, 30, 6-14.	0.8	11
935	Demonstration of advanced glycation end product (AGE) expression in bladder cancer tissue in type-2 diabetic and non-diabetic patients and the relationship between AGE accumulation and endoplasmic reticulum stress with bladder cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14526.	1.7	1

#	ARTICLE	IF	CITATIONS
936	Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. , 2021, 3, 115-136.		2
937	A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer. Cancers, 2021, 13, 3089.	3.7	13
938	Living With Urinary Diversions: Patient Insights to Improve the Perioperative Experience. Urology, 2021, 152, 190-194.	1.0	4
939	Validation of Vesical Imaging Reporting and Data System score for the diagnosis of muscle-invasive bladder cancer: A prospective cross-sectional study. Asian Journal of Urology, 2022, 9, 467-472.	1.2	6
940	PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 56-61.	1.2	3
941	Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort. Cancer Medicine, 2021, 10, 4107-4116.	2.8	4
942	Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics. BMC Bioinformatics, 2021, 22, 305.	2.6	12
943	The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis. Frontiers in Oncology, 2021, 11, 683951.	2.8	17
944	Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review. Bladder Cancer, 2021, 7, 463-475.	0.4	0
945	Circular RNA TAF4B Promotes Bladder Cancer Progression by Sponging miR-1298-5p and Regulating TGFA Expression. Frontiers in Oncology, 2021, 11, 643362.	2.8	8
946	Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer. Frontiers in Oncology, 2021, 11, 704039.	2.8	11
947	A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients. Frontiers in Oncology, 2021, 11, 698856.	2.8	10
948	Approaches to Non-Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 105.	4.0	14
949	Quality of Life in Female Patients Following Ileal Neobladder and Ileal Conduit: Where Are We?. Journal of Clinical Medicine, 2021, 10, 3042.	2.4	8
950	Lnc-STYK1-2 regulates bladder cancer cell proliferation, migration, and invasion by targeting miR-146b-5p expression and AKT/STAT3/NF-kB signaling. Cancer Cell International, 2021, 21, 408.	4.1	12
951	The efficacy and reliability of Viâ€RADS in determining candidates for repeated transurethral resection in patients with highâ€risk nonâ€muscle invasive bladder cancer. International Journal of Clinical Practice, 2021, 75, e14584.	1.7	9
952	Circ_0030586 inhibits cell proliferation and stemness in bladder cancer by inactivating the ERK signaling via miR-665/NR4A3 axis. Acta Histochemica, 2021, 123, 151745.	1.8	11
953	Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells. Phytomedicine, 2021, 87, 153587.	5.3	9

#	ARTICLE	IF	CITATIONS
954	OCT3/4 enhances tumor immune response by upregulating the TET1-dependent NRF2/MDM2 axis in bladder cancer. <i>Genomics</i> , 2021, 113, 2122-2133.	2.9	7
955	Comparative pharmacoeconomic analysis of biologicals used for metastatic urothelial carcinoma. <i>Onkourologiya</i> , 2021, 17, 112-127.	0.3	0
957	ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A. <i>Cell Death and Disease</i> , 2021, 12, 661.	6.3	7
958	Evaluation of P53 and CK20 Immunohistochemical Markers in Comparison with Morphologic Findings in Low- and High-grade Urothelial Carcinomas. <i>Iranian Journal of Pathology</i> , 2021, 16, 297-303.	0.5	0
959	Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 437.e11-437.e19.	1.6	9
960	Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment. <i>Frontiers in Oncology</i> , 2021, 11, 633462.	2.8	1
961	Association of the Healthy Nordic Food Index with risk of bladder cancer: a case-control study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 482-486.	2.9	3
962	Bladder Cancer: Current Challenges and Future Directions. <i>Medicina (Lithuania)</i> , 2021, 57, 749.	2.0	122
963	Dihydropyrimidinase Like 2 Promotes Bladder Cancer Progression via Pyruvate Kinase M2-Induced Aerobic Glycolysis and Epithelial-Mesenchymal Transition. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641432.	3.7	12
964	Factors affecting recurrence after transurethral treatment of non-muscle-invasive bladder cancer. <i>African Journal of Urology</i> , 2021, 27, .	0.4	1
965	Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence. <i>Journal of Epidemiology</i> , 2021, 31, 426-450.	2.4	73
966	Circular RNA circSETD3 hampers cell growth, migration, and stem cell properties in bladder cancer through sponging miR-641 to upregulate PTEN. <i>Cell Cycle</i> , 2021, 20, 1589-1602.	2.6	12
967	Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer. <i>Cancer Science</i> , 2021, 112, 3669-3681.	3.9	4
968	Nicotinic Acetylcholine Receptors as Potential Tumor Biomarkers in Genitourinary Cancers: a Review Study. <i>Immunoanalysis</i> , 2021, 1, 4-4.	0.8	1
969	Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression. <i>Environmental Toxicology</i> , 2021, 36, 2138-2145.	4.0	7
970	Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 61.e1-61.e8.	1.6	6
971	CircIMPACT: An R Package to Explore Circular RNA Impact on Gene Expression and Pathways. <i>Genes</i> , 2021, 12, 1044.	2.4	3
972	Identification and Validation of a Novel Immune-Related lncRNA Signature for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704946.	2.8	4

#	ARTICLE	IF	CITATIONS
973	Association of Dietary Carrot Intake With Bladder Cancer Risk in a Prospective Cohort of 99,650 Individuals With 12.5 Years of Follow-Up. <i>Frontiers in Nutrition</i> , 2021, 8, 669630.	3.7	5
974	Association of dietary tomato intake with bladder cancer risk in a prospective cohort of 101,683 individuals with 12.5 years of follow-up. <i>Aging</i> , 2021, 13, 17629-17637.	3.1	3
975	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	1.6	5
977	<scp>MiR</scp>â€186â€5p suppresses cell migration, invasion, and epithelial mesenchymal transition in bladder cancer by targeting <scp>RAB27A</scp>/B. <i>Environmental Toxicology</i> , 2021, 36, 2174-2185.	4.0	18
978	Major differences in glycosylation and fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines. <i>Glycobiology</i> , 2021, 31, 1444-1463.	2.5	8
979	An Overview of Hepatocellular Carcinoma with Emphasis on Dietary Products and Herbal Remedies. <i>Nutrition and Cancer</i> , 2022, 74, 1549-1567.	2.0	2
980	Anestesia nella chirurgia urologica degli adulti. <i>EMC - Anestesia-Rianimazione</i> , 2021, 26, 1-15.	0.1	0
981	High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer. <i>Oncotarget</i> , 2021, 12, 1580-1586.	1.8	3
982	Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas. <i>Journal of Histotechnology</i> , 2021, 44, 196-205.	0.5	3
983	Possible connection between diet and microRNA in cancer scenario. <i>Seminars in Cancer Biology</i> , 2021, 73, 4-18.	9.6	9
984	Downâ€regulation of Poloâ€like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer. <i>FEBS Open Bio</i> , 2021, 11, 2631-2646.	2.3	11
985	Identification of Notch signaling pathway gene mutations as a prognostic biomarker for bladder cancer. <i>Future Oncology</i> , 2021, 17, 4307-4320.	2.4	2
986	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021, 13, 953-964.	2.0	5
987	Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score. <i>Cancer Management and Research</i> , 2021, Volume 13, 6473-6487.	1.9	5
988	Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 724541.	4.8	3
989	Combination of AST to ALT and neutrophils to lymphocytes ratios as predictors of locally advanced disease in patients with bladder cancer subjected to radical cystectomy: Results from a single-institutional series. <i>Urologia</i> , 2021, , 039156032110351.	0.7	5
990	A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 943.	2.6	32
991	MD-UNET: Multi-input dilated U-shape neural network for segmentation of bladder cancer. <i>Computational Biology and Chemistry</i> , 2021, 93, 107510.	2.3	16

#	ARTICLE	IF	CITATIONS
992	Bioinformatics analysis based on immune-autophagy-related lncRNAs combined with immune infiltration in bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 3440-3455.	1.4	6
993	Three Primary Cancers in a Veteran With Agent Orange and Agent Blue Exposures. , 2021, 38, S40-S45.		0
994	Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 696422.	2.8	4
995	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	3.7	31
996	Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 603-611.	1.0	4
997	Accuracy of the Vesical Imagingâ€“Reporting and Data System (VIRADS) for preâ€“treatment staging of bladder cancer in an Australian cohort. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	1.8	7
998	LINC01410 leads the migration, invasion and EMT of bladder cancer cells by modulating miR-4319 / Snail1. <i>Cancer Cell International</i> , 2021, 21, 429.	4.1	3
999	Curative resection of bladder cancer with pancreas head metastasis. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2021, 25, 440-444.	0.1	0
1000	Enhanced Expression but Decreased Specific Activity of Matrix Metalloproteinase 10 (MMP-10) in Comparison with Matrix Metalloproteinase 3 (MMP-3) in Human Urinary Bladder Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 3683.	2.4	4
1001	Intra-arterial infusion chemotherapy utilizing cisplatin inhibits bladder cancer by decreasing the i-brocytic myeloid-derived suppressor cells in an m6A-dependent manner. <i>Molecular Immunology</i> , 2021, 137, 28-40.	2.2	17
1002	circNUDT21 promotes bladder cancer progression by modulating the miR-16-1-3p/MDM2/p53 axis. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 625-636.	5.1	10
1003	Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. <i>Cancer Medicine</i> , 2021, 10, 7534-7541.	2.8	5
1004	Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 4673.	3.7	5
1005	Single-Cell Analyses Reveal Mechanisms of Cancer Stem Cell Maintenance and Epithelialâ€“Mesenchymal Transition in Recurrent Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 27, 6265-6278.	7.0	43
1006	Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 707271.	3.5	1
1007	Circular RNA CircPPP1CB Suppresses Tumorigenesis by Interacting With the MiR-1307-3p/SMG1 Axis in Human Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 704683.	3.7	9
1008	SLC25A21 Suppresses Cell Growth in Bladder Cancer via an Oxidative Stress-Mediated Mechanism. <i>Frontiers in Oncology</i> , 2021, 11, 682710.	2.8	8
1009	Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells. <i>Micron</i> , 2021, 151, 103152.	2.2	20

#	ARTICLE	IF	CITATIONS
1010	HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer. Cellular Signalling, 2021, 85, 110044.	3.6	7
1011	Silencing circBIRC6 inhibits the proliferation, invasion, migration and epithelial-mesenchymal transition of bladder cancer cells by targeting the miR-495-3p/XBP1 signaling axis. Molecular Medicine Reports, 2021, 24, .	2.4	10
1012	Difficulties in Diagnosing and Treating Disseminated Bacillus Calmette-Guérin (BCG) Infection After Intravesical BCG Therapy in a Patient with Liver Cirrhosis: A Case Report. American Journal of Case Reports, 2021, 22, e933006.	0.8	3
1013	Antimony exposure promotes bladder tumor cell growth by inhibiting PINK1-Parkin-mediated mitophagy. Ecotoxicology and Environmental Safety, 2021, 221, 112420.	6.0	15
1014	R11 peptides can promote the molecular imaging of spherical nucleic acids for bladder cancer margin identification. Nano Research, 2022, 15, 2278-2287.	10.4	11
1015	A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer. Clinical and Translational Radiation Oncology, 2021, 30, 65-70.	1.7	2
1016	CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene, 2021, 40, 6223-6234.	5.9	42
1017	A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate. Molecular and Cellular Oncology, 2021, 8, 1974278.	0.7	2
1018	Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation. Future Oncology, 2021, 17, 3281-3283.	2.4	1
1019	CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. Annals of Translational Medicine, 2021, 9, 1441-1441.	1.7	13
1020	Low Preoperative Lymphocyte-to-Monocyte Ratio Is Predictive of the 5-Year Recurrence of Bladder Tumor after Transurethral Resection. Journal of Personalized Medicine, 2021, 11, 947.	2.5	3
1021	Chronic Diseases and Labor Force Participation Among Presenile and Senile Chinese. Frontiers in Public Health, 2021, 9, 675927.	2.7	2
1022	MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells. Biochemical and Biophysical Research Communications, 2021, 570, 154-161.	2.1	10
1023	Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading. Asian Journal of Urology, 2021, , .	1.2	0
1024	The Emerging Functions of Circular RNAs in Bladder Cancer. Cancers, 2021, 13, 4618.	3.7	9
1025	Testicular Nuclear Receptor 4 Regulates Proliferation and Apoptosis of Bladder Cancer via Bcl-2. Frontiers in Molecular Biosciences, 2021, 8, 670409.	3.5	1
1026	Design, Hemiysnthesis, crystal structure and anticancer activity of 1, 2, 3-triazoles derivatives of totarol. Bioorganic Chemistry, 2021, 115, 105165.	4.1	27
1027	Validation of the COBRA nomogram for the prediction of cancer specific survival in patients treated with radical cystectomy for bladder cancer: An international wide cohort study. European Journal of Surgical Oncology, 2021, 47, 2646-2650.	1.0	4

#	ARTICLE	IF	CITATIONS
1028	PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 734.e1-734.e10.	1.6	4
1029	Primary cilia presence and implications in bladder cancer progression and invasiveness. Histochemistry and Cell Biology, 2021, 155, 547-560.	1.7	11
1030	Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells. International Journal of Biological Sciences, 2021, 17, 3456-3475.	6.4	14
1031	A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 44.	8.6	17
1033	Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer. Bioengineered, 2021, 12, 6559-6571.	3.2	13
1034	Cancer mortality and predictions for 2020 in selected Australasian countries, Russia and Ukraine. European Journal of Cancer Prevention, 2021, 30, 1-14.	1.3	7
1035	Clinical Value of Postoperative Neutrophil-to-Lymphocyte Ratio Change as a Detection Marker of Bladder Cancer Recurrence. Cancer Management and Research, 2021, Volume 13, 849-860.	1.9	6
1036	SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. Cells, 2021, 10, 80.	4.1	12
1037	Negative Correlation Between Circular RNA SMARC5 and MicroRNA 432, and Their Clinical Implications in Bladder Cancer Patients. Technology in Cancer Research and Treatment, 2021, 20, 153303382110391.	1.9	7
1038	<i>MAFG</i> promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma. Clinical and Translational Medicine, 2020, 10, e241.	4.0	35
1039	Expression profile of microRNAs in bladder cancer and their application as biomarkers. Biomedicine and Pharmacotherapy, 2020, 131, 110703.	5.6	19
1040	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	1.8	39
1041	National burden of cancer in Italy, 1990â€“2017: a systematic analysis for the global burden of disease study 2017. Scientific Reports, 2020, 10, 22099.	3.3	19
1042	Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells. Anti-Cancer Drugs, 2018, 29, 29-39.	1.4	13
1043	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.4	32
1044	DHCR24 predicts poor clinicopathological features of patients with bladder cancer. Medicine (United Tj ETQq1 1 0,784314 rgBT /Overle	1.0	11
1046	SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7. Cancer Science, 2020, 111, 2349-2360.	3.9	9
1047	In-vivo Raman spectroscopy: from basics to applications. Journal of Biomedical Optics, 2018, 23, 1.	2.6	132

#	ARTICLE	IF	CITATIONS
1048	Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2020, 2020, 1-13.	1.3	4
1049	Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. <i>Cancer Control</i> , 2020, 27, 107327482097666.	1.8	25
1050	Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients's Clinical Features. <i>Medical Science Monitor</i> , 2018, 24, 7178-7185.	1.1	19
1051	Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers: A Review. <i>Medical Science Monitor</i> , 2019, 25, 3425-3434.	1.1	15
1052	miR-325-3p Overexpression Inhibits Proliferation and Metastasis of Bladder Cancer Cells by Regulating MT3. <i>Medical Science Monitor</i> , 2020, 26, e920331.	1.1	7
1053	Bioinformatics Analysis of the Expression of Key Long Intergenic Non-Protein Coding RNA Genes in Bladder Cancer. <i>Medical Science Monitor</i> , 2020, 26, e920504.	1.1	8
1054	Diagnostic accuracy of NMP 22 and urine cytology for detection of transitional cell carcinoma urinary bladder taking cystoscopy as gold standard. <i>Pakistan Journal of Medical Sciences</i> , 2020, 36, 705-710.	0.6	7
1055	Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy. <i>Biomedical Optics Express</i> , 2019, 10, 3533.	2.9	43
1056	The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice. <i>PLoS ONE</i> , 2017, 12, e0186214.	2.5	5
1057	Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model. <i>PLoS ONE</i> , 2017, 12, e0188093.	2.5	9
1058	Dietary fat intake and risk of bladder cancer: Evidence from a meta-analysis of observational studies. <i>Cellular and Molecular Biology</i> , 2019, 65, 5-9.	0.9	7
1059	Bladder cancer trends and mortality in the brazilian public health system. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 224-233.	1.5	13
1060	Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF- κ B dependent apoptosis. <i>EXCLI Journal</i> , 2018, 17, 1157-1166.	0.7	10
1061	Histomorphologic study of cystoscopic urinary bladder biopsies: A gold standard. <i>Indian Journal of Pathology and Oncology</i> , 2019, 6, 174-181.	0.1	2
1062	Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis. <i>Aging</i> , 2018, 10, 1964-1976.	3.1	94
1063	Prognostic value of long non-coding RNA signatures in bladder cancer. <i>Aging</i> , 2019, 11, 6237-6251.	3.1	32
1064	An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer. <i>Aging</i> , 2019, 11, 6930-6940.	3.1	31
1065	ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653. <i>Aging</i> , 2019, 11, 11202-11223.	3.1	15

#	ARTICLE	IF	CITATIONS
1066	A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. <i>Aging</i> , 2020, 12, 2857-2879.	3.1	31
1067	Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation. <i>Aging</i> , 2020, 12, 6865-6879.	3.1	24
1068	High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer. <i>Aging</i> , 2020, 12, 8728-8741.	3.1	15
1069	Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer. <i>Aging</i> , 2020, 12, 12051-12073.	3.1	24
1070	Circular RNA circSEMA5A promotes bladder cancer progression by upregulating ENO1 and SEMA5A expression. <i>Aging</i> , 2020, 12, 21674-21686.	3.1	27
1071	Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 48263-48271.	1.8	15
1072	Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. <i>Oncotarget</i> , 2017, 8, 44326-44334.	1.8	19
1073	The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. <i>Oncotarget</i> , 2017, 8, 59527-59538.	1.8	51
1074	Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. <i>Oncotarget</i> , 2018, 9, 217-223.	1.8	10
1075	CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 102078-102087.	1.8	13
1076	Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor. <i>Oncotarget</i> , 2018, 9, 18627-18636.	1.8	11
1077	EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. <i>Oncotarget</i> , 2018, 9, 12261-12272.	1.8	59
1078	“Two hits - one stone” increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling. <i>Oncotarget</i> , 2018, 9, 32448-32465.	1.8	35
1079	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 626-635.	1.4	20
1080	Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study. <i>Translational Andrology and Urology</i> , 2020, 9, 2113-2121.	1.4	2
1081	Circular RNA SMARCA5 is overexpressed and promotes cell proliferation, migration as well as invasion while inhibits cell apoptosis in bladder cancer. <i>Translational Cancer Research</i> , 2019, 8, 1663-1671.	1.0	14
1082	Perioperative immunotherapy in muscle-invasive bladder cancer. <i>Translational Cancer Research</i> , 2020, 9, 6546-6553.	1.0	8
1083	DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype. <i>Current Genomics</i> , 2020, 21, 34-36.	1.6	17

#	ARTICLE	IF	CITATIONS
1084	Circular RNAs Serve as Novel Biomarkers and Therapeutic Targets in Cancers. <i>Current Gene Therapy</i> , 2019, 19, 125-133.	2.0	29
1085	Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 667-677.	1.7	12
1086	Bladder-sparing treatment in MIBC: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 101-112.	3.9	17
1087	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 1-12.	3.9	13
1088	Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2219-2224.	1.2	39
1089	Establishment of Real-Time Multispectral Imaging for the Detection of Bladder Cancer Using a Preclinical in Vivo Model. <i>Bladder Cancer</i> , 2020, 6, 285-294.	0.4	2
1090	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecancermedalscience</i> , 2020, 14, 1036.	1.1	5
1091	Urothelial Carcinoma: Highlights and Reviews on Various Pathologies. <i>European Medical Journal Urology</i> , 0, , .	0.0	2
1092	Genomic Landscape of Young-Onset Bladder Cancer and Its Prognostic Implications on Adult Bladder Cancer. <i>Cancers</i> , 2020, 12, 307.	3.7	3
1093	Expression of PD-L1 for Predicting Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2020, 27, 656-663.	2.2	8
1094	NIMA related kinase 2 promotes gastric cancer cell proliferation via ERK/MAPK signaling. <i>World Journal of Gastroenterology</i> , 2019, 25, 2898-2910.	3.3	16
1095	Overexpression of thymosin β 10 correlates with disease progression and poor prognosis in bladder cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3759-3766.	1.8	7
1096	Roles and regulatory mechanisms of miR-30b in cancer, cardiovascular disease, and metabolic disorders (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 44.	1.8	11
1097	Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2189-2200.	4.0	21
1098	Sulforaphane suppresses the viability and metastasis, and promotes the apoptosis of bladder cancer cells by inhibiting the expression of FAT1. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1085-1095.	4.0	13
1099	The role of long noncoding RNA SNHG7 in human cancers (Review). <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	13
1100	LINC01638 lncRNA mediates the postoperative distant recurrence of bladder cancer by upregulating ROCK2. <i>Oncology Letters</i> , 2019, 18, 5392-5398.	1.8	9
1101	Propofol exhibits a tumor-suppressive effect and regulates cell viability, migration and invasion in bladder carcinoma by targeting the microRNA-10b/HOXD10 signaling pathway. <i>Oncology Letters</i> , 2019, 18, 6228-6236.	1.8	7

#	ARTICLE	IF	CITATIONS
1102	Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs. <i>Oncology Letters</i> , 2020, 20, 2928-2936.	1.8	22
1103	Systemic therapy in bladder cancer. <i>Indian Journal of Urology</i> , 2017, 33, 118.	0.6	9
1104	The current status of robot-assisted cystectomy. <i>Indian Journal of Urology</i> , 2018, 34, 101.	0.6	17
1105	Worldwide incidence and mortality of bladder cancer and human development index: An ecological study. <i>Indian Journal of Medical Specialities</i> , 2020, 11, 88.	0.1	4
1106	Monthly maintenance protocol <i>Bacillus Calmette-Guérin</i> as a viable alternative to Southwest Oncology Group maintenance protocol in nonmuscle-invasive bladder cancer: A prospective randomized study. <i>Urology Annals</i> , 2020, 12, 116.	0.6	6
1107	The association between variant urothelial histologies, pathological stage and disease specific survival in patients with bladder cancer. <i>Turkish Journal of Urology</i> , 2018, 44, 24-30.	1.3	4
1108	Alternative therapies in patients with non-muscle invasive bladder cancer. <i>Turkish Journal of Urology</i> , 2017, 43, 414-424.	1.3	8
1109	The Correlation Between Bladder Cancer and Obesity, Overweight, Physical Inactivity, and Tobacco Use: An Ecological Study in Asian Countries. <i>Annals of Global Health</i> , 2019, 85, .	2.0	7
1110	Renal Tuberculosis Following Intravesical <i>Bacillus Calmette-Guérin</i> (BCG) Immunotherapy for the Treatment of Bladder Cancer. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2020, 74, 146.	0.9	5
1111	Analysis of Cancer Incidence and Mortality in Iran Using Joinpoint Regression Analysis. <i>Iranian Red Crescent Medical Journal</i> , 2016, 19, .	0.5	5
1112	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 329-354.	4.9	383
1113	Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. <i>Annals of Medicine</i> , 2021, 53, 1827-1838.	3.8	31
1114	Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients. <i>Journal of International Medical Research</i> , 2021, 49, 0300060521110499.	1.0	5
1115	CircFAM114A2 Promotes Cisplatin Sensitivity via miR-222-3p/P27 and miR-146a-5p/P21 Cascades in Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 659166.	2.8	2
1116	MiR-10a-5p: A Promising Biomarker for Early Diagnosis and Prognosis Evaluation of Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7841-7850.	1.9	8
1117	Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , 2021, 15, 253.	1.0	7
1118	Glucose/Glutathione Co-triggered Tumor Hypoxia Relief and Chemodynamic Therapy to Enhance Photothermal Therapy in Bladder Cancer. <i>ACS Applied Bio Materials</i> , 2021, 4, 7485-7496.	4.6	12
1119	Functional variants of RPS6KB1 and PIK3R1 in the autophagy pathway genes and risk of bladder cancer. <i>Archives of Toxicology</i> , 2021, , 1.	4.2	4

#	ARTICLE	IF	CITATIONS
1120	<i>Circ0008399</i> Interaction with WTAP Promotes Assembly and Activity of the m6A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer. <i>Cancer Research</i> , 2021, 81, 6142-6156.	0.9	86
1121	SERPINE2 Overexpression Is Associated with Poor Prognosis of Urothelial Carcinoma. <i>Diagnostics</i> , 2021, 11, 1928.	2.6	10
1122	Urothelial cancer organoids: a tool for bladder cancer research. <i>Der Pathologe</i> , 2021, 42, 165-169.	1.6	2
1123	Role of <i>miR-490a-3p</i> in blocking bladder cancer growth through targeting the <i>RNA-binding protein PCBP2</i> . <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 30-37.	1.9	1
1124	Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population. <i>Oncology Letters</i> , 2021, 22, 845.	1.8	0
1125	Circular RNA regulates the onset and progression of cancer through the mitogen-activated protein kinase signaling pathway (Review). <i>Oncology Letters</i> , 2021, 22, 817.	1.8	5
1126	Copy number variation analysis of <i>m6A</i> regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 7804-7815.	2.8	7
1127	Role of Pentacyclic Triterpenoid Acids in the Treatment of Bladder Cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, .	2.4	2
1128	A novel self-learning framework for bladder cancer grading using histopathological images. <i>Computers in Biology and Medicine</i> , 2021, 138, 104932.	7.0	5
1130	Radiotherapy for the Treatment of Muscle-Invasive Bladder Cancer. , 2018, , 83-89.		0
1131	Immunohistochemical Expression of Androgen and Estrogen Receptors and their Prognostic Significance in Urothelial Carcinoma of the Urinary Bladder. <i>Medical Journal of the University of Cairo Faculty of Medicine</i> , 2018, 86, 305-310.	0.0	0
1132	Evaluation of <i>in vitro</i> Antioxidant and Anticancer Activity of <i>Tabernaemontana divaricata</i> Leaf Extracts Against T-24 Human Bladder Cancer Cell Lines. <i>International Journal of Cancer Research</i> , 2018, 14, 100-108.	0.2	5
1133	Prediction of early postoperative complications of radical cystectomy with different method of urinary derivation through methods of mathematical modeling. <i>Urology</i> , 2018, 22, .	0.1	1
1134	Suppressing cell growth and inducing apoptosis by inhibiting <i>miR-23a-5p</i> in human bladder cancer. <i>Molecular Medicine Reports</i> , 2018, 18, 5256-5260.	2.4	3
1135	Peculiarities of Histochemical Glutamate dehydrogenase Changes in Artificial Urinary Bladder in Dynamics (Experimental Study). <i>Health of Man</i> , 2018, .	0.0	0
1136	Epidemiology, Etiology, and Histopathology. , 2019, , 3-7.		0
1137	Sarcomatoid carcinoma of the urinary bladder: A case report and short review of the literature. <i>Journal of Surgery and Medicine</i> , 0, , .	0.1	0
1138	Effect of Educational Intervention and Telephone Follow-Up Program on Knowledge, Practice and Quality Of Life among Patients with Urinary Diversion: A Quasi-Experimental Study. <i>International Journal of Nursing (New York, N Y)</i> , 2019, 6, .	0.2	3

#	ARTICLE	IF	CITATIONS
1139	Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience. Central European Journal of Urology, 2019, 72, 113-120.	0.3	3
1140	Bimanual palpation for staging of bladder cancer-clinical use and its predictors. Turkish Journal of Urology, 2019, 45, 22-26.	1.3	4
1141	Improving the efficiency of bladder cancer diagnostic cystoscopy with 5-ALA hexyl ester. Biomedical Photonics, 2019, 8, 29-37.	1.2	2
1142	MicroRNA-663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2. Molecular Medicine Reports, 2019, 19, 3896-3902.	2.4	5
1143	The segmentation of bladder cancer using the voxel-features-based method. , 2019, , .		0
1144	Effect of Implementing Nursing Instructions on Patients' Outcomes Undergoing Transurethral Resection of Bladder tumor. Assiut Scientific Nursing Journal, 2019, 7, 166-176.	0.0	0
1145	Notch signaling pathway: dual role in tumour progression and therapeutic opportunities for bladder cancer. Onkourologiya, 2019, 15, 108-116.	0.3	0
1146	Role of PRMT5 in bladder cancer: a comprehensive study. Translational Cancer Research, 2019, 8, 491-498.	1.0	0
1147	New approach of staging and grading in bladder cancer with optical coherence tomography and Raman spectroscopy. , 2019, , .		0
1149	Background on Bladder Cancer. , 2020, , 3-3.		0
1150	A histological analysis of urinary bladder specimens with elaboration of various neoplastic lesions. Indian Journal of Pathology and Oncology, 2019, 6, 688-694.	0.1	1
1151	The bladder cancer: the risk factors and prognostic markers. Klinichna Khirurgiia, 2019, 86, 78-84.	0.2	1
1152	Keratin 17 Immunohisto chemical Expression and Prognostic Value in Bladder Urothelial Carcinoma. Medical Journal of the University of Cairo Faculty of Medicine, 2019, 87, 4737-4746.	0.0	0
1153	Assessment of health-related quality of life of male patients with ileal orthotopic neobladder compared to cutaneous ureterostomy. Central European Journal of Urology, 2020, 73, 160-166.	0.3	2
1154	Long Non-Coding RNAs to Predict Postoperative Recurrence in Muscle-Invasive Bladder Cancer and to Develop a New Molecular Classification System. SSRN Electronic Journal, 0, , .	0.4	0
1155	Self-Assembled Nanoparticle-Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition. Advanced Therapeutics, 2020, 3, 2000032.	3.2	10
1156	TECHNICAL ASPECTS OF LASER EN BLOC RESECTION OF THE BLADDER TUMOR FOR NON-MUSCLE-INVASIVE BLADDER CANCER. Surgical Practice, 2020, , 53-58.	0.1	1
1159	Development of a novel prognostic signature for predicting the overall survival of bladder cancer patients. Bioscience Reports, 2020, 40, .	2.4	3

#	ARTICLE	IF	CITATIONS
1160	Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1573-1583.	1.2	5
1161	MIR22HG regulates miR-486/PTEN axis in bladder cancer to promote cell proliferation. Bioscience Reports, 2020, 40, .	2.4	4
1163	Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer. Oncology Reports, 2020, 44, 1831-1850.	2.6	4
1164	Editorial Comment: Does the Use of a Robot Decrease the Complication Rate Adherent to Radical Cystectomy? A Systematic Review and Meta-Analysis of Studies Comparing Open with Robotic Counterparts. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 657-658.	1.5	1
1165	UV-Related Melanoma Cancer and Its Association with the Human Development Index (HDI): GLOBOCAN Sources and Methods. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	0
1166	Oncological Outcomes of Non-Urothelial Bladder Cancers in a Specialized Cancer Hospital of a Developing Country. Cureus, 2020, 12, e9957.	0.5	0
1167	Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis. , 2021, , 141-157.		1
1168	A Google Trendsâ„¢ Analysis of Bladder Cancer: Determining Awareness Campaign Success, and Patientsâ€™ Needs in Clinical Management. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3115-3120.	1.2	3
1169	Multi-Slice Spiral Computed Tomography Image Features under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer. Journal of Healthcare Engineering, 2021, 2021, 1-9.	1.9	1
1170	Single-Cell Proteomic Analysis Dissects the Complexity of Tumor Microenvironment in Muscle Invasive Bladder Cancer. Cancers, 2021, 13, 5440.	3.7	7
1171	Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features. Modern Pathology, 2022, 35, 533-538.	5.5	21
1172	Prognostic Value of Lymphocyteâ€“C-Reactive Protein Ratio in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study. Frontiers in Oncology, 2021, 11, 760389.	2.8	4
1173	Analysis of urinary kallikrein-related peptidase 13 for monitoring bladder cancer. Biomarkers, 2021, 26, 1-30.	1.9	1
1174	High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma. Annals of Diagnostic Pathology, 2021, 56, 151847.	1.3	0
1175	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. Biologics: Targets and Therapy, 2021, Volume 15, 441-450.	3.2	2
1176	Long non-coding RNA EGFRâ€™AS1 sponges micorRNAâ€™381 to upregulate ROCK2 in bladder cancer. Oncology Letters, 2020, 19, 1899-1905.	1.8	5
1177	Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. Journal of Surgery and Medicine, 2020, 4, 1104-1107.	0.1	1
1178	Significance of Expression of IMP3, PPARG & PD-L1 in Urothelial Carcinoma (Immunohistochemical) Tj ETQq1 10,0784314 rgBT /Ov	0.0	0

#	ARTICLE	IF	CITATIONS
1179	<p>±-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer</p>. Cancer Management and Research, 2020, Volume 12, 12747-12758.	1.9	13
1180	MicroRNAâ€³4aâ€³5p serves as a tumor suppressor by regulating the cell motility of bladder cancer cells through matrix metalloproteinaseâ€² silencing. Oncology Reports, 2020, 45, 911-920.	2.6	13
1181	Knowledge of bladder cancer in the French population: results of the EDIFICE 6 survey. European Journal of Cancer Care, 2021, 30, e13392.	1.5	1
1182	Urological Cancer. , 2021, , 77-93.		0
1183	The optimal management of variant histology in muscle invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2965-2975.	1.4	3
1184	Binuclear Cu(II) complex based on N-acetylanthranilic acid induces significant cytotoxic effect on three cancer cell lines. Journal of Molecular Structure, 2022, 1249, 131634.	3.6	4
1185	Fluorometric optical sensor arrays for the detection of urinary bladder cancer specific volatile organic compounds in the urine of patients with frank hematuria: a prospective case-control study. Biomedical Optics Express, 2020, 11, 1175.	2.9	9
1186	Overexpression of Karyopherin Subunit alpha 2 (KPNA2) Predicts Unfavorable Prognosis and Promotes Bladder Cancer Tumorigenicity via the P53 Pathway. Medical Science Monitor, 2020, 26, e921087.	1.1	8
1187	A rare case of small cell neuroendocrine tumor of the urinary bladder. Indian Journal of Pathology and Microbiology, 2020, 63, 298.	0.2	1
1188	Global Burden of Cancer: Prevalence, Pattern, and Trends. , 2020, , 1-36.		0
1189	Beneficial effect of fluid warming in elderly patients with bladder cancer undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy. Clinics, 2020, 75, e1639.	1.5	5
1190	Value of separate tumor base biopsy in transurethral resection of bladder tumors. Central European Journal of Urology, 2020, 73, 440-444.	0.3	1
1191	Dihydropyrimidinase Like 2 Promotes Bladder Cancer Progression via Pyruvate Kinase M2-Induced Aerobic Glycolysis and Epithelialâ€³Mesenchymal Transition. SSRN Electronic Journal, 0, , .	0.4	0
1192	Safety, feasibility, and quality of holmium laser en-bloc resection of nonmuscle invasive bladder tumors â€³ A single-center experience. Indian Journal of Urology, 2020, 36, 106.	0.6	11
1193	EPIDEMIOLOGIA DA NEOPLASIA MALIGNA DE BEXIGA: UM ESTUDO DAS TAXAS DE MORTALIDADE E DE INTERNAÃƒÃƒO HOSPITALAR. Revista De AtenÃƒÃƒo Ãƒ SaÃƒde, 2020, 17, .	0.1	0
1194	Metastasiertes Urothelkarzinom. Springer Reference Medizin, 2020, , 1-11.	0.0	0
1195	Oncogenic roles of the cholesterol metabolite 25â€³hydroxycholesterol in bladder cancer. Oncology Letters, 2020, 19, 3671-3676.	1.8	4
1196	Expression and correlation of Bmi-1, AEG-1 and FHIT in bladder transitional cell carcinoma. Translational Cancer Research, 2020, 9, 1326-1336.	1.0	0

#	ARTICLE	IF	CITATIONS
1197	Small cell carcinoma of the upper urinary tract and factors associated with progress survival: a systematic review and pooled analysis. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 115-122.	3.9	2
1198	Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patients' Perspectives. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151226.	1.5	4
1199	Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. <i>Frontiers in Chemistry</i> , 2021, 9, 765552.	3.6	21
1200	A brief review and case report of urothelial carcinoma and metachronous leiomyosarcoma of the bladder at the same anatomic region. <i>Urology Case Reports</i> , 2021, 40, 101931.	0.3	1
1201	Robotic-Assisted Ileal Conduit Urinary Diversion. , 2022, , 295-310.		0
1202	Incidencia y mortalidad del cáncer de vejiga en Costa Rica y Panamá, 2007-2013. <i>Acta Medica Costarricense</i> , 2019, 61, .	0.1	0
1203	Integrating Diagnosis Rules into Deep Neural Networks for Bladder Cancer Staging. , 2020, , .		4
1205	Novel and Experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma. , 2021, , 215-220.		0
1206	Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update. <i>European Medical Journal Oncology</i> , 0, , .	0.0	0
1207	The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors. <i>Radiology and Oncology</i> , 2020, 55, 196-202.	1.7	7
1208	Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 629-638.	0.0	10
1209	Deep Learning data integration for better risk stratification models of bladder cancer. <i>AMIA Summits on Translational Science Proceedings</i> , 2018, 2017, 197-206.	0.4	18
1210	Expression of Inhibitor of Apoptosis Gene Family Members in Bladder Cancer Tissues and the 5637 Tumor Cell Line. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 529-532.	1.2	4
1211	Cancer-associated methylated lncRNAs in patients with bladder cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 3790-3800.	0.0	7
1212	Loss of E-cadherin expression in recurrent non-invasive urothelial carcinoma of the bladder. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4163-4168.	0.5	5
1213	The antitumor effect of the novel cancer-specific adenovirus Ad-VEGFR on bladder cancer in vitro and in vivo. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4795-4805.	0.5	0
1214	The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3033-3045.	0.0	4
1216	A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 355-365.	0.5	2

#	ARTICLE	IF	CITATIONS
1217	Estrogen receptor- β signaling induces cisplatin resistance in bladder cancer. American Journal of Cancer Research, 2020, 10, 2523-2534.	1.4	5
1218	Identification and validation of an immune-related gene-based prognostic index for bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 5188-5204.	0.0	6
1219	CircHIPK3: a promising cancer-related circular RNA. American Journal of Translational Research (discontinued), 2020, 12, 6694-6704.	0.0	17
1220	P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma. Oncology Letters, 2021, 21, 95.	1.8	9
1221	Comparative Bioinformatics Characteristic of Bladder Cancer Stage 2 from Stage 4 Expression Profile: A Network-Based Study. Galen, 2018, 7, e1279.	0.6	0
1222	Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada. BMJ Open, 2021, 11, e050728.	1.9	1
1223	Clinical effect of robot-assisted radical cystectomy in bladder cancer. American Journal of Translational Research (discontinued), 2021, 13, 10545-10553.	0.0	0
1224	Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion. Urological Science, 2019, 30, 157-163.	0.6	0
1225	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. European Journal of Radiology, 2022, 146, 110059.	2.6	2
1226	Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project. JCO Global Oncology, 2021, 7, 1547-1555.	1.8	2
1227	The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabolomics. Genomics, 2022, 114, 125-137.	2.9	14
1228	A Novel Assessment Model Based on Molecular Subtypes of Hypoxia-Related LncRNAs for Prognosis of Bladder Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 718991.	3.7	5
1229	OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts. Frontiers in Oncology, 2021, 11, 650678.	2.8	5
1230	Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer. Frontiers in Oncology, 2021, 11, 717622.	2.8	5
1231	Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Global Health, 2021, 6, e004128.	4.7	41
1232	A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. Scandinavian Journal of Urology, 2022, 56, 20-26.	1.0	2
1233	Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. Cancer Science, 2022, 113, 784-795.	3.9	10
1234	Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system. Cancer Medicine, 2021, , .	2.8	2

#	ARTICLE	IF	CITATIONS
1235	A Systematic Review and Meta-Analysis Protocol of Chemoablation vs. Transurethral Resection of Bladder Tumor in Patients With Non-Muscle-Invasive Bladder Cancer. <i>Frontiers in Surgery</i> , 2021, 8, 753547.	1.4	4
1236	Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. <i>International Urology and Nephrology</i> , 2022, 54, 71-79.	1.4	1
1237	An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. <i>BMC Cancer</i> , 2021, 21, 1256.	2.6	12
1238	Effect of Traditional Chinese Medicine Combined with Bladder Perfusion with Hydroxycamptothecin on Color Ultrasound and Clinical Efficacy in Patients with Bladder Cancer Surgery. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-8.	1.2	3
1239	Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. <i>BMC Cancer</i> , 2021, 21, 1267.	2.6	8
1240	Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies. <i>Future Oncology</i> , 2022, 18, 105-115.	2.4	6
1241	Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 6123-6133.	1.1	5
1242	Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 5989.	3.7	11
1243	Usefulness of Preoperative High Systemic Immune-Inflammation Index as a Prognostic Biomarker in Patients Who Undergo Radical Cystectomy for Bladder Cancer: Multicenter Analysis. <i>Diagnostics</i> , 2021, 11, 2194.	2.6	8
1244	CircRNA hsa_circ_0014130 function as a miR-132-3p sponge for playing oncogenic roles in bladder cancer via upregulating KCNJ12 expression. <i>Cell Biology and Toxicology</i> , 2022, 38, 1079-1096.	5.3	21
1245	MicroRNA as a Biomarker for Diagnostic, Prognostic, and Therapeutic Purpose in Urinary Tract Cancer. <i>Processes</i> , 2021, 9, 2136.	2.8	0
1246	Determinants and Dynamic Changes of Generic Quality of Life in Human Bladder Cancer Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 5472.	2.4	2
1247	miR-200a-3p facilitates bladder cancer cell proliferation by targeting the A20 gene. <i>Translational Andrology and Urology</i> , 2021, 10, 4262-4274.	1.4	4
1248	Biological Functions and Prognostic Value of Ferroptosis-Related Genes in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 631152.	3.5	19
1249	FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. <i>Cancer Research</i> , 2022, 82, 114-129.	0.9	50
1250	Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort. <i>Molecular Biology Reports</i> , 2022, 49, 1233-1258.	2.3	4
1251	Increased risk of bladder cancer in young adult men with hyperlipidemia. <i>Medicine (United States)</i> , 2021, 100, e28125.	1.0	4
1252	Circular RNA circFLNA inhibits the development of bladder carcinoma through microRNA miR-216a-3p/BTG2 axis. <i>Bioengineered</i> , 2021, 12, 11376-11389.	3.2	7

#	ARTICLE	IF	CITATIONS
1254	Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. International Journal of Hyperthermia, 2021, 38, 1627-1632.	2.5	1
1255	The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?. Immunotherapy, 2022, , .	2.0	2
1256	Reasoning about bladder cancer treatment outcomes using clinical trials within a knowledge-based clinical evidence approach. Procedia Computer Science, 2022, 196, 631-639.	2.0	1
1257	Biomaterials assisted reconstructive urology: The pursuit of an implantable bioengineered neo-urinary bladder. Biomaterials, 2022, 281, 121331.	11.4	11
1258	LncRNA TUG1 promotes bladder cancer malignant behaviors by regulating the miR-320a/FOXQ1 axis. Cellular Signalling, 2022, 91, 110216.	3.6	13
1259	P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma. Oncology Letters, 2020, 21, 95.	1.8	27
1260	Urological Cancers in French Overseas Territories: A Population-Based Cancer Registry Pooled Analysis in Martinique, Guadeloupe and French Guiana (2007â€“2014). Journal of Epidemiology and Global Health, 2022, 12, 232-238.	2.9	2
1261	Recent Progress in Understanding the Action of Natural Compounds at Novel Therapeutic Drug Targets for the Treatment of Liver Cancer. Frontiers in Oncology, 2021, 11, 795548.	2.8	11
1262	Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 809620.	3.7	6
1263	Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	2.5	4
1264	Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors. Investigative and Clinical Urology, 2022, 63, 14.	2.0	0
1265	Association of Recommended and Non-Recommended Food Score and Risk of Bladder Cancer: A Case-Control Study. Nutrition and Cancer, 2022, 74, 2105-2112.	2.0	4
1266	Risk Stratification for the Rate and Location of Residual Bladder Tumor for the Decision of Re-Transurethral Resection of Bladder Tumor. Frontiers in Oncology, 2022, 12, 788568.	2.8	2
1267	Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDOT1: a review. Cellular and Molecular Biology Letters, 2022, 27, 9.	7.0	13
1268	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncology, 2022, 18, 739-748.	2.4	11
1269	DNA Methylome Changes of Muscle- and Neuronal-Related Processes Precede Bladder Cancer Invasiveness. Cancers, 2022, 14, 487.	3.7	2
1270	Indoleamine 2,3-Dioxygenase-1 Expression is Changed During Bladder Cancer Cell Invasion. International Journal of Tryptophan Research, 2022, 15, 117864692110656.	2.3	2
1271	CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patientsâ€™ Survival. Cancer Investigation, 2022, 40, 228-233.	1.3	4

#	ARTICLE	IF	CITATIONS
1272	Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF- κ B and PI3K/AKT Signaling In Vitro and In Vivo. Chinese Journal of Integrative Medicine, 2022, 28, 349-356.	1.6	5
1273	Advances in Management of Bladder Cancer—The Role of Photodynamic Therapy. Molecules, 2022, 27, 731.	3.8	31
1274	Family History and Risk of Bladder Cancer: An Analysis Accounting for First- and Second-degree Relatives. Cancer Prevention Research, 2022, 15, 319-326.	1.5	5
1275	Comprehensive Analysis of N6-Methyladenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer. Frontiers in Oncology, 2022, 12, 774307.	2.8	4
1276	Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. European Urology Focus, 2022, 8, 1246-1252.	3.1	6
1277	Deciphering the influence of urinary microbiota on FoxP3+ regulatory T cell infiltration and prognosis in Chinese patients with non-muscle-invasive bladder cancer. Human Cell, 2022, 35, 511-521.	2.7	11
1278	Screening Differential CircRNAs Expression Profiles Reveals the Regulatory Role of the <i>circTPT1_003</i> – <i>miR-218-5p</i> – <i>CCNE2/SMC4</i> Signaling Axis in Bladder Carcinoma Progression. DNA and Cell Biology, 2022, 41, 128-141.	1.9	2
1279	Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer. Central European Journal of Urology, 2022, 75, 41-46.	0.3	3
1280	<i>miR-148a-3p</i> inhibits the proliferation and migration of bladder cancer <i>via</i> regulating the expression of ROCK-1. PeerJ, 2022, 10, e12724.	2.0	5
1281	PET imaging in renal and bladder cancers. , 2022, , .		0
1282	Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer. Disease Markers, 2022, 2022, 1-14.	1.3	12
1283	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	4.4	19
1284	Accuracy of cytokeratin 19 fragment in the diagnosis of bladder cancer. Biomarkers in Medicine, 2022, 16, 197-216.	1.4	4
1285	Comprehensive Investigation of Genes Associated Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma. Journal of Environmental Pathology, Toxicology and Oncology, 2022, , .	1.2	0
1286	KLF16 Downregulates the Expression of Tumor Suppressor Gene TGFBR3 to Promote Bladder Cancer Proliferation and Migration. Cancer Management and Research, 2022, Volume 14, 465-477.	1.9	8
1287	Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered <i>circPRMT5</i> siRNA. Biomaterials Research, 2022, 26, 6.	6.9	11
1288	Inferring Latent Disease-lncRNA Associations by Label-Propagation Algorithm and Random Projection on a Heterogeneous Network. Frontiers in Genetics, 2022, 13, 798632.	2.3	0
1289	MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 757137.	3.7	13

#	ARTICLE	IF	CITATIONS
1290	Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis. <i>Biology</i> , 2022, 11, 259.	2.8	7
1291	Prognostic Value of Pretreatment Inflammatory Markers in Patients Receiving Radical Cystectomy for Urothelial Bladder Cancer: Does Age Matter?. <i>Urologia Internationalis</i> , 2022, 106, 832-839.	1.3	2
1292	Continent cutaneous urinary diversion with an ileal pouch with the Mitrofanoff principle versus a Miami pouch in patients undergoing cystectomy for bladder cancer: results of a comparative study. <i>World Journal of Urology</i> , 2022, , 1.	2.2	1
1293	Mortality Trends Related to Bladder Cancer in Spain, 1999â€“2018. <i>Journal of Clinical Medicine</i> , 2022, 11, 930.	2.4	2
1294	Socio-economic burden of disease: Survivorship costs for bladder cancer. <i>Journal of Cancer Policy</i> , 2022, 32, 100326.	1.4	13
1295	Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 795242.	2.8	3
1296	Associations between body mass index and bladder cancer survival: Is the obesity paradox short-lived?. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	2
1297	An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 780329.	3.5	5
1298	MIR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer. <i>Journal of Biosciences</i> , 2019, 44, .	1.1	9
1299	CDKN1A/p21, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. <i>American Journal of Cancer Research</i> , 2021, 11, 5452-5471.	1.4	2
1300	Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722210794.	2.0	6
1301	LncRNA CCHE1 participate in the postoperative distant recurrence of urothelial bladder cancer possibly by regulating ROCK1 expression. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2022, , .	0.9	0
1302	Bladder Cancer in Young Patients: Management and Outcomes. <i>Journal of Cancer Therapy</i> , 2022, 13, 168-178.	0.4	0
1303	Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1038.	2.4	3
1305	Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression. <i>Frontiers in Oncology</i> , 2022, 12, 835074.	2.8	3
1306	Registration of Urothelial Tumours in Cancer Registries: How to Improve and Make It More Useful?. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2714.	2.6	1
1307	The Role of Keratin17 in Human Tumours. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818416.	3.7	11
1308	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer. <i>Genes</i> , 2022, 13, 422.	2.4	2

#	ARTICLE	IF	CITATIONS
1309	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmetteâ€“Guerin Immunotherapy. <i>Diagnostics</i> , 2022, 12, 586.	2.6	14
1310	Clinicopathological Review of Micropapillary Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 603.	4.0	3
1311	Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 52-58.	0.1	0
1312	In vivo Raman spectroscopy for bladder cancer detection using a superficial Raman probe compared to a nonsuperficial Raman probe. <i>Journal of Biophotonics</i> , 2022, 15, e202100354.	2.3	7
1313	Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer. <i>Cancers</i> , 2022, 14, 1576.	3.7	3
1314	Associations of selfâ€“efficacy, social support and coping strategies with healthâ€“related quality of life after radical cystectomy for bladder cancer: A crossâ€“sectional study. <i>European Journal of Cancer Care</i> , 2022, , .	1.5	2
1315	Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 837754.	3.5	5
1316	Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 725024.	3.7	0
1317	Utility of urinary biomarkers in primary haematuria: Systematic review and metaâ€“analysis. <i>BJUI Compass</i> , 2022, 3, 334-343.	1.3	6
1318	PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. <i>BMC Cancer</i> , 2022, 22, 312.	2.6	3
1319	Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells. <i>Precision Clinical Medicine</i> , 2022, 5, .	3.3	4
1320	Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis. <i>Bioengineered</i> , 2022, 13, 7986-7999.	3.2	2
1321	Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-15.	1.9	14
1322	Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.6	0
1323	Can Diet Prevent Urological Cancers? An Update on Carotenoids as Chemopreventive Agents. <i>Nutrients</i> , 2022, 14, 1367.	4.1	5
1324	An HDAC9-associated immune-related signature predicts bladder cancer prognosis. <i>PLoS ONE</i> , 2022, 17, e0264527.	2.5	2
1325	Bladder cancer prospective cohort study on highâ€“risk nonâ€“muscle invasive bladder cancer after photodynamic diagnosisâ€“assisted transurethral resection of the bladder tumor (BRIGHT study). <i>International Journal of Urology</i> , 2022, 29, 632-638.	1.0	10
1326	Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 759153.	2.8	5

#	ARTICLE	IF	CITATIONS
1327	The Antibiotic and Antiprotozoal Agent Dibromopropamidine Dihydrochloride is a New EGFR Inhibitor and Potential Anticancer Drug for Bladder Cancer. <i>ChemistrySelect</i> , 2022, 7, .	1.5	0
1328	Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment. <i>Nutrients</i> , 2022, 14, 1132.	4.1	3
1329	SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 864156.	4.8	11
1330	MiR-7-5p suppresses invasion via downregulation of the autophagy-related gene ATG7 and increases chemoresistance to cisplatin in BCa. <i>Bioengineered</i> , 2022, 13, 7328-7339.	3.2	9
1331	An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 837301.	2.3	2
1332	Trends in the cause of death among patients with bladder cancer in the US SEER population, 1992â€“2018. <i>World Journal of Urology</i> , 2022, , 1.	2.2	3
1333	The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype. <i>BMC Cancer</i> , 2022, 22, 373.	2.6	9
1334	Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain <i>FGFR</i> genetic alterations. <i>Future Oncology</i> , 2022, 18, 2455-2464.	2.4	4
1335	Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1635-1646.	6.7	4
1336	In vitro and in vivo anti-tumor efficacy of krill oil against bladder cancer: Involvement of tumor-associated angiogenic vasculature. <i>Food Research International</i> , 2022, 156, 111144.	6.2	7
1337	OncoTheradÂ® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway. <i>Tissue and Cell</i> , 2022, 76, 101762.	2.2	9
1338	Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada. <i>BMJ Open</i> , 2021, 11, e050728.	1.9	10
1339	Overexpression of the PPARâ€“Î³ protein in primary Ta/T1 nonâ€“muscleâ€“invasive urothelial carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 36.	1.0	2
1340	Effect of treatment modality on quality of life among patients with urinary bladder cancer. <i>International Journal of Urological Nursing</i> , 0, , .	0.2	0
1341	METTL1â€“m ⁷ Gâ€“EGFR/EFEMP1 axis promotes the bladder cancer development. <i>Clinical and Translational Medicine</i> , 2021, 11, e675.	4.0	87
1342	PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 783050.	3.7	7
1343	Predictive value of inflammatory indices LMR, PLR and NLR in patients with muscle-invasive bladder cancer. <i>Urologicheskie Vedomosti</i> , 2021, 11, 285-294.	0.3	0
1344	Effectiveness and Safety of a Modified Technique of Transvesical Obturator Nerve Block to Avoid Adductor Contractions during Transurethral Resection of Bladder Tumors. <i>Urologia Internationalis</i> , 2022, 106, 775-783.	1.3	2

#	ARTICLE	IF	CITATIONS
1345	Impact of bacillus Calmetteâ€Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with highâ€grade bladder cancer. Cancer Cytopathology, 2022, 130, 294-302.	2.4	2
1346	Benchmarking PASADENA Consensus along the Learning Curve of Robotic Radical Cystectomy with Intracorporeal Neobladder: CUSUM Based Assessment. Journal of Clinical Medicine, 2021, 10, 5969.	2.4	12
1347	Dotting the â€œâ€of Interoperability in FAIR Cancer-Registry Data Sets. , 0, , .		1
1348	Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection. BMC Urology, 2021, 21, 180.	1.4	4
1349	Identification and Validation of Hub Genes Associated with Bladder Cancer by Integrated Bioinformatics and Experimental Assays. Frontiers in Oncology, 2021, 11, 782981.	2.8	11
1350	miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression. Frontiers in Oncology, 2021, 11, 762946.	2.8	7
1351	Berberine enhances gemcitabineâ€induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway. Oncology Reports, 2021, 47, .	2.6	8
1352	ZNF652-Induced circRHOT1 Promotes SMAD5 Expression to Modulate Tumorigenic Properties and Nature Killer Cell-Mediated Toxicity in Bladder Cancer via Targeting miR-3666. Journal of Immunology Research, 2021, 2021, 1-17.	2.2	7
1353	TRIM38 triggers the ubiquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. Journal of Translational Medicine, 2021, 19, 508.	4.4	18
1355	Urologic Cancer Molecular Biology. , 0, , .		0
1356	Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 47-57.	2.3	2
1357	Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p. BMC Cancer, 2022, 22, 313.	2.6	9
1358	Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes. Journal of Immunology Research, 2022, 2022, 1-16.	2.2	9
1359	Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 197.e25-197.e25.	1.6	3
1360	KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment. Scientific Reports, 2022, 12, 6015.	3.3	8
1392	The Incidence and Geographical Distribution of Brucellosis in Iran Using Geographic Information System and Prediction of its Incidence in 2021.. Journal of Preventive Medicine and Hygiene, 2021, 62, E635-E634.	0.9	5
1397	Saikosaponin A inhibits growth of human bladder carcinoma T24 and 5637 cells both <i>in vitro<i> and <i>in vivo<i>. Biological and Pharmaceutical Bulletin, 2022, , .	1.4	1
1398	JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. Cancer Research, 2022, 82, 1789-1802.	0.9	66

#	ARTICLE	IF	CITATIONS
1399	Urothelial bladder cancer in young versus older adults: Presentations, clinical characteristics, and outcomes. Zanco Journal of Medical Sciences, 2022, 26, 29-37.	0.1	0
1400	Classification of tissue biopsies by Raman spectroscopy guided by quantitative phase imaging and its application to bladder cancer. Journal of Biophotonics, 2022, 15, e202200009.	2.3	2
1401	Classification of retinoblastoma-1 gene mutation with machine learning-based models in bladder cancer. Heliyon, 2022, 8, e09311.	3.2	6
1402	Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World Journal of Urology, 2022, 40, 1715-1721.	2.2	12
1403	Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor. Pakistan Journal of Medical Sciences, 2022, 38, .	0.6	0
1404	Risk of malignancy in kidney transplant recipients: a nationwide population-based cohort study. BMC Nephrology, 2022, 23, 160.	1.8	2
1405	Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduction and Targeted Therapy, 2022, 7, 142.	17.1	62
1406	CircMCTP2 (has-circ-0000658) facilitates the proliferation and metastasis of bladder carcinoma through modulating the miR-498/murine double minute-2 axis. Bioengineered, 2022, 13, 10734-10748.	3.2	1
1407	Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma. Frontiers in Public Health, 2022, 10, 837854.	2.7	1
1408	Potential risk of colonization of Bulinus globosus in the mainland of China under climate change. Infectious Diseases of Poverty, 2022, 11, 52.	3.7	1
1409	Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. Frontiers in Oncology, 2022, 12, .	2.8	0
1410	circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5. Cell Death Discovery, 2022, 8, 243.	4.7	9
1411	Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry. Frontiers in Oncology, 2022, 12, .	2.8	5
1412	CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?. International Journal of Molecular Sciences, 2022, 23, 5453.	4.1	7
1413	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Caseâ€“Control Studies. Environmental Health Perspectives, 2022, 130, 57006.	6.0	5
1415	Identification of a pyroptosis related gene signature for predicting prognosis and estimating tumor immune microenvironment in bladder cancer. Translational Cancer Research, 2021, .	1.0	0
1416	The potential role of N7-methylguanosine (m7G) in cancer. Journal of Hematology and Oncology, 2022, 15, 63.	17.0	94
1417	Metastatic urinary bladder carcinoma on palliative chemotherapy showing rapid progression on interim fluorodeoxyglucose positron emission tomography/computed tomography. Indian Journal of Nuclear Medicine, 2022, 37, 105.	0.3	0

#	ARTICLE	IF	CITATIONS
1418	Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 381.e9-381.e16.	1.6	3
1420	Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	1
1421	Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer. <i>International Urology and Nephrology</i> , 2022, 54, 1845-1855.	1.4	1
1422	Enhanced Recovery After Surgery Program for Radical Cystectomy. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 92-106.	0.1	0
1423	Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
1424	Associations of MTHFR rs1801133 (677C>T) and rs180113 (1298A>C) Polymorphisms with Susceptibility to Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1465-1482.	1.2	1
1425	Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 239-247.	2.9	3
1426	Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 2545.	3.7	37
1427	Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment. <i>International Journal of Urology</i> , 2022, 29, 1120-1129.	1.0	4
1428	The Additional Value of Tri-parametric MRI in Identifying Muscle-invasive Status in Bladder Cancer. <i>Academic Radiology</i> , 2023, 30, 64-76.	2.5	5
1429	Identification of Feature Genes of a Novel Neural Network Model for Bladder Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
1430	Grading Systems for Canine Urothelial Carcinoma of the Bladder: A Comparative Overview. <i>Animals</i> , 2022, 12, 1455.	2.3	2
1431	Tumors of the Urinary Bladder. , 2021, , 345-559.		0
1432	Multiparametric MRI Evaluation of VI-RADS for Bladder Tumors Located at the Ureteral Orifice. <i>Radiology</i> , 2022, 304, 593-599.	7.3	4
1433	SOX5 promotes cell growth and migration through modulating DNMT1/p21 pathway in bladder cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 987-998.	2.0	1
1434	Comparison of the effectiveness of two combinations of antibiotic used for perioperative prophylactic therapy during radical cystectomy: A retrospective cohort study. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	1
1436	A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
1437	IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10

#	ARTICLE	IF	CITATIONS
1438	Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	0
1439	Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
1440	Bioinformatic Analysis of the Expression and Clinical Significance of the DNA Replication Regulator MCM Complex in Bladder Cancer. <i>International Journal of General Medicine</i> , 0, Volume 15, 5465-5485.	1.8	4
1441	The Emerging Roles of circSMARCA5 in Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	1
1443	Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer. <i>Oncogene</i> , 2022, 41, 3587-3598.	5.9	8
1444	EGFR, NF- κ B and noncoding RNAs in precision medicine. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 189-218.	1.7	1
1445	Differentiation of Bladder Cancer from Inflammation with Polarization-Sensitive Optical Coherence Tomography. , 2022, , .		0
1446	Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. <i>Bioengineered</i> , 2022, 13, 13986-13999.	3.2	6
1447	Management of gastro-intestinal emergencies in patients with ileal conduit ureteral diversion. <i>Journal of Visceral Surgery</i> , 2022, , .	0.8	0
1448	The dynamic roles of the bladder tumour microenvironment. <i>Nature Reviews Urology</i> , 2022, 19, 515-533.	3.8	24
1449	Risk-based assessment of the impact of intravesical therapy on recurrence-free survival rate following resection of suspected low-grade, non-muscle-invasive bladder cancer (NMIBC): a Southwest Oncology Groups (SWOG) S0337 post-hoc analysis. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
1451	Amide Proton Transferâ€“weighted MRI: Insight into Cancer Cell Biology. <i>Radiology</i> , 0, , .	7.3	0
1452	Downregulation of PTC1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	3
1453	The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	0
1454	Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325.		4
1455	CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-18.	1.3	3
1456	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
1457	Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4

#	ARTICLE	IF	CITATIONS
1459	NEAT1/MALAT1/XIST/PKD-Hsa-Mir-101-3p-DLGAP5 Axis as a Novel Diagnostic and Prognostic Biomarker Associated With Immune Cell Infiltration in Bladder Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	6
1460	CNN1 Represses Bladder Cancer Progression and Metabolic Reprogramming by Modulating HIF-1 α Signaling Pathway. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
1461	Prediction of the postoperative prognosis in patients with non-muscle-invasive bladder cancer based on preoperative serum surface-enhanced Raman spectroscopy. <i>Biomedical Optics Express</i> , 2022, 13, 4204.	2.9	4
1462	MiR-183-5p-PNPT1 Axis Enhances Cisplatin-induced Apoptosis in Bladder Cancer Cells. <i>Current Medical Science</i> , 2022, 42, 785-796.	1.8	5
1463	Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer. <i>Oncology Letters</i> , 2022, 24, .	1.8	3
1464	Green one-step reduction approach to prepare rGO@AgNPs coupled with molecularly imprinted polymer for selective electrochemical detection of lactic acid as a cancer biomarker. <i>Materials Chemistry and Physics</i> , 2022, 289, 126456.	4.0	16
1465	NCAPG promotes tumorigenesis of bladder cancer through NF- κ B signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2022, 622, 101-107.	2.1	5
1466	The rising burden of acute urologic disease at an urban, academic hospital network. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	1
1467	A Review of the Etiology and Epidemiology of Bladder Cancer: All You Need To Know. <i>Cureus</i> , 2022, , .	0.5	4
1468	Integrated Urinalysis Devices Based on Interface-Engineered Field-Effect Transistor Biosensors Incorporated With Electronic Circuits. <i>Advanced Materials</i> , 2022, 34, .	21.0	32
1469	Tumor-infiltrating lymphocytes predict survival in γ -H2T urothelial bladder cancer. <i>Pathology Research and Practice</i> , 2022, 237, 154037.	2.3	3
1470	MITF-Mediated lncRNA CCDC183-As1 Promotes the Tumorigenic Properties and Aerobic Glycolysis of Bladder Cancer via Upregulating TCF7L2. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	1.3	3
1471	Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
1472	Novel immunotherapy in the management of advanced urothelial cancer - review of the literature. <i>Journal of Education, Health and Sport</i> , 2022, 12, 348-357.	0.1	0
1473	Dynamic changes of quality of life in muscle-invasive bladder cancer survivors. <i>BMC Urology</i> , 2022, 22, .	1.4	4
1474	Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis. <i>Current Oncology</i> , 2022, 29, 5846-5854.	2.2	2
1475	Dietary consumption of cruciferous vegetables and bladder cancer risk: A systematic review and meta-analysis. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	1
1476	Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder. <i>Cancers</i> , 2022, 14, 3999.	3.7	2

#	ARTICLE	IF	CITATIONS
1477	Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study. BMC Urology, 2022, 22, .	1.4	6
1478	Preoperative Free Ferrous Protoporphyrin and Reactive Oxygen Species Status of Voided Urine Predicts Potential Recurrence Risk in NMIBC. Cancer Management and Research, 0, Volume 14, 2291-2297.	1.9	3
1479	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. British Journal of Clinical Pharmacology, 0, , .	2.4	1
1481	Central Venous Access and the Risk for Thromboembolic Events in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Life, 2022, 12, 1198.	2.4	1
1482	Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study. International Urology and Nephrology, 2022, 54, 3123-3137.	1.4	1
1483	Fucoidan from Sargassum hemiphyllum inhibits the stemness of cancer stem cells and epithelial-mesenchymal transitions in bladder cancer cells. International Journal of Biological Macromolecules, 2022, 221, 623-633.	7.5	4
1484	PENet: Prior evidence deep neural network for bladder cancer staging. Methods, 2022, 207, 20-28.	3.8	2
1485	Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis. Frontiers in Genetics, 0, 13, .	2.3	2
1486	Dynamic alteration and prognostic significance of tumor-associated CD68 ⁺ and CD68 ⁺ PD-L1 ⁺ macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Cancer Medicine, 0, , .	2.8	1
1487	Identification and verification of the pyroptosis-related prognostic signature and its associated regulatory axis in bladder cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	3
1488	Incidence, prognostic factors and survival in bladder cancer patients: a population-based study. Translational Cancer Research, 2022, 11, 2742-2756.	1.0	0
1489	Comprehensive analysis of alternative polyadenylation regulators concerning CD276 and immune infiltration in bladder cancer. BMC Cancer, 2022, 22, .	2.6	3
1490	State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer. Biosensors, 2022, 12, 796.	4.7	11
1491	Development of a Pocket Nomogram to Predict Cancer and Disease Specific Survival After Radical Cystectomy For Bladder Cancer: The CRAB Nomogram. Clinical Genitourinary Cancer, 2023, 21, 108-114.	1.9	1
1492	The impact of genetic variants in the CYP2C8 gene on bladder cancer susceptibility. Frontiers in Endocrinology, 0, 13, .	3.5	1
1493	The Safety and Efficacy of Vela Laser En-Bloc Endoscopic Resection versus Conventional Transurethral Resection of Bladder Tumor—A Single Center Experience. Journal of Clinical Medicine, 2022, 11, 5233.	2.4	3
1494	Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet, The, 2022, 400, 1712-1721.	13.7	67
1495	Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation. Cellular Oncology (Dordrecht), 2022, 45, 1203-1215.	4.4	1

#	ARTICLE	IF	CITATIONS
1496	Effects of the COVID-19 Pandemic on Bladder Cancer Diagnosis and Treatment Processes; A Turkish Multicenter Study. <i>Journal of Urological Surgery</i> , 2022, 9, 165-171.	0.1	0
1497	Exploring the casual association between coffee intake and bladder cancer risk using Mendelian Randomization. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
1499	Identification of Epigenetic Interactions between miRNA and Gene Expression as Potential Prognostic Markers in Bladder Cancer. <i>Genes</i> , 2022, 13, 1629.	2.4	5
1500	Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. <i>BMC Cancer</i> , 2022, 22, .	2.6	6
1501	CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
1502	Clinicopathological Characteristics and Prognostic Factors of Primary Bladder Signet Ring Cell Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-7.	1.9	1
1503	LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPAR γ Ubiquitination in Bladder Cancer. <i>Cancers</i> , 2022, 14, 4740.	3.7	6
1504	Artificial intelligenceâ€driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multiâ€center integration analysis. <i>Molecular Oncology</i> , 2022, 16, 4023-4042.	4.6	13
1508	A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	5
1509	Significance of tumor-associated macrophages in bladder cancer development. <i>Uspehi Molekularnoj Onkologii</i> , 2022, 9, 8-14.	0.3	0
1510	Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 311-322.	5.1	4
1511	Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer. <i>Anti-Cancer Drugs</i> , 2023, 34, 269-280.	1.4	2
1512	Multomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy. <i>Translational Cancer Research</i> , 2022, 11, 4089-4104.	1.0	1
1513	Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. , 2022, , 201-231.		0
1514	Cigarette smoking, smoking cessation and bladder cancer risk: A pooled analysis of ten cohort studies in Japan. <i>Journal of Epidemiology</i> , 2022, , .	2.4	3
1515	The Emerging Roles and Clinical Potential of circSMARCA5 in Cancer. <i>Cells</i> , 2022, 11, 3074.	4.1	4
1516	A Novel m7G-Related Genes-Based Signature with Prognostic Value and Predictive Ability to Select Patients Responsive to Personalized Treatment Strategies in Bladder Cancer. <i>Cancers</i> , 2022, 14, 5346.	3.7	5
1517	Adaptive-mixture-categorization (AMC)-based g-computation and its application to trace element mixtures and bladder cancer risk. <i>Scientific Reports</i> , 2022, 12, .	3.3	0

#	ARTICLE	IF	CITATIONS
1518	Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). <i>Kreativna Ć Hirurģi Ć I Onkologi Ć</i> , 2022, 12, 205-216.	0.3	0
1520	Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). <i>Cancers</i> , 2022, 14, 5286.	3.7	0
1521	Treatment decisions of bladder cancer in patients older than 85 years: a SEER-based analysis 2011–2015. <i>Translational Cancer Research</i> , 2022, 11, 3584-3592.	1.0	1
1522	Preoperative Fibrinogen-to-Albumin Ratio as Potential Predictor of Bladder Cancer: A Monocentric Retrospective Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1490.	2.0	8
1523	Immunogenic cell death mediation patterns reveal novel paradigm for characterizing the immune microenvironment and immunotherapeutic responses in bladder cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	3
1524	SENP3 affects the expression of PYCR1 to promote bladder cancer proliferation and EMT transformation by deSUMOylation of STAT3. <i>Aging</i> , 2022, 14, 8032-8045.	3.1	3
1525	Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
1526	Caveolin-1, GATA-3, and Ki67 expressions and their correlation with pathological findings in canine bladder urothelial carcinoma. <i>Frontiers in Veterinary Science</i> , 0, 9, .	2.2	1
1527	Fatty foods and the risk of bladder cancer: A case-control study. <i>Nutrition</i> , 2023, 106, 111868.	2.4	1
1528	Network-based Pharmacology and In vitro Validation Reveal that Galangin Induces Apoptosis in Bladder Cancer Cells by Promoting the P53 Signaling Pathway. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 847-857.	1.7	2
1530	<scp>LncRNA SNHG3</scp> enhances <scp>BMI1 mRNA</scp> stability by binding and regulating <scp>câ€MYC</scp>: Implications for the carcinogenic role of <scp>SNHG3</scp> in bladder cancer. <i>Cancer Medicine</i> , 2023, 12, 5718-5735.	2.8	6
1531	A Novel Risk Model for lncRNAs Associated with Oxidative Stress Predicts Prognosis of Bladder Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	4
1532	A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990–2019. <i>PLoS ONE</i> , 2022, 17, e0275574.	2.5	2
1533	Prognostic significance and identification of basement membrane-associated lncRNA in bladder cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
1534	Analysis of sex-based differences to <i>Bacillus Calmette-Guérin</i> for non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 539.e1-539.e8.	1.6	3
1535	Circ_0002099 is a novel molecular therapeutic target for bladder cancer. <i>Drug Development Research</i> , 2022, 83, 1890-1905.	2.9	4
1536	MSEDNet: Multi-Scale Encoder and Decoder with Transformer for Bladder Tumor Segmentation. <i>Electronics (Switzerland)</i> , 2022, 11, 3347.	3.1	1
1537	Single-cell sequencing technologies in bladder cancer research: Applications and challenges. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4

#	ARTICLE	IF	CITATIONS
1538	Epidemiology, Screening, and Prevention of Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 628-639.	5.4	65
1539	OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5025-5036.	2.5	3
1540	R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer. <i>Journal of Controlled Release</i> , 2022, 351, 834-846.	9.9	13
1541	Effect of Conjugated Linoleic Acid (CLA) Supplementation on Expression of B-Cell Lymphoma-2 (Bcl-2) in the Bladder Epithelium of Wistar (<i>Rattus norvegicus</i>) Rats Exposed to Cigarette Smoke. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2022, 76, 343.	0.9	1
1542	The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
1543	Temporal Trends and Projections of Bladder Cancer Burden in China from 1990 to 2030: Findings from the Global Burden of Disease Study. <i>Clinical Epidemiology</i> , 0, Volume 14, 1305-1315.	3.0	7
1545	Systematic review on oncologic outcomes on adjuvant endovesical treatment for non-muscle invasive bladder cancer in patients with solid organ transplant. <i>World Journal of Urology</i> , 0, , .	2.2	0
1546	Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 692-700.	6.4	1
1547	The Indispensability of Snail Control for Accelerating Schistosomiasis Elimination: Evidence from Zanzibar. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 347.	2.3	3
1548	A Comparative Study of Deep Neural Networks for Real-Time Semantic Segmentation during the Transurethral Resection of Bladder Tumors. <i>Diagnostics</i> , 2022, 12, 2849.	2.6	3
1549	Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
1550	Evaluation of grade and invasiveness of bladder urothelial carcinoma using infrared imaging and machine learning. <i>Analyst, The</i> , 2023, 148, 278-285.	3.5	4
1551	Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition. <i>International Journal of Biological Sciences</i> , 2023, 19, 1-12.	6.4	5
1552	Recent Progress in Urothelial Bladder Carcinoma: Basic Biology, Molecular Characterization, Conventional and Innovative Therapies and Tumour-Stroma Interactions. , 2022, , .		0
1553	Exosomal miR-93-5p from cancer-associated fibroblasts confers malignant phenotypes on bladder cancer cells by targeting PAFAH1B1. <i>Anti-Cancer Drugs</i> , 2023, 34, 439-450.	1.4	2
1554	The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. <i>BMC Urology</i> , 2022, 22, .	1.4	1
1555	Resveratrol induces the production of reactive oxygen species, interferes with the cell cycle, and inhibits the cell migration of bladder tumour cells with different TP53 status. <i>Natural Product Research</i> , 2023, 37, 3838-3843.	1.8	2
1556	A reporting quality evaluation of the clinical practice guidelines for bladder cancer based on the RIGHT checklist. <i>Translational Andrology and Urology</i> , 2022, 11, 1586-1597.	1.4	0

#	ARTICLE	IF	CITATIONS
1557	Afectación metastásica de la orbitaria por carcinoma de vejiga simulando una celulitis periorbitaria: reporte de caso. Revista Mexicana De Urología, 2022, 82, 1-9.	0.0	0
1558	Synthesis, X-ray structure and anticancer activity evaluation of a binuclear La(III) complex with anthranilic acid. Natural Product Research, 0, , 1-10.	1.8	1
1559	Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 148.e1-148.e7.	1.6	12
1560	Regulatory Components of Oxidative Stress and Inflammation and Their Complex Interplay in Carcinogenesis. Applied Biochemistry and Biotechnology, 2023, 195, 2893-2916.	2.9	7
1561	Adherence to Mediterranean-Style Dietary Pattern and Risk of Bladder Cancer: A Case-Control Study in Iran. Nutrition and Cancer, 0, , 1-8.	2.0	0
1563	Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer. Frontiers in Oncology, 0, 12, .	2.8	0
1564	Fibronectin 1 as a Key Gene in the Genesis and Progression of Cadmium-Related Bladder Cancer. Biological Trace Element Research, 2023, 201, 4349-4359.	3.5	5
1565	CT-based deep learning radiomics signature for the preoperative prediction of the muscle-invasive status of bladder cancer. Frontiers in Oncology, 0, 12, .	2.8	6
1566	Bladder cancer tissue-derived exosomes suppress ferroptosis of <scp>T24</scp> bladder cancer cells by transporting <scp>miR</scp>. Environmental and Molecular Mutagenesis, 2023, 64, 39-49.	2.2	6
1567	Development of a 7-miRNA prognostic signature for patients with bladder cancer. Aging, 2022, 14, 10093-10106.	3.1	2
1569	Epigenetic Regulation in Urothelial Carcinoma. Current Molecular Medicine, 2022, 23, .	1.3	0
1570	Integrated molecular analyses of an interferon- γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. Heliyon, 2022, 8, e12102.	3.2	0
1571	Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways. Journal of the Egyptian National Cancer Institute, 2022, 34, .	1.5	0
1572	Prognostic nomogram based on the lymph node metastasis indicators for patients with bladder cancer: A <scp>SEER</scp> population-based study and external validation. Cancer Medicine, 2023, 12, 6853-6866.	2.8	2
1573	Meat Intake and the Risk of Bladder Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Nutrition and Cancer, 2023, 75, 825-845.	2.0	2
1574	Urine and fecal microbiota in a canine model of bladder cancer and comparison of canine and human urine microbiota. International Journal of Transgender Health, 2022, 15, 1245-1263.	2.3	3
1575	Identification and genetic analysis of major gene ST3GAL4 related to serum alkaline phosphatase in chicken. Research in Veterinary Science, 2023, 155, 115-123.	1.9	1
1576	Neoadjuvant chemotherapy and radical cystectomy in patients with bladder cancer. Onkourologiya, 2022, 18, 92-98.	0.3	0

#	ARTICLE	IF	CITATIONS
1577	Clinical efficacy and prognostic analysis of radical cystectomy plus modified ureterosigmoidostomy (Mainz II) in bladder cancer. Asian Journal of Surgery, 2022, , .	0.4	0
1578	Bladder cancer-associated microbiota: Recent advances and future perspectives. Heliyon, 2023, 9, e13012.	3.2	6
1579	Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against Cancer Cells. Biological Trace Element Research, 2023, 201, 4688-4696.	3.5	1
1581	Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncology, The, 2023, 24, 22-32.	10.7	15
1582	Telomere maintenance-related genes are important for survival prediction and subtype identification in bladder cancer. Frontiers in Genetics, 0, 13, .	2.3	2
1583	Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma. Annals of Diagnostic Pathology, 2023, , 152081.	1.3	0
1584	An IFN- γ -related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts. Frontiers in Genetics, 0, 13, .	2.3	2
1585	VI-RADS in bladder cancer: Overview, pearls and pitfalls. European Journal of Radiology, 2023, 160, 110666.	2.6	4
1586	CirCHGS enhances the progression of bladder cancer by regulating the miR-513a-5p/VEGFC axis and activating the AKT/mTOR signaling pathway. Cell Cycle, 2023, 22, 919-938.	2.6	3
1587	Risk Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain: A Case- Control Study. Journal of Clinical Medicine, 2023, 12, 728.	2.4	3
1588	Bladder Wall Stiffness after Cystectomy in Bladder Cancer Patients: A Preliminary Study. Cancers, 2023, 15, 359.	3.7	1
1589	Designing Intelligent Nanomaterials to Achieve Highly Sensitive Diagnoses and Multimodality Therapy of Bladder Cancer. Small Methods, 2023, 7, .	8.6	4
1590	Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin $\alpha 5/\beta 1$ -FAK/Src axis: A novel strategy for drug application. Pharmacological Research, 2023, 188, 106654.	7.1	8
1591	A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation. Medicine (United States), 2022, 101, e32558.	1.0	6
1593	Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis. Actas Urológicas Españolas (English Edition), 2022, , .	0.2	0
1594	Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment. Biomedicines, 2023, 11, 69.	3.2	1
1595	Performance of Node-RADS Scoring System for a Standardized Assessment of Regional Lymph Nodes in Bladder Cancer Patients. Cancers, 2023, 15, 580.	3.7	4
1596	Transcription factor EB regulates phosphatidylinositol-3-phosphate levels that control lysosome positioning in the bladder cancer model. Communications Biology, 2023, 6, .	4.4	5

#	ARTICLE	IF	CITATIONS
1597	CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 813.	3.7	1
1598	Rotating Night Shift Work and Bladder Cancer Risk in Women: Results of Two Prospective Cohort Studies. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2202.	2.6	1
1600	Evaluation of the Small Heat Shock Protein Family Members HSPB2 and HSPB3 in Bladder Cancer Prognosis and Progression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2609.	4.1	0
1601	Accuracy of actual stage prediction using Vesical Imaging Reporting and Data System (VI-RADS) before radical cystectomy for urothelial carcinoma in SUPER-UC-Cx. <i>Translational Andrology and Urology</i> , 2023, 12, 168-175.	1.4	1
1602	HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	13
1603	Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial. <i>IMIR Research Protocols</i> , 0, 12, e42254.	1.0	1
1604	Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation. <i>Cancers</i> , 2023, 15, 1886.	3.7	2
1606	Circular RNAs as a potential source of neoepitopes in cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1607	The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells. <i>Tissue and Cell</i> , 2023, 82, 102096.	2.2	0
1608	Genitourinary cancer: A perspective review. , 2022, 8, 111.		0
1609	Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF- β 2 signaling axis. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	12
1610	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0
1611	Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
1612	Recent Advances in the Classification of Bladder Cancer “ Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors. <i>Bladder Cancer</i> , 2023, 9, 1-14.	0.4	1
1613	μ -opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial. <i>Cancer Communications</i> , 2023, 43, 365-386.	9.2	5
1614	Ligustilide induces apoptosis and reduces proliferation in human bladder cancer cells by $\text{NF-}\kappa\text{B}$ and mitochondria pathway. <i>Chemical Biology and Drug Design</i> , 2023, 101, 1252-1261.	3.2	5
1615	Molecular Dynamics and Multi-Spectroscopic of the Interaction Behavior between Bladder Cancer Cells and Calf Thymus DNA with Rebeccamycin: Apoptosis through the Down Regulation of PI3K/AKT Signaling Pathway. <i>Journal of Fluorescence</i> , 2023, 33, 1537-1557.	2.5	40
1616	Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	5

#	ARTICLE	IF	CITATIONS
1617	GNRH family genes contributed to gender-specific disparity of bladder cancer prognosis through exerting opposite regulatory roles between males and females. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6827-6840.	2.5	6
1618	To determine correlation between VIRADS scoring and pathological staging in bladder cancer: A prospective study and review of literature. <i>Urologia</i> , 2023, 90, 476-481.	0.7	1
1619	Role of Multiparametric-MRI in Bladder Cancer. <i>Current Radiology Reports</i> , 2023, 11, 69-80.	1.4	0
1620	Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?. <i>Cancers</i> , 2023, 15, 1455.	3.7	1
1622	A Short Overview on Therapeutic Biomarkers for Muscle Invasive Bladder Carcinoma. <i>European Medical Journal Urology</i> , 0, , .	0.0	0
1623	Study of Preoperative NLR in Common Malignancies. <i>Advances in Clinical Medicine</i> , 2023, 13, 2926-2931.	0.0	0
1624	PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. <i>Cell and Bioscience</i> , 2023, 13, .	4.8	5
1625	Phenotype of Urine Sediment Cells in Patients with Bladder Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2023, 174, 473-477.	0.8	0
1626	Efficacy and Safety of a 5-Alpha Reductase Inhibitor, Dutasteride, Added to Bacillus Calmette-Guérin Immunotherapy for Prevention of Recurrence and Progression of Intermediate- and High-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Phase 2 Clinical Trial. <i>Journal of Urological Surgery</i> , 2023, 10, 36-42.	0.1	0
1627	The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study ¹ . <i>Bladder Cancer</i> , 2023, 9, 73-82.	0.4	0
1628	The Short- and Long-Term Effect of Radical Cystectomy in Frail Patients With Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e291-e298.	1.9	3
1629	Pretreatment red blood cell distribution width may be a potential biomarker of prognosis in urologic cancer: a systematic review and meta-analysis. <i>Biomarkers in Medicine</i> , 2022, 16, 1289-1300.	1.4	2
1630	Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 287-304.	27.6	34
1631	Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug. , 2023, , .		0
1632	High expression of ABCF1 is an independent predictor of poor prognosis in bladder cancer. <i>BMC Urology</i> , 2023, 23, .	1.4	0
1633	Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through miR-1184/RAP2B Axis. <i>Urologia Internationalis</i> , 2023, 107, 632-645.	1.3	0
1636	The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells. <i>Anticancer Research</i> , 2023, 43, 1521-1531.	1.1	1
1637	<sc>CircSMARCA5</sc> functions as a potential biomarker for clinicopathology and therapy in solid tumors: A systematic review and meta-analysis. <i>Precision Medical Sciences</i> , 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1638	Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020. <i>Cancers</i> , 2023, 15, 2069.	3.7	1
1639	CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway. <i>Oncology Reports</i> , 2023, 49, .	2.6	3
1640	Adherence to guidelines in the follow up of non- muscle invasive bladder cancer among urology trainers and trainees in jordan: a cross-sectional study. <i>Annals of Medicine and Surgery</i> , 0, Publish Ahead of Print, .	1.1	0
1641	Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2023, 37, 039463202311667.	2.1	1
1642	Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer. <i>Pathology and Oncology Research</i> , 0, 29, .	1.9	0
1643	When N7-methyladenosine modification meets cancer: Emerging frontiers and promising therapeutic opportunities. <i>Cancer Letters</i> , 2023, 562, 216165.	7.2	4
1644	Implementing Blue Light Flexible Cystoscopy in Non-Muscle Invasive Bladder Cancer Surveillance. <i>European Medical Journal Urology</i> , 0, , 2-10.	0.0	1
1645	Renal BCGosis managed conservatively with antituberculous medications. <i>Urology Annals</i> , 2023, 15, 232.	0.6	1
1646	Pathological and Imaging Characteristics of Bladder Tumor with LUTS as the First Symptom. <i>Advances in Clinical Medicine</i> , 2023, 13, 5292-5296.	0.0	0
1648	Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer. <i>Diagnostics</i> , 2023, 13, 1393.	2.6	4
1649	The androgen receptor in bladder cancer. <i>Nature Reviews Urology</i> , 2023, 20, 560-574.	3.8	5
1650	Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial. <i>Acta OncolÃ³gica</i> , 2023, 62, 814-819.	1.8	1
1651	Characterization and treatment of gemcitabineâ€•and cisplatinâ€•resistant bladder cancer cells with a <scp>panâ€•RAS</scp> inhibitor. <i>FEBS Open Bio</i> , 0, , .	2.3	0
1652	Association of human papillomavirus (HPV), p16, p53 and p63 expression with non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm construction for histopathological grading prediction. <i>Einstein (Sao Paulo, Brazil)</i> , 2023, 21, .	0.7	0
1653	STIL/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	3
1654	DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. <i>Nature Communications</i> , 2023, 14, .	12.8	4
1655	Differential Expression of LncRNA in Bladder Cancer Development. <i>Diagnostics</i> , 2023, 13, 1745.	2.6	4
1657	How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?. <i>Cancers</i> , 2023, 15, 2836.	3.7	1

#	ARTICLE	IF	CITATIONS
1658	Diagnostic Value of the Sentinel Lymph Node Technique in Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 3092.	2.4	0
1659	Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling study. <i>International Journal for Equity in Health</i> , 2023, 22, .	3.5	0
1660	LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
1661	Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients. <i>Medicine (United States)</i> , 2023, 102, e33719.	1.0	0
1664	Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
1665	Diagnostic, Therapeutic and Prognostic Implications of Urothelial Carcinoma, A Review. , 0, , 08-15.		0
1666	CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1 complex in bladder cancer. <i>Discover Oncology</i> , 2023, 14, .	2.1	0
1667	Cancer in Migrants: A Population-Based Study in Italy. <i>Cancers</i> , 2023, 15, 3103.	3.7	0
1668	Changes in male sexuality after urologic cancer: a narrative review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2023, 49, 175-183.	1.5	6
1669	Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study. <i>Annals of Epidemiology</i> , 2023, 84, 60-66.	1.9	0
1670	Nursing Care in Robotic Radical Cystectomy and Intracorporeal Orthotopic Urinary Diversion Surgeries. <i>Åeroonkoloji BÅ¼lteni</i> , 2023, 22, 50-56.	0.1	0
1671	Disparity of Bladder Cancer Incidence among Male Workers across Industries: A Population-based Cohort Study from South Korea. <i>Journal of Occupational and Environmental Medicine</i> , 0, Publish Ahead of Print, .	1.7	0
1672	Immunohistochemical expression of CD117/KIT, HER2, and ErÎ² in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients. <i>International Urology and Nephrology</i> , 0, , .	1.4	0
1673	Bladder cancer mortality trends in Spain: 1980â€“2021. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2023, 47, 517-526.	0.2	0
1674	Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019. <i>Cancer Medicine</i> , 2023, 12, 16469-16481.	2.8	1
1675	Antisense lncRNAâ€RP11â€498C9.13 promotes bladder cancer progression by enhancing reactive oxygen speciesâ€induced mitophagy. <i>Journal of Gene Medicine</i> , 0, , .	2.8	0
1676	Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients. <i>Heliyon</i> , 2023, 9, e17690.	3.2	0
1677	Nano theranostics involved in bladder cancer treatment. , 0, , 81-106.		0

#	ARTICLE	IF	CITATIONS
1678	Development and validation of a tobacco smoking-related index for predicting overall survival and immunotherapy response in bladder cancer. <i>Environmental Science and Pollution Research</i> , 2023, 30, 68701-68715.	5.3	1
1679	Opium alkaloids, biosynthesis, pharmacology and association with cancer occurrence. <i>Open Biology</i> , 2023, 13, .	3.6	4
1680	Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 5295-5303.	1.5	3
1681	PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/ β^2 -catenin signaling pathway. <i>Pathology Research and Practice</i> , 2023, 247, 154536.	2.3	4
1682	Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing β^2 -integrin. <i>Aging</i> , 2023, 15, 4182-4201.	3.1	1
1683	Recent Progress on Urinary Exosomal miRNAs in Bladder Cancer. <i>Annals of Urologic Oncology</i> , 2023, , 1-8.	0.1	0
1684	Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by Activating p38 and suppressing Wnt/ β^2 -catenin pathways. <i>Genes and Diseases</i> , 2024, 11, 1050-1065.	3.4	2
1685	Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, , .	0.8	2
1686	Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9258.	4.1	2
1687	TROP2 translation mediated by dual m6A/m7G RNA modifications promotes bladder cancer development. <i>Cancer Letters</i> , 2023, 566, 216246.	7.2	2
1688	Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells. <i>Acta Pharmaceutica</i> , 2023, 73, 211-225.	2.0	1
1689	The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics. <i>Journal of Clinical Medicine</i> , 2023, 12, 4259.	2.4	1
1690	Bibliometric analysis of the association between drinking water pollution and bladder cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1691	Crosstalk between autophagy and bladder transitional cell carcinoma by autophagy-related lncRNAs. <i>Medicine (United States)</i> , 2023, 102, e34130.	1.0	0
1692	An Inception based Urothelial Cell Classification Network for the detection of Bladder Carcinoma from Urine Cytology Microscopic Images. , 2023, , .		0
1693	High monoamine oxidase a expression predicts poor prognosis for prostate cancer patients. <i>BMC Urology</i> , 2023, 23, .	1.4	1
1695	Signet ring cell carcinoma of the bladder. <i>Asian Journal of Surgery</i> , 2023, , .	0.4	0
1696	CD105 and CD34 as Markers of Angiogenesis of Urothelial Carcinoma: A Cross Sectional Study. <i>Asia-Pacific Journal of Oncology</i> , 2023, , 1-7.	0.1	0

#	ARTICLE	IF	CITATIONS
1697	Rare Manifestation of the Cutaneous and Cervical Lymph Node Metastases of Urothelial Carcinoma of Urinary Bladder: A Case Report. Journal of the Korean Society of Radiology, 0, 84, .	0.2	0
1698	Implication of KDM6A in bladder cancer. Pharmacogenomics, 0, , .	1.3	0
1699	<scp>MTHFD2</scp> promotes <scp>PD↑</scp> expression via activation of the <scp>JAK</scp>/<scp>STAT</scp> signalling pathway in bladder cancer. Journal of Cellular and Molecular Medicine, 2023, 27, 2922-2936.	3.6	2
1700	BCCitis with aortoiliac aneurysm involvement: Report of two cases and review of the literature. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2024, 42, 152-157.	0.3	0
1701	Mechanical Way To Study Molecular Structure of Pericellular Layer. ACS Applied Materials & Interfaces, 0, , .	8.0	2
1702	Intratumoral PD1+CD38+Tim3+ CD8+ T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer. Cells, 2023, 12, 1939.	4.1	1
1703	Preoperative CT-based radiomics for diagnosing muscle invasion of bladder cancer. Egyptian Journal of Radiology and Nuclear Medicine, 2023, 54, .	0.6	0
1704	Chronic conditions and depressive symptoms in middle-aged and older Chinese adults: Roles of perceived social support and area of residence. Journal of Affective Disorders, 2023, 340, 290-298.	4.1	1
1705	From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs. Current Pharmaceutical Design, 2023, 29, 1747-1774.	1.9	1
1706	Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma. Medicina (Lithuania), 2023, 59, 1452.	2.0	0
1707	Reactive arthritis as a rare complication of intravesical bacillus Calmette–GuÅrin treatment: Report of two cases. International Journal of Rheumatic Diseases, 2024, 27, .	1.9	0
1708	Using the Multidimensional Health Locus of Control Scale Form C to Investigate Health Beliefs About Bladder Cancer Prevention and Treatment Among Male Patients: Cross-Sectional Study. JMIR Formative Research, 0, 7, e43345.	1.4	0
1710	Application of targeted drug delivery based on nano platform in diagnosis and treatment of bladder cancer. Journal of Drug Delivery Science and Technology, 2023, 87, 104873.	3.0	0
1711	Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System. European Urology Focus, 2024, 10, 131-138.	3.1	1
1712	Prediction for recurrent non-muscle invasive bladder cancer. Cancer Biomarkers, 2023, , 1-11.	1.7	0
1713	The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in Leonurus artemisia Extract-Induced Inhibition of the Proliferation of Human Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro. Pharmaceuticals, 2023, 16, 1338.	3.8	0
1714	Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species. Clinical and Translational Discovery, 2023, 3, .	0.5	0
1715	Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia. Asia-Pacific Journal of Clinical Oncology, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1716	Distinguishing Bladder Cancer from Cystitis Patients Using Deep Learning. <i>Mathematics</i> , 2023, 11, 4118.	2.2	0
1717	Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer. <i>Diagnostics</i> , 2023, 13, 3067.	2.6	0
1718	A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
1719	Anticancer and apoptosis inducing potential of quercetin against a wide range of human malignancies. <i>International Journal of Food Properties</i> , 2023, 26, 2590-2626.	3.0	1
1720	11-item modified frailty index and outcomes after radical cystectomy. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101627.	1.0	0
1721	Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ. <i>Nature Communications</i> , 2023, 14, .	12.8	1
1722	Biological roles of RNA m7G modification and its implications in cancer. <i>Biology Direct</i> , 2023, 18, .	4.6	1
1723	Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
1724	The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
1725	CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. <i>Molecular Cancer</i> , 2023, 22, .	19.2	7
1726	Causal associations between gut microbiota and urological tumors: a two-sample mendelian randomization study. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
1727	Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?. <i>Cancers</i> , 2023, 15, 3683.	3.7	1
1728	Role of human papillomavirus and associated viruses in bladder cancer: An updated review. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	1
1729	Molecular mechanism of long non-coding RNA SNHG12 regulating bladder cancer cell activities. <i>Molecular and Cellular Toxicology</i> , 0, , .	1.7	0
1730	Cancer-Associated Fibroblasts Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer. <i>Advanced Science</i> , 2023, 10, .	11.2	3
1731	Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer. <i>BMC Urology</i> , 2023, 23, .	1.4	0
1732	Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1733	Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed?. <i>Natural Products and Bioprospecting</i> , 2023, 13, .	4.3	0

#	ARTICLE	IF	CITATIONS
1734	Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	1
1735	Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1328-1337.	2.5	4
1736	Changing Pattern of Cancer Distribution: Experience From a Tertiary Health Institution in Nigeria and Review of Literature. <i>Nigerian Journal of Clinical Practice</i> , 2023, 26, 902-907.	0.6	0
1737	Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes. <i>International Urology and Nephrology</i> , 2023, 55, 2765-2772.	1.4	1
1738	A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	0
1740	Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis. <i>Aging</i> , 2023, 15, 8325-8344.	3.1	1
1741	Reproductive Factors in the Risk of Bladder Cancer and Upper Urinary Tract Cancer: The Japan Public Health Center-Based Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1572-1582.	2.5	0
1742	Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
1743	Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e34828.	1.0	0
1745	Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
1746	Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1747	Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
1748	The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. <i>Journal of Global Health</i> , 0, 13, .	2.7	1
1749	Bladder Cancer Microarray Analysis and Biomarker Discovery Using Machine Learning. <i>Lecture Notes on Data Engineering and Communications Technologies</i> , 2023, , 269-283.	0.7	0
1750	Adherence to the Diabetes Risk Reduction Diet and Bladder Cancer Risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1726-1733.	2.5	0
1751	Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway. <i>Chemico-Biological Interactions</i> , 2023, 384, 110725.	4.0	0
1752	Tripartite Motif Containing 66 Promotes Malignant Progression of Bladder Cancer by Activating Matrix Metalloproteinase 11. <i>Journal of Biomedical Nanotechnology</i> , 2023, 19, 1550-1557.	1.1	0
1753	TGFB Induced Factor Homeobox 2 Induces Deterioration of Bladder Carcinoma via Activating CD2 Cytoplasmic Tail Binding Protein 2. <i>Journal of Biomedical Nanotechnology</i> , 2023, 19, 1670-1676.	1.1	0

#	ARTICLE	IF	CITATIONS
1754	A glycosylation risk score comprehensively assists the treatment of bladder neoplasm in the real-world cohort, including the tumor microenvironment, molecular and clinical prognosis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
1756	Identification of hub genes in bladder transitional cell carcinoma through ceRNA network construction integrated with gene network analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2024, 28, .	3.6	0
1757	UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells. <i>Aging</i> , 2023, 15, 10593-10606.	3.1	0
1758	Management of Non-Muscle Invasive Bladder Cancer. , 2023, , 141-152.		0
1759	<scp>miRNAs</scp> involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway. <i>Precision Medical Sciences</i> , 2023, 12, 206-223.	0.5	0
1760	Comparison of the efficacy of BCG intravesical immunotherapy using the conventional Rotisserie method with the non-Rotisserie method. <i>African Journal of Urology</i> , 2023, 29, .	0.4	0
1761	A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer. <i>Heliyon</i> , 2023, 9, e21058.	3.2	0
1762	Contribution and underlying mechanisms of lncRNA TRPM2-AS in the development and progression of human cancers. <i>Pathology Research and Practice</i> , 2023, 251, 154887.	2.3	0
1763	Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF- κ B pathways. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 0, , .	4.9	0
1764	Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer. <i>Biochemical Pharmacology</i> , 2023, 218, 115870.	4.4	1
1765	Trimodal therapy versus radical cystectomy for cT2NOMO urothelial muscle-invasive bladder cancer: Single-center experience. <i>Urology Annals</i> , 2023, 15, 406-411.	0.6	1
1767	Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis. <i>Frontiers in Surgery</i> , 0, 10, .	1.4	0
1768	Overexpression of MicroRNA-138 Affects the Proliferation and Invasion of Urothelial Carcinoma Cells by Suppressing SOX9 Expression. <i>Biomedicines</i> , 2023, 11, 3064.	3.2	0
1769	Inflammatory bowel disease and bladder cancer risk: based on a Mendelian randomization study. <i>BMC Urology</i> , 2023, 23, .	1.4	0
1770	Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer. <i>Pharmaceutics</i> , 2023, 15, 2688.	4.5	0
1771	NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?. <i>Expert Review of Anticancer Therapy</i> , 2024, 24, 1-4.	2.4	0
1772	Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2023, 30, 9940-9952.	2.2	0
1773	Arsenic toxicity: sources, pathophysiology and mechanism. <i>Toxicology Research</i> , 2024, 13, .	2.1	2

#	ARTICLE	IF	CITATIONS
1774	Role of multiparametric MRI in predicting muscle invasiveness in urinary bladder neoplasms with pathological correlations. <i>Urologia</i> , 0, , .	0.7	0
1775	Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features. <i>Asian Journal of Urology</i> , 2023, , .	1.2	0
1777	Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
1778	Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis. <i>Life Sciences</i> , 2023, 335, 122253.	4.3	1
1779	Bladder Cancer and Probiotics: What Do We Know So Far?. <i>Cancers</i> , 2023, 15, 5551.	3.7	0
1781	Incidence, mortality and survival of transitional cell carcinoma in the urinary system: A population-based analysis. <i>Medicine (United States)</i> , 2023, 102, e36063.	1.0	1
1782	Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis. <i>Cancers</i> , 2023, 15, 5704.	3.7	0
1783	C15:0 and C17:0 partially mediate the association of milk & dairy products with bladder cancer risk. <i>Journal of Dairy Science</i> , 2023, , .	3.4	0
1784	Interobserver agreement for the Vesical Imaging-Reporting and Data System (VI-RADS) in differentiating non-muscle-invasive and muscle-invasive urinary bladder tumors. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2023, 54, .	0.6	0
1785	Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy combined with machine learning algorithms in a rat model. <i>Biosensors and Bioelectronics</i> , 2024, 246, 115915.	10.1	2
1786	Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of RAB1A stabilization. <i>Cellular Signalling</i> , 2024, 114, 110996.	3.6	1
1787	CD47 expression in urothelial carcinoma and its correlation with histopathological findings. <i>Indian Journal of Cancer</i> , 0, , .	0.2	0
1789	Immunohistochemical expression of CXCL5 as a valuable prognostic marker in urinary bladder urothelial carcinoma. <i>Egyptian Journal of Pathology</i> , 2023, 43, 29-34.	0.0	0
1790	Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	0
1791	Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999â€“2020. <i>Investigative and Clinical Urology</i> , 0, 65, .	2.0	0
1792	Alkaloids from <i>Corydalis saxicola</i> and their antiproliferative activity against cancer cells. <i>FÃ¬toterapÃ¬Ã¢</i> , 2024, 173, 105791.	2.2	0
1793	Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment. <i>BMC Urology</i> , 2024, 24, .	1.4	0
1794	Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice. <i>International Journal of Clinical Oncology</i> , 2024, 29, 309-317.	2.2	0

#	ARTICLE	IF	CITATIONS
1795	Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance. <i>Cancer and Metastasis Reviews</i> , 0, , .	5.9	0
1796	EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2024, 43, .	8.6	0
1797	E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer. <i>Medicine (United States)</i> , 2024, 103, e35722.	1.0	0
1798	Thirty-two-year trends of cancer incidence by sex and cancer site in the Veneto Region from 1987 to 2019. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
1799	Urinary Bladder Cancer Induced by N-Butyl-N-(4-Hydroxybutyl)-Nitrosamine. <i>Methods in Molecular Biology</i> , 2024, , 25-32.	0.9	0
1800	Classification of bladder cancer based on immune cell infiltration and construction of a risk prediction model for prognosis. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2024, 53, 47-57.	0.3	0
1801	A comparison between conventional and the Paris systems of reporting urinary cytopathology with a literature update. <i>Diagnostic Cytopathology</i> , 2024, 52, 187-199.	1.0	0
1803	Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
1804	Clinical features and oncological outcomes of bladder cancer microsatellite instability. <i>International Journal of Urology</i> , 2024, 31, 438-445.	1.0	0
1806	N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128â€“3p/MAPK1 axis. <i>Cancer Letters</i> , 2024, 585, 216613.	7.2	0
1807	Other Formed Elements in Urine. , 2024, , 173-191.		0
1808	Urease-powered nanobots for radionuclide bladder cancer therapy. <i>Nature Nanotechnology</i> , 2024, 19, 554-564.	31.5	2
1809	Relevance of HOTAIR rs920778 and rs12826786 Genetic Variants in Bladder Cancer Risk and Survival. <i>Cancers</i> , 2024, 16, 434.	3.7	0
1810	The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005â€“2020. <i>International Journal for Equity in Health</i> , 2024, 23, .	3.5	0
1812	Tumor cell dissociationâ€“enhanced intravesical chemotherapy of orthotopic bladder cancer. <i>SmartMat</i> , 0, , .	10.7	0
1813	THE EFFECT OF IMMUNOLOGICAL BIOMARKERS - NLR, PLR, LMR, PD-L1 ON THE SURVIVAL OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. , 0, , .		0
1814	Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial. <i>BMJ Open</i> , 2024, 14, e076663.	1.9	0
1815	Role of Additional <sc>MRI</sc>â€“Based Morphologic Measurements on the Performance of <sc>VIâ€“RADS</sc> for Muscleâ€“invasive Bladder Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	3.4	0

#	ARTICLE	IF	CITATIONS
1816	Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study. <i>Insights Into Imaging</i> , 2024, 15, .	3.4	0
1817	Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma. <i>JCO Global Oncology</i> , 2024, , .	1.8	0
1818	Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
1819	The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1732.	4.1	0
1820	A Continuous Transversus Abdominis Plane Block Decreases Hospital Length of Stay Compared to Thoracic Epidural Analgesia After Open Radical Cystectomy Surgery: A Retrospective Study. <i>Anesthesiology and Pain Medicine</i> , 2024, 14, .	1.3	0
1821	TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. <i>European Journal of Medical Research</i> , 2024, 29, .	2.2	0
1822	Trihalomethanes in global drinking water: Distributions, risk assessments, and attributable disease burden of bladder cancer. <i>Journal of Hazardous Materials</i> , 2024, 469, 133760.	12.4	0
1823	Roles of Androgen Receptor Signaling in Urothelial Carcinoma. <i>Cancers</i> , 2024, 16, 746.	3.7	0
1824	A modified ureteroileal anastomosis can reduce ureteroileal anastomotic stricture after ileal conduit. <i>International Urology and Nephrology</i> , 0, , .	1.4	0
1825	Outcomes of intravesical <i>Bacillus Calmette-Guerin</i> in patients with non-muscle invasive bladder cancer: a retrospective study in Australia. <i>Frontiers in Urology</i> , 0, 4, .	0.5	0
1826	Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study. <i>Integrative Cancer Therapies</i> , 2024, 23, .	2.0	0
1828	Efficacy and safety of short-term intravesical gemcitabine vs. long-term intravesical epirubicin in the treatment of moderate to high-risk non-muscle-invasive bladder cancer: a pilot study. , 2024, 3, .		0
1829	Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy. <i>Biomaterials</i> , 2024, 307, 122514.	11.4	0
1830	Addressing disparities in European cancer outcomes: a qualitative study Protocol of the BEACON project. <i>Frontiers in Psychology</i> , 0, 15, .	2.1	0
1831	Harnblasenkrebs. , 2024, , 355-373.		0
1832	Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2024, 7, e241215.	5.9	0
1834	SMMF: a self-attention-based multi-parametric MRI feature fusion framework for the diagnosis of bladder cancer grading. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
1835	Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma. <i>Biology Direct</i> , 2024, 19, .	4.6	0

#	ARTICLE	IF	CITATIONS
1836	Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Nonâ€‘muscle-invasive Bladder Cancer. European Urology Open Science, 2024, 62, 99-106.	0.4	0
1837	A New Strategy to Authenticate Prognosis and Tumor Immunity Model Based on Cancer-Associated Fibroblasts lncRNA in Bladder Cancer. Journal of Biomedical Nanotechnology, 2024, 20, 1169-1186.	1.1	0
1838	Single-cell and multi-omics analyses highlight cancer-associated fibroblasts-induced immune evasion and epithelial mesenchymal transition for smoking bladder cancer. Toxicology, 2024, 504, 153782.	4.2	0
1839	Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis. Abdominal Radiology, 0, , .	2.1	0
1840	Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database. BMJ Open, 2024, 14, e080092.	1.9	0
1841	Primary pure large cell neuroendocrine carcinoma of the urinary bladder: a case report and literature review. Frontiers in Oncology, 0, 14, .	2.8	0
1842	Epidemiological, Clinical and Therapeutic Aspects of Bladder Tumors in a Schistosomiasis-Endemic Country. Open Journal of Urology, 2024, 14, 151-159.	0.1	0
1843	Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. Veterinary and Comparative Oncology, 0, , .	1.8	0
1844	Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients. International Journal of Molecular Sciences, 2024, 25, 3473.	4.1	0